5 | spleen wet weight | Hsd:WI | male | 0.708 | g | vehicle control condition (for 91 days) | 76115 | vehicle control condition (for 91 days) | | | | | | | | | | |

5 | serum total protein level | Hsd:WI | male | 9.38 | g/dl | vehicle control condition (for 91 days) | 76125 | vehicle control condition (for 91 days) | | | | | | | | | | |

5 | serum total cholesterol level | Hsd:WI | male | 68.12 | mg/dl | vehicle control condition (for 91 days) | 76130 | vehicle control condition (for 91 days) | | | | | | | | | | |

6 | kidney superoxide dismutase activity to total protein level ratio | Hsd:WI | male | 13.53 | U/mg | vehicle control condition (for 10 days) | 76187 | vehicle control condition (for 10 days) | | | | | | | | | | |

6 | kidney superoxide dismutase activity to total protein level ratio | Hsd:WI | male | 8.13 | U/mg | vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) | 76188 | vehicle control condition (for 10 days) | | | cisplatin (7.5 mg/kg) | | | | | | | |

8 | body weight | BluHsd:LE | male | 353.1 | g | vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) | 75955 | vehicle control condition (for 30 days) | controlled in utero environment (for 9 days) | | maternal milk (for 21 days) | | | | | | | |

8 | total food calorie intake rate | BluHsd:LE | male | 2995.2 | kcal/d | controlled in utero environment (for 9 days) and vehicle control condition (for 30 days) then maternal milk (for 21 days) then controlled fat content diet (21.2 %) (for 28 days) | 76182 | controlled in utero environment (for 9 days) | vehicle control condition (for 30 days) | | maternal milk (for 21 days) | | controlled fat content diet (21.2 %) (for 28 days) | | | | | |

8 | food calorie intake level to change in body weight ratio | BluHsd:LE | male | 10.1 | kcal/g | controlled in utero environment (for 9 days) and vehicle control condition (for 30 days) then maternal milk (for 21 days) | 76204 | controlled in utero environment (for 9 days) | vehicle control condition (for 30 days) | | maternal milk (for 21 days) | | | | | | | |

6 | kidney catalase activity to total protein level ratio | Hsd:WI | male | 35.98 | nmol/mg | vehicle control condition (for 10 days) | 76234 | vehicle control condition (for 10 days) | | | | | | | | | | |

6 | kidney catalase activity to total protein level ratio | Hsd:WI | male | 21.73 | nmol/mg | vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) | 76235 | vehicle control condition (for 10 days) | | | cisplatin (7.5 mg/kg) | | | | | | | |

8 | food intake weight to change in body weight ratio | BluHsd:LE | male | 6.7 | g/g | controlled in utero environment (for 9 days) and vehicle control condition (for 30 days) then maternal milk (for 21 days) | 76203 | controlled in utero environment (for 9 days) | vehicle control condition (for 30 days) | | maternal milk (for 21 days) | | | | | | | |

6 | body weight | Hsd:WI | male | 140.6 | g | vehicle control condition (for 10 days) | 75951 | vehicle control condition (for 10 days) | | | | | | | | | | |

6 | body weight | Hsd:WI | male | 137.6 | g | vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) | 75952 | vehicle control condition (for 10 days) | | | cisplatin (7.5 mg/kg) | | | | | | | |

8 | body weight | BluHsd:LE | male | 457.7 | g | vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) | 75962 | vehicle control condition (for 30 days) | controlled in utero environment (for 9 days) | | maternal milk (for 21 days) | | | | | | | |

6 | timed urine volume | Hsd:WI | male | 6.8 | ml/d | vehicle control condition (for 10 days) | 75965 | vehicle control condition (for 10 days) | | | | | | | | | | |

6 | timed urine volume | Hsd:WI | male | 21.8 | ml/d | vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) | 75966 | vehicle control condition (for 10 days) | | | cisplatin (7.5 mg/kg) | | | | | | | |

8 | body weight gain | BluHsd:LE | male | 104.6 | g | vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) | 75969 | vehicle control condition (for 30 days) | controlled in utero environment (for 9 days) | | maternal milk (for 21 days) | | | | | | | |

6 | serum creatinine level | Hsd:WI | male | 0.54 | mg/dl | vehicle control condition (for 10 days) | 75972 | vehicle control condition (for 10 days) | | | | | | | | | | |

6 | serum creatinine level | Hsd:WI | male | 1.69 | mg/dl | vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) | 75973 | vehicle control condition (for 10 days) | | | cisplatin (7.5 mg/kg) | | | | | | | |

6 | serum urea nitrogen level | Hsd:WI | male | 69.64 | mg/dl | vehicle control condition (for 10 days) | 75976 | vehicle control condition (for 10 days) | | | | | | | | | | |

6 | serum urea nitrogen level | Hsd:WI | male | 96.11 | mg/dl | vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) | 75977 | vehicle control condition (for 10 days) | | | cisplatin (7.5 mg/kg) | | | | | | | |

5 | body weight | Hsd:WI | male | 388 | g | vehicle control condition (for 91 days) | 76041 | vehicle control condition (for 91 days) | | | | | | | | | | |

5 | change in body weight to body weight ratio | Hsd:WI | male | 255 | % | vehicle control condition (for 91 days) | 76065 | vehicle control condition (for 91 days) | | | | | | | | | | |

5 | right kidney wet weight | Hsd:WI | male | 1.214 | g | vehicle control condition (for 91 days) | 76070 | vehicle control condition (for 91 days) | | | | | | | | | | |

5 | left kidney wet weight | Hsd:WI | male | 1.192 | g | vehicle control condition (for 91 days) | 76075 | vehicle control condition (for 91 days) | | | | | | | | | | |

5 | right kidney wet weight to body weight ratio | Hsd:WI | male | 3.138 | mg/g | vehicle control condition (for 91 days) | 76080 | vehicle control condition (for 91 days) | | | | | | | | | | |

5 | left kidney wet weight to body weight ratio | Hsd:WI | male | 3.072 | mg/g | vehicle control condition (for 91 days) | 76085 | vehicle control condition (for 91 days) | | | | | | | | | | |

5 | liver wet weight | Hsd:WI | male | 13.6 | g | vehicle control condition (for 91 days) | 76090 | vehicle control condition (for 91 days) | | | | | | | | | | |

5 | liver weight to body weight ratio | Hsd:WI | male | 34.846 | g/kg | vehicle control condition (for 91 days) | 76095 | vehicle control condition (for 91 days) | | | | | | | | | | |

5 | spleen weight to body weight ratio | Hsd:WI | male | 0.1832 | % | vehicle control condition (for 91 days) | 76120 | vehicle control condition (for 91 days) | | | | | | | | | | |

5 | serum triglyceride level | Hsd:WI | male | 156.94 | mg/dl | vehicle control condition (for 91 days) | 76135 | vehicle control condition (for 91 days) | | | | | | | | | | |

8 | body weight | BluHsd:LE | male | 345.8 | g | vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) | 76140 | vehicle control condition (for 30 days) | controlled in utero environment (for 9 days) | | maternal milk (for 21 days) | | | | | | | |

5 | serum calcium level | Hsd:WI | male | 12.82 | mg/dl | vehicle control condition (for 91 days) | 76141 | vehicle control condition (for 91 days) | | | | | | | | | | |

8 | body weight | BluHsd:LE | male | 491.1 | g | vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) then controlled fat content diet (21.2 %) (for 28 days) | 76148 | vehicle control condition (for 30 days) | controlled in utero environment (for 9 days) | | maternal milk (for 21 days) | | controlled fat content diet (21.2 %) (for 28 days) | | | | | |

5 | serum albumin level | Hsd:WI | male | 0.04486 | g/dl | vehicle control condition (for 91 days) | 76149 | vehicle control condition (for 91 days) | | | | | | | | | | |

5 | total serum bilirubin level | Hsd:WI | male | 0.96 | mg/dl | vehicle control condition (for 91 days) | 76156 | vehicle control condition (for 91 days) | | | | | | | | | | |

8 | body weight gain | BluHsd:LE | male | 145.3 | g | vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) then controlled fat content diet (21.2 %) (for 28 days) | 76161 | vehicle control condition (for 30 days) | controlled in utero environment (for 9 days) | | maternal milk (for 21 days) | | controlled fat content diet (21.2 %) (for 28 days) | | | | | |

5 | serum urea nitrogen level | Hsd:WI | male | 77.76 | mg/dl | vehicle control condition (for 91 days) | 76164 | vehicle control condition (for 91 days) | | | | | | | | | | |

8 | total food calorie intake rate | BluHsd:LE | male | 2103.7 | kcal/d | vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) | 76169 | vehicle control condition (for 30 days) | controlled in utero environment (for 9 days) | | maternal milk (for 21 days) | | | | | | | |

5 | serum creatinine level | Hsd:WI | male | 0.68 | mg/dl | vehicle control condition (for 91 days) | 76170 | vehicle control condition (for 91 days) | | | | | | | | | | |

5 | serum lactate dehydrogenase activity level | Hsd:WI | male | 1068 | U/l | vehicle control condition (for 91 days) | 76177 | vehicle control condition (for 91 days) | | | | | | | | | | |

6 | kidney glutathione peroxidase activity to total protein level ratio | Hsd:WI | male | 22.63 | U/mg | vehicle control condition (for 10 days) | 76191 | vehicle control condition (for 10 days) | | | | | | | | | | |

6 | kidney glutathione peroxidase activity to total protein level ratio | Hsd:WI | male | 7.54 | U/mg | vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) | 76192 | vehicle control condition (for 10 days) | | | cisplatin (7.5 mg/kg) | | | | | | | |

8 | food intake weight to change in body weight ratio | BluHsd:LE | male | 4.7 | g/g | controlled in utero environment (for 9 days) and vehicle control condition (for 30 days) then maternal milk (for 21 days) then controlled fat content diet (21.2 %) (for 28 days) | 76197 | controlled in utero environment (for 9 days) | vehicle control condition (for 30 days) | | maternal milk (for 21 days) | | controlled fat content diet (21.2 %) (for 28 days) | | | | | |

8 | food calorie intake level to change in body weight ratio | BluHsd:LE | male | 10.4 | kcal/g | controlled in utero environment (for 9 days) and vehicle control condition (for 30 days) then maternal milk (for 21 days) then controlled fat content diet (21.2 %) (for 28 days) | 76198 | controlled in utero environment (for 9 days) | vehicle control condition (for 30 days) | | maternal milk (for 21 days) | | controlled fat content diet (21.2 %) (for 28 days) | | | | | |

8 | both testes wet weight | BluHsd:LE | male | 3.4 | g | vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) | 76233 | vehicle control condition (for 30 days) | controlled in utero environment (for 9 days) | | maternal milk (for 21 days) | | | | | | | |

6 | kidney glutathione level | Hsd:WI | male | 12384.996 | ug/g | vehicle control condition (for 10 days) | 76238 | vehicle control condition (for 10 days) | | | | | | | | | | |

6 | kidney glutathione level | Hsd:WI | male | 7882.758 | ug/g | vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) | 76239 | vehicle control condition (for 10 days) | | | cisplatin (7.5 mg/kg) | | | | | | | |

8 | both testes wet weight | BluHsd:LE | male | 3.4 | g | vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) then controlled fat content diet (21.2 %) (for 28 days) | 76249 | vehicle control condition (for 30 days) | controlled in utero environment (for 9 days) | | maternal milk (for 21 days) | | controlled fat content diet (21.2 %) (for 28 days) | | | | | |

8 | serum testosterone level | BluHsd:LE | male | 7.3 | ng/ml | vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) | 76252 | vehicle control condition (for 30 days) | controlled in utero environment (for 9 days) | | maternal milk (for 21 days) | | | | | | | |

8 | serum testosterone level | BluHsd:LE | male | 10 | ng/ml | vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) then controlled fat content diet (21.2 %) (for 28 days) | 76253 | vehicle control condition (for 30 days) | controlled in utero environment (for 9 days) | | maternal milk (for 21 days) | | controlled fat content diet (21.2 %) (for 28 days) | | | | | |

8 | serum estradiol level | BluHsd:LE | male | 370 | pg/ml | vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) | 76254 | vehicle control condition (for 30 days) | controlled in utero environment (for 9 days) | | maternal milk (for 21 days) | | | | | | | |

8 | serum estradiol level | BluHsd:LE | male | 290 | pg/ml | vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) then controlled fat content diet (21.2 %) (for 28 days) | 76255 | vehicle control condition (for 30 days) | controlled in utero environment (for 9 days) | | maternal milk (for 21 days) | | controlled fat content diet (21.2 %) (for 28 days) | | | | | |

6 | kidney lipid peroxide level | Hsd:WI | male | 0.75 | nmol/mg | vehicle control condition (for 10 days) | 76256 | vehicle control condition (for 10 days) | | | | | | | | | | |

6 | kidney lipid peroxide level | Hsd:WI | male | 1.51 | nmol/mg | vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) | 76257 | vehicle control condition (for 10 days) | | | cisplatin (7.5 mg/kg) | | | | | | | |

32 | serum estradiol level | Crl:CD(SD) | female | 34.4 | pg/ml | maternal milk (for 20 days) and vehicle control condition (for 15 days) | 76260 | maternal milk (for 20 days) | vehicle control condition (for 15 days) | | | | | | | | | |

32 | serum progesterone level | Crl:CD(SD) | female | 12.5 | ng/ml | maternal milk (for 20 days) and vehicle control condition (for 15 days) | 76262 | maternal milk (for 20 days) | vehicle control condition (for 15 days) | | | | | | | | | |

32 | mammary tumor number | Crl:CD(SD) | female | 2.84 | | maternal milk (for 20 days) and vehicle control condition (for 15 days) then 7,12-dimethyltetraphene (DMBA) (30 mg/kg) (for 1 days) | 76264 | maternal milk (for 20 days) | vehicle control condition (for 15 days) | | 7,12-dimethyltetraphene (DMBA) (30 mg/kg) (for 1 days) | | | | | | | |

32 | post-insult time to mammary tumor formation | Crl:CD(SD) | female | 65 | d | maternal milk (for 20 days) and vehicle control condition (for 15 days) then 7,12-dimethyltetraphene (DMBA) (30 mg/kg) (for 1 days) | 76267 | maternal milk (for 20 days) | vehicle control condition (for 15 days) | | 7,12-dimethyltetraphene (DMBA) (30 mg/kg) (for 1 days) | | | | | | | |

18 | body weight gain | HanTac:WH | female | 82.4 | g | vehicle control condition (for 14 days) | 76270 | vehicle control condition (for 14 days) | | | | | | | | | | |

6 | both kidneys wet weight | Hsd:WI | male | 0.82 | g | vehicle control condition (for 10 days) | 75956 | vehicle control condition (for 10 days) | | | | | | | | | | |

6 | both kidneys wet weight | Hsd:WI | male | 1.2 | g | vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) | 75957 | vehicle control condition (for 10 days) | | | cisplatin (7.5 mg/kg) | | | | | | | |

17 | body weight | HanTac:WH | male | 6.2 | g | vehicle control condition (for 1 days) | 96612 | vehicle control condition (for 1 days) | | | | | | | | | | |

15 | body weight | HanTac:WH | female | 29.1 | g | vehicle control condition (between 16 and 17 days) | 96687 | vehicle control condition (between 16 and 17 days) | | | | | | | | | | |

18 | number of fetuses lost perinatally to litter size ratio | HanTac:WH | female | 8.5 | % | vehicle control condition (for 14 days) | 96592 | vehicle control condition (for 14 days) | | | | | | | | | | |

18 | number of perinatal live-born offspring deaths to litter size ratio | HanTac:WH | female | 3.2 | % | vehicle control condition (for 14 days) | 96602 | vehicle control condition (for 14 days) | | | | | | | | | | |

17 | anogenital distance | HanTac:WH | male | 4.1 | mm | vehicle control condition (for 1 days) | 96617 | vehicle control condition (for 1 days) | | | | | | | | | | |

18 | right testis wet weight | HanTac:WH | male | 51.3 | mg | vehicle control condition (between 16 and 17 days) | 96637 | vehicle control condition (between 16 and 17 days) | | | | | | | | | | |

18 | both epididymides wet weight | HanTac:WH | male | 0.0228 | g | vehicle control condition (between 16 and 17 days) | 96652 | vehicle control condition (between 16 and 17 days) | | | | | | | | | | |

18 | both seminal vesicles wet weight | HanTac:WH | male | 7.1 | mg | vehicle control condition (between 16 and 17 days) | 96657 | vehicle control condition (between 16 and 17 days) | | | | | | | | | | |

18 | combined levator ani and bulbocavernosus muscle weight | HanTac:WH | male | 26 | mg | vehicle control condition (between 16 and 17 days) | 96662 | vehicle control condition (between 16 and 17 days) | | | | | | | | | | |

18 | liver wet weight | HanTac:WH | male | 0.7537 | g | vehicle control condition (between 16 and 17 days) | 96672 | vehicle control condition (between 16 and 17 days) | | | | | | | | | | |

18 | both adrenal glands wet weight | HanTac:WH | male | 7.5 | mg | vehicle control condition (between 16 and 17 days) | 96677 | vehicle control condition (between 16 and 17 days) | | | | | | | | | | |

15 | left ovary wet weight | HanTac:WH | female | 3.2 | mg | vehicle control condition (between 16 and 17 days) | 96697 | vehicle control condition (between 16 and 17 days) | | | | | | | | | | |

6 | absolute change in mean arterial blood pressure | WKY/Izm | male | 27 | mmHg | vehicle control condition (2 ul) (for 0 hours) then air-jet exposure (for 0 hours) then angiotensin II (20 ng) | 84566 | vehicle control condition (2 ul) (for 0 hours) | | | air-jet exposure (for 0 hours) | | angiotensin II (20 ng) | | | | | |

6 | absolute change in mean arterial blood pressure | WKY.SHRSP-(D1Wox29-D1Arb21)/Izm | male | 32 | mmHg | vehicle control condition (2 ul) (for 0 hours) then air-jet exposure (for 0 hours) then angiotensin II (20 ng) | 84568 | vehicle control condition (2 ul) (for 0 hours) | | | air-jet exposure (for 0 hours) | | angiotensin II (20 ng) | | | | | |

6 | absolute change in mean arterial blood pressure | WKY/Izm | male | 50 | mmHg | vehicle control condition (2 ul) (for 0 hours) then air-jet exposure (for 0 hours) then angiotensin II (20 ng) then phenylephrine (3 ug) | 84570 | vehicle control condition (2 ul) (for 0 hours) | | | air-jet exposure (for 0 hours) | | angiotensin II (20 ng) | | phenylephrine (3 ug) | | | |

6 | absolute change in mean arterial blood pressure | WKY.SHRSP-(D1Wox29-D1Arb21)/Izm | male | 50 | mmHg | vehicle control condition (2 ul) (for 0 hours) then air-jet exposure (for 0 hours) then angiotensin II (20 ng) then phenylephrine (3 ug) | 84572 | vehicle control condition (2 ul) (for 0 hours) | | | air-jet exposure (for 0 hours) | | angiotensin II (20 ng) | | phenylephrine (3 ug) | | | |

4 | serum alanine aminotransferase activity level | F344/NHsd | not specified | 35 | U/l | fasting (between 12 and 15 hours) then vehicle control condition (for 1 days) | 84754 | fasting (between 12 and 15 hours) | | | vehicle control condition (for 1 days) | | | | | | | |

6 | absolute change in mean arterial blood pressure | WKY/Izm | male | -3 | mmHg | air-jet exposure (for 0 hours) then vehicle control condition (2 ul) (for 0 hours) | 84553 | air-jet exposure (for 0 hours) | | | vehicle control condition (2 ul) (for 0 hours) | | | | | | | |

6 | absolute change in mean arterial blood pressure | WKY.SHRSP-(D1Wox29-D1Arb21)/Izm | male | -1 | mmHg | air-jet exposure (for 0 hours) then vehicle control condition (2 ul) (for 0 hours) | 84555 | air-jet exposure (for 0 hours) | | | vehicle control condition (2 ul) (for 0 hours) | | | | | | | |

6 | absolute change in heart rate | WKY/Izm | male | 0 | beats/min | air-jet exposure (for 0 hours) then vehicle control condition (2 ul) (for 0 hours) | 84562 | air-jet exposure (for 0 hours) | | | vehicle control condition (2 ul) (for 0 hours) | | | | | | | |

6 | absolute change in heart rate | WKY.SHRSP-(D1Wox29-D1Arb21)/Izm | male | -5 | beats/min | air-jet exposure (for 0 hours) then vehicle control condition (2 ul) (for 0 hours) | 84564 | air-jet exposure (for 0 hours) | | | vehicle control condition (2 ul) (for 0 hours) | | | | | | | |

4 | serum alanine aminotransferase activity level | Hsd:SD | not specified | 30 | U/l | fasting (between 12 and 15 hours) then vehicle control condition (for 1 days) | 84757 | fasting (between 12 and 15 hours) | | | vehicle control condition (for 1 days) | | | | | | | |

18 | gestation period length | HanTac:WH | female | 23 | d | vehicle control condition (for 14 days) | 96583 | vehicle control condition (for 14 days) | | | | | | | | | | |

18 | litter size | HanTac:WH | female | 11.8 | | vehicle control condition (for 14 days) | 96597 | vehicle control condition (for 14 days) | | | | | | | | | | |

18 | number of male offspring to litter size ratio | HanTac:WH | female | 50.5 | % | vehicle control condition (for 14 days) | 96607 | vehicle control condition (for 14 days) | | | | | | | | | | |

17 | anogenital distance | HanTac:WH | female | 2.2 | mm | vehicle control condition (for 1 days) | 96622 | vehicle control condition (for 1 days) | | | | | | | | | | |

17 | areola mammae/nipple number | HanTac:WH | male | 0.1 | | vehicle control condition (for 14 days) | 96627 | vehicle control condition (for 14 days) | | | | | | | | | | |

18 | body weight | HanTac:WH | male | 28.6 | g | vehicle control condition (between 16 and 17 days) | 96632 | vehicle control condition (between 16 and 17 days) | | | | | | | | | | |

18 | left testis wet weight | HanTac:WH | male | 50.9 | mg | vehicle control condition (between 16 and 17 days) | 96642 | vehicle control condition (between 16 and 17 days) | | | | | | | | | | |

18 | ventral prostate gland wet weight | HanTac:WH | male | 0.0117 | g | vehicle control condition (between 16 and 17 days) | 96647 | vehicle control condition (between 16 and 17 days) | | | | | | | | | | |

15 | right ovary wet weight | HanTac:WH | female | 2.9 | mg | vehicle control condition (between 16 and 17 days) | 96692 | vehicle control condition (between 16 and 17 days) | | | | | | | | | | |

15 | thyroid gland wet weight | HanTac:WH | female | 4.7 | mg | vehicle control condition (between 16 and 17 days) | 96707 | vehicle control condition (between 16 and 17 days) | | | | | | | | | | |

15 | retroperitoneal fat pad weight | HanTac:WH | female | 0.0295 | g | vehicle control condition (between 16 and 17 days) | 96712 | vehicle control condition (between 16 and 17 days) | | | | | | | | | | |

18 | number of zygotes/embryos lost postimplantation to litter size ratio | HanTac:WH | female | 7.9 | % | vehicle control condition (for 14 days) | 96588 | vehicle control condition (for 14 days) | | | | | | | | | | |

18 | bulbourethral gland wet weight | HanTac:WH | male | 1.7 | mg | vehicle control condition (between 16 and 17 days) | 96667 | vehicle control condition (between 16 and 17 days) | | | | | | | | | | |

18 | retroperitoneal fat pad weight | HanTac:WH | male | 0.038 | g | vehicle control condition (between 16 and 17 days) | 96682 | vehicle control condition (between 16 and 17 days) | | | | | | | | | | |

15 | liver wet weight | HanTac:WH | female | 0.7988 | g | vehicle control condition (between 16 and 17 days) | 96702 | vehicle control condition (between 16 and 17 days) | | | | | | | | | | |

6 | left ventricular end-diastolic blood pressure | SD | male | 13 | mmHg | artificial aortocaval fistula (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98826 | artificial aortocaval fistula (for 2 days) | | | vehicle control condition (for 2 days) | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | | | | |

6 | left ventricular end-diastolic blood pressure | SD | male | 3 | mmHg | sham surgical control condition (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98827 | sham surgical control condition (for 2 days) | | | vehicle control condition (for 2 days) | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | left ventricular end-systolic blood pressure | SD | male | 56 | mmHg | artificial aortocaval fistula (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98838 | artificial aortocaval fistula (for 2 days) | | | vehicle control condition (for 2 days) | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | | | | |

6 | left ventricular end-systolic blood pressure | SD | male | 64 | mmHg | sham surgical control condition (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98839 | sham surgical control condition (for 2 days) | | | vehicle control condition (for 2 days) | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | heart left ventricle weight to body weight ratio | SD | male | 2.6 | mg/g | artificial aortocaval fistula (for 2 days) then vehicle control condition (for 2 days) | 98874 | artificial aortocaval fistula (for 2 days) | | | vehicle control condition (for 2 days) | | | | | | | |

6 | heart left ventricle weight to body weight ratio | SD | male | 2.3 | mg/g | sham surgical control condition (for 2 days) then vehicle control condition (for 2 days) | 98875 | sham surgical control condition (for 2 days) | | | vehicle control condition (for 2 days) | | | | | | | |

7 | creatinine clearance | WKY/NHsd | male | 3.1 | ml/min | standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) | 99179 | standard rat chow (for 8 days) | | | vehicle control condition (0.5 ml) (for 8 days) | | | | | | | |

7 | creatinine clearance | WKY/NHsd | male | 3.5 | ml/min | controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) | 99181 | controlled sodium content diet (8 %) (for 8 days) | | | 0.9% sodium chloride solution (0.9 %) (for 8 days) | | vehicle control condition (0.5 ml) (for 8 days) | | | | | |

6 | maximum rate of positive change in left ventricular blood pressure | SD | male | 8259 | mmHg/s | artificial aortocaval fistula (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98886 | artificial aortocaval fistula (for 2 days) | | | vehicle control condition (for 2 days) | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | | | | |

6 | maximum rate of positive change in left ventricular blood pressure | SD | male | 8231 | mmHg/s | sham surgical control condition (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98887 | sham surgical control condition (for 2 days) | | | vehicle control condition (for 2 days) | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | maximum rate of negative change in left ventricular blood pressure | SD | male | -6032 | mmHg/s | artificial aortocaval fistula (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98890 | artificial aortocaval fistula (for 2 days) | | | vehicle control condition (for 2 days) | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | | | | |

6 | maximum rate of negative change in left ventricular blood pressure | SD | male | -7197 | mmHg/s | sham surgical control condition (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98891 | sham surgical control condition (for 2 days) | | | vehicle control condition (for 2 days) | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | heart rate | SD | male | 420 | beats/min | artificial aortocaval fistula (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98801 | artificial aortocaval fistula (for 2 days) | | | vehicle control condition (for 2 days) | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | heart rate | SD | male | 380 | beats/min | sham surgical control condition (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98802 | sham surgical control condition (for 2 days) | | | vehicle control condition (for 2 days) | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | | | | |

6 | mean arterial blood pressure | SD | male | 72 | mmHg | artificial aortocaval fistula (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98814 | artificial aortocaval fistula (for 2 days) | | | vehicle control condition (for 2 days) | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | | | | |

6 | mean arterial blood pressure | SD | male | 86 | mmHg | sham surgical control condition (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98815 | sham surgical control condition (for 2 days) | | | vehicle control condition (for 2 days) | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

10 | blood glucose level | WKY | male | 160.56 | mg/dl | vehicle control condition (1 null) | 99101 | vehicle control condition (1 null) | | | | | | | | | | |

10 | body weight | WKY | male | 450.39 | g | vehicle control condition (1 null) | 99107 | vehicle control condition (1 null) | | | | | | | | | | |

10 | single kidney wet weight as percentage of body weight | WKY | male | 0.341 | % | vehicle control condition (1 null) | 99113 | vehicle control condition (1 null) | | | | | | | | | | |

10 | timed urine volume | WKY | male | 17.1 | ml/d | vehicle control condition (1 null) | 99119 | vehicle control condition (1 null) | | | | | | | | | | |

11 | blood glucose level | WKY | male | 76 | mg/dl | unilateral nephrectomy (for 28 days) then vehicle control condition | 99970 | unilateral nephrectomy (for 28 days) | | | vehicle control condition | | | | | | | |

17 | blood glucose level | WKY | male | 324 | mg/dl | unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition | 99971 | unilateral nephrectomy (for 28 days) | | | streptozotocin (35 mg/kg) | | vehicle control condition | | | | | |

11 | hematocrit | WKY | male | 45.2 | % | unilateral nephrectomy (for 28 days) then vehicle control condition | 99975 | unilateral nephrectomy (for 28 days) | | | vehicle control condition | | | | | | | |

17 | hematocrit | WKY | male | 44.8 | % | unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition | 99976 | unilateral nephrectomy (for 28 days) | | | streptozotocin (35 mg/kg) | | vehicle control condition | | | | | |

11 | glomerular filtration rate to body weight ratio | WKY | male | 0.517 | ml/min/100g | unilateral nephrectomy (for 28 days) then vehicle control condition | 99980 | unilateral nephrectomy (for 28 days) | | | vehicle control condition | | | | | | | |

17 | glomerular filtration rate to body weight ratio | WKY | male | 0.496 | ml/min/100g | unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition | 99981 | unilateral nephrectomy (for 28 days) | | | streptozotocin (35 mg/kg) | | vehicle control condition | | | | | |

11 | renal filtration fraction | WKY | male | 0.23 | | unilateral nephrectomy (for 28 days) then vehicle control condition | 99985 | unilateral nephrectomy (for 28 days) | | | vehicle control condition | | | | | | | |

17 | renal filtration fraction | WKY | male | 0.293 | | unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition | 99986 | unilateral nephrectomy (for 28 days) | | | streptozotocin (35 mg/kg) | | vehicle control condition | | | | | |

11 | renal plasma flow to body weight ratio | WKY | male | 2.28 | ml/min/100g | unilateral nephrectomy (for 28 days) then vehicle control condition | 99990 | unilateral nephrectomy (for 28 days) | | | vehicle control condition | | | | | | | |

17 | renal plasma flow to body weight ratio | WKY | male | 1.72 | ml/min/100g | unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition | 99991 | unilateral nephrectomy (for 28 days) | | | streptozotocin (35 mg/kg) | | vehicle control condition | | | | | |

11 | renal vascular resistance | WKY | male | 6.3 | mmHg/ml/min | unilateral nephrectomy (for 28 days) then vehicle control condition | 99995 | unilateral nephrectomy (for 28 days) | | | vehicle control condition | | | | | | | |

17 | renal vascular resistance | WKY | male | 16.7 | mmHg/ml/min | unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition | 99996 | unilateral nephrectomy (for 28 days) | | | streptozotocin (35 mg/kg) | | vehicle control condition | | | | | |

11 | timed urine volume | WKY | male | 11.664 | ml/d | unilateral nephrectomy (for 28 days) then vehicle control condition | 100000 | unilateral nephrectomy (for 28 days) | | | vehicle control condition | | | | | | | |

17 | timed urine volume | WKY | male | 39.456 | ml/d | unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition | 100001 | unilateral nephrectomy (for 28 days) | | | streptozotocin (35 mg/kg) | | vehicle control condition | | | | | |

7 | heart left ventricular end-diastolic diameter | SS-Nppbem2Mcwi-/- | male | 7.52 | mm | vehicle control condition | 99768 | vehicle control condition | | | | | | | | | | |

7 | heart left ventricular end-diastolic diameter | SS-Nppbem2Mcwi-/- | male | 8.68 | mm | vehicle control condition | 99770 | vehicle control condition | | | | | | | | | | |

7 | heart left ventricular end-diastolic diameter | SS-Nppbem2Mcwi-/- | male | 7.99 | mm | vehicle control condition | 99772 | vehicle control condition | | | | | | | | | | |

7 | heart left ventricle end-diastolic posterior wall thickness | SS-Nppbem2Mcwi-/- | male | 2.03 | mm | vehicle control condition | 99774 | vehicle control condition | | | | | | | | | | |

7 | heart left ventricle end-systolic posterior wall thickness | SS-Nppbem2Mcwi-/- | male | 3.29 | mm | vehicle control condition | 99792 | vehicle control condition | | | | | | | | | | |

7 | heart left ventricle fractional shortening | SS-Nppbem2Mcwi-/- | male | 47.3 | % | vehicle control condition | 99804 | vehicle control condition | | | | | | | | | | |

7 | diastolic blood pressure | SS-Nppbem2Mcwi-/- | male | 128 | mmHg | vehicle control condition | 99822 | vehicle control condition | | | | | | | | | | |

7 | diastolic blood pressure | SS-Nppbem2Mcwi-/- | male | 142 | mmHg | vehicle control condition | 99824 | vehicle control condition | | | | | | | | | | |

7 | diastolic blood pressure | SS-Nppbem2Mcwi-/- | male | 145 | mmHg | vehicle control condition | 99826 | vehicle control condition | | | | | | | | | | |

7 | systolic blood pressure | SS-Nppbem2Mcwi-/- | male | 172 | mmHg | vehicle control condition | 99828 | vehicle control condition | | | | | | | | | | |

7 | systolic blood pressure | SS-Nppbem2Mcwi-/- | male | 195 | mmHg | vehicle control condition | 99830 | vehicle control condition | | | | | | | | | | |

7 | systolic blood pressure | SS-Nppbem2Mcwi-/- | male | 197 | mmHg | vehicle control condition | 99832 | vehicle control condition | | | | | | | | | | |

7 | mean arterial blood pressure | SS-Nppbem2Mcwi-/- | male | 142 | mmHg | vehicle control condition | 99834 | vehicle control condition | | | | | | | | | | |

7 | mean arterial blood pressure | SS-Nppbem2Mcwi-/- | male | 158 | mmHg | vehicle control condition | 99836 | vehicle control condition | | | | | | | | | | |

7 | mean arterial blood pressure | SS-Nppbem2Mcwi-/- | male | 162 | mmHg | vehicle control condition | 99838 | vehicle control condition | | | | | | | | | | |

7 | timed urine volume | SS-Nppbem2Mcwi-/- | male | 14.7 | ml/d | vehicle control condition | 99840 | vehicle control condition | | | | | | | | | | |

7 | timed urine volume | SS-Nppbem2Mcwi-/- | male | 21.1 | ml/d | vehicle control condition | 99842 | vehicle control condition | | | | | | | | | | |

7 | timed urine volume | SS-Nppbem2Mcwi-/- | male | 19.5 | ml/d | vehicle control condition | 99844 | vehicle control condition | | | | | | | | | | |

7 | body weight | WKY | male | 268 | g | unilateral nephrectomy (for 28 days) then vehicle control condition | 99935 | unilateral nephrectomy (for 28 days) | | | vehicle control condition | | | | | | | |

8 | body weight | WKY | male | 215 | g | unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition | 99936 | unilateral nephrectomy (for 28 days) | | | streptozotocin (35 mg/kg) | | vehicle control condition | | | | | |

7 | blood glucose level | WKY | male | 74 | mg/dl | unilateral nephrectomy (for 28 days) then vehicle control condition | 99940 | unilateral nephrectomy (for 28 days) | | | vehicle control condition | | | | | | | |

8 | blood glucose level | WKY | male | 350 | mg/dl | unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition | 99941 | unilateral nephrectomy (for 28 days) | | | streptozotocin (35 mg/kg) | | vehicle control condition | | | | | |

7 | glomerular filtration rate to body weight ratio | WKY | male | 0.494 | ml/min/100g | unilateral nephrectomy (for 28 days) then vehicle control condition | 99945 | unilateral nephrectomy (for 28 days) | | | vehicle control condition | | | | | | | |

8 | glomerular filtration rate to body weight ratio | WKY | male | 0.792 | ml/min/100g | unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition | 99946 | unilateral nephrectomy (for 28 days) | | | streptozotocin (35 mg/kg) | | vehicle control condition | | | | | |

7 | renal plasma flow to body weight ratio | WKY | male | 2.16 | ml/min/100g | unilateral nephrectomy (for 28 days) then vehicle control condition | 99950 | unilateral nephrectomy (for 28 days) | | | vehicle control condition | | | | | | | |

8 | renal plasma flow to body weight ratio | WKY | male | 3.09 | ml/min/100g | unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition | 99951 | unilateral nephrectomy (for 28 days) | | | streptozotocin (35 mg/kg) | | vehicle control condition | | | | | |

7 | renal filtration fraction | WKY | male | 0.233 | | unilateral nephrectomy (for 28 days) then vehicle control condition | 99955 | unilateral nephrectomy (for 28 days) | | | vehicle control condition | | | | | | | |

8 | renal filtration fraction | WKY | male | 0.26 | | unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition | 99956 | unilateral nephrectomy (for 28 days) | | | streptozotocin (35 mg/kg) | | vehicle control condition | | | | | |

7 | renal vascular resistance | WKY | male | 10 | mmHg/ml/min | unilateral nephrectomy (for 28 days) then vehicle control condition | 99960 | unilateral nephrectomy (for 28 days) | | | vehicle control condition | | | | | | | |

8 | renal vascular resistance | WKY | male | 9 | mmHg/ml/min | unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition | 99961 | unilateral nephrectomy (for 28 days) | | | streptozotocin (35 mg/kg) | | vehicle control condition | | | | | |

7 | timed urine volume | WKY | male | 12.384 | ml/d | unilateral nephrectomy (for 28 days) then vehicle control condition | 99965 | unilateral nephrectomy (for 28 days) | | | vehicle control condition | | | | | | | |

8 | timed urine volume | WKY | male | 23.472 | ml/d | unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition | 99966 | unilateral nephrectomy (for 28 days) | | | streptozotocin (35 mg/kg) | | vehicle control condition | | | | | |

7 | heart left ventricle end-systolic posterior wall thickness | SS-Nppbem2Mcwi-/- | male | 3.17 | mm | vehicle control condition | 99794 | vehicle control condition | | | | | | | | | | |

7 | heart left ventricle end-systolic posterior wall thickness | SS-Nppbem2Mcwi-/- | male | 3.41 | mm | vehicle control condition | 99796 | vehicle control condition | | | | | | | | | | |

7 | ejection fraction | SS-Nppbem2Mcwi-/- | male | 83.3 | % | vehicle control condition | 99798 | vehicle control condition | | | | | | | | | | |

7 | ejection fraction | SS-Nppbem2Mcwi-/- | male | 80.2 | % | vehicle control condition | 99800 | vehicle control condition | | | | | | | | | | |

7 | ejection fraction | SS-Nppbem2Mcwi-/- | male | 77.4 | % | vehicle control condition | 99802 | vehicle control condition | | | | | | | | | | |

7 | skin chloride level to skin dry weight ratio | WKY/NHsd | male | 0.051 | mmol/g | standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) | 99135 | standard rat chow (for 8 days) | | | vehicle control condition (0.5 ml) (for 8 days) | | | | | | | |

7 | skin chloride level to skin dry weight ratio | WKY/NHsd | male | 0.068 | mmol/g | controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) | 99137 | controlled sodium content diet (8 %) (for 8 days) | | | 0.9% sodium chloride solution (0.9 %) (for 8 days) | | vehicle control condition (0.5 ml) (for 8 days) | | | | | |

7 | skin water level to skin dry weight ratio | WKY/NHsd | male | 1.432 | ml/g | controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) | 99141 | controlled sodium content diet (8 %) (for 8 days) | | | 0.9% sodium chloride solution (0.9 %) (for 8 days) | | vehicle control condition (0.5 ml) (for 8 days) | | | | | |

7 | skin potassium level plus skin sodium level to skin water level ratio | WKY/NHsd | male | 0.17 | | standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) | 99143 | standard rat chow (for 8 days) | | | vehicle control condition (0.5 ml) (for 8 days) | | | | | | | |

7 | skin potassium level plus skin sodium level to skin water level ratio | WKY/NHsd | male | 0.176 | | controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) | 99145 | controlled sodium content diet (8 %) (for 8 days) | | | 0.9% sodium chloride solution (0.9 %) (for 8 days) | | vehicle control condition (0.5 ml) (for 8 days) | | | | | |

7 | skin chloride level to skin water level ratio | WKY/NHsd | male | 90 | mmol/l | standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) | 99147 | standard rat chow (for 8 days) | | | vehicle control condition (0.5 ml) (for 8 days) | | | | | | | |

7 | skin chloride level to skin water level ratio | WKY/NHsd | male | 101 | mmol/l | controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) | 99149 | controlled sodium content diet (8 %) (for 8 days) | | | 0.9% sodium chloride solution (0.9 %) (for 8 days) | | vehicle control condition (0.5 ml) (for 8 days) | | | | | |

7 | skin chloride level to skin water level ratio | WKY/NHsd | male | 42 | mmol/l | standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) | 99151 | standard rat chow (for 8 days) | | | vehicle control condition (0.5 ml) (for 8 days) | | | | | | | |

7 | skin chloride level to skin water level ratio | WKY/NHsd | male | 48 | mmol/l | controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) | 99153 | controlled sodium content diet (8 %) (for 8 days) | | | 0.9% sodium chloride solution (0.9 %) (for 8 days) | | vehicle control condition (0.5 ml) (for 8 days) | | | | | |

7 | skin potassium level to skin water level ratio | WKY/NHsd | male | 80 | mmol/l | standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) | 99155 | standard rat chow (for 8 days) | | | vehicle control condition (0.5 ml) (for 8 days) | | | | | | | |

7 | skin potassium level to skin water level ratio | WKY/NHsd | male | 71 | mmol/l | controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) | 99157 | controlled sodium content diet (8 %) (for 8 days) | | | 0.9% sodium chloride solution (0.9 %) (for 8 days) | | vehicle control condition (0.5 ml) (for 8 days) | | | | | |

7 | plasma sodium level | WKY/NHsd | male | 143.7 | mmol/l | standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) | 99159 | standard rat chow (for 8 days) | | | vehicle control condition (0.5 ml) (for 8 days) | | | | | | | |

7 | plasma sodium level | WKY/NHsd | male | 141.4 | mmol/l | controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) | 99161 | controlled sodium content diet (8 %) (for 8 days) | | | 0.9% sodium chloride solution (0.9 %) (for 8 days) | | vehicle control condition (0.5 ml) (for 8 days) | | | | | |

7 | plasma potassium level | WKY/NHsd | male | 3.9 | mmol/l | standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) | 99163 | standard rat chow (for 8 days) | | | vehicle control condition (0.5 ml) (for 8 days) | | | | | | | |

7 | plasma potassium level | WKY/NHsd | male | 4.2 | mmol/l | controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) | 99165 | controlled sodium content diet (8 %) (for 8 days) | | | 0.9% sodium chloride solution (0.9 %) (for 8 days) | | vehicle control condition (0.5 ml) (for 8 days) | | | | | |

7 | plasma chloride level | WKY/NHsd | male | 98.2 | mmol/l | standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) | 99167 | standard rat chow (for 8 days) | | | vehicle control condition (0.5 ml) (for 8 days) | | | | | | | |

7 | plasma creatinine level | WKY/NHsd | male | 0.30882306 | mg/dl | standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) | 99171 | standard rat chow (for 8 days) | | | vehicle control condition (0.5 ml) (for 8 days) | | | | | | | |

7 | plasma creatinine level | WKY/NHsd | male | 0.30090452 | mg/dl | controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) | 99173 | controlled sodium content diet (8 %) (for 8 days) | | | 0.9% sodium chloride solution (0.9 %) (for 8 days) | | vehicle control condition (0.5 ml) (for 8 days) | | | | | |

7 | plasma cystatin C level | WKY/NHsd | male | 4 | mg/l | standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) | 99175 | standard rat chow (for 8 days) | | | vehicle control condition (0.5 ml) (for 8 days) | | | | | | | |

7 | plasma cystatin C level | WKY/NHsd | male | 3.5 | mg/l | controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) | 99177 | controlled sodium content diet (8 %) (for 8 days) | | | 0.9% sodium chloride solution (0.9 %) (for 8 days) | | vehicle control condition (0.5 ml) (for 8 days) | | | | | |

7 | heart left ventricle fractional shortening | SS-Nppbem2Mcwi-/- | male | 44.3 | % | vehicle control condition | 99806 | vehicle control condition | | | | | | | | | | |

7 | heart left ventricle fractional shortening | SS-Nppbem2Mcwi-/- | male | 41.6 | % | vehicle control condition | 99808 | vehicle control condition | | | | | | | | | | |

7 | heart left ventricle weight | SS-Nppbem2Mcwi-/- | male | 1.53 | g | vehicle control condition | 99810 | vehicle control condition | | | | | | | | | | |

7 | heart left ventricle weight | SS-Nppbem2Mcwi-/- | male | 1.67 | g | vehicle control condition | 99812 | vehicle control condition | | | | | | | | | | |

7 | heart left ventricle weight | SS-Nppbem2Mcwi-/- | male | 1.78 | g | vehicle control condition | 99814 | vehicle control condition | | | | | | | | | | |

7 | heart rate | SS-Nppbem2Mcwi-/- | male | 382 | beats/min | vehicle control condition | 99816 | vehicle control condition | | | | | | | | | | |

7 | heart rate | SS-Nppbem2Mcwi-/- | male | 349 | beats/min | vehicle control condition | 99818 | vehicle control condition | | | | | | | | | | |

7 | heart rate | SS-Nppbem2Mcwi-/- | male | 327 | beats/min | vehicle control condition | 99820 | vehicle control condition | | | | | | | | | | |

7 | skin sodium level to skin dry weight ratio | WKY/NHsd | male | 0.11 | REQUEST NEW VALUE | standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) | 99131 | standard rat chow (for 8 days) | | | vehicle control condition (0.5 ml) (for 8 days) | | | | | | | |

7 | skin sodium level to skin dry weight ratio | WKY/NHsd | male | 0.144 | REQUEST NEW VALUE | controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) | 99133 | controlled sodium content diet (8 %) (for 8 days) | | | 0.9% sodium chloride solution (0.9 %) (for 8 days) | | vehicle control condition (0.5 ml) (for 8 days) | | | | | |

7 | plasma chloride level | WKY/NHsd | male | 104.8 | mmol/l | controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) | 99169 | controlled sodium content diet (8 %) (for 8 days) | | | 0.9% sodium chloride solution (0.9 %) (for 8 days) | | vehicle control condition (0.5 ml) (for 8 days) | | | | | |

7 | urine sodium excretion rate | WKY/NHsd | male | 1 | mEq/d | standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) | 99183 | standard rat chow (for 8 days) | | | vehicle control condition (0.5 ml) (for 8 days) | | | | | | | |

7 | urine sodium excretion rate | WKY/NHsd | male | 41.9 | mEq/d | controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) | 99185 | controlled sodium content diet (8 %) (for 8 days) | | | 0.9% sodium chloride solution (0.9 %) (for 8 days) | | vehicle control condition (0.5 ml) (for 8 days) | | | | | |

7 | mean arterial blood pressure | WKY/NHsd | male | 101 | mmHg | standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) | 99187 | standard rat chow (for 8 days) | | | vehicle control condition (0.5 ml) (for 8 days) | | | | | | | |

7 | mean arterial blood pressure | WKY/NHsd | male | 116 | mmHg | controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days) | 99189 | controlled sodium content diet (8 %) (for 8 days) | | | 0.9% sodium chloride solution (0.9 %) (for 8 days) | | vehicle control condition (0.5 ml) (for 8 days) | | | | | |

6 | right ventricular end-systolic blood pressure | SS/JrHsdMcwi | male | 26 | mmHg | vehicle control condition | 106796 | vehicle control condition | | | | | | | | | | |

15 | right ventricular end-systolic blood pressure | SS-Sod3m1Mcwi | male | 25.1 | mmHg | vehicle control condition | 106797 | vehicle control condition | | | | | | | | | | |

7 | body weight | SS-Nppbem2Mcwi-/- | male | 425 | g | vehicle control condition | 99758 | vehicle control condition | | | | | | | | | | |

7 | body weight | SS-Nppbem2Mcwi-/- | male | 452 | g | vehicle control condition | 99760 | vehicle control condition | | | | | | | | | | |

7 | heart intraventricular end-diastolic wall thickness | SS-Nppbem2Mcwi-/- | male | 2.01 | mm | vehicle control condition | 99762 | vehicle control condition | | | | | | | | | | |

7 | heart intraventricular end-diastolic wall thickness | SS-Nppbem2Mcwi-/- | male | 1.92 | mm | vehicle control condition | 99764 | vehicle control condition | | | | | | | | | | |

7 | heart intraventricular end-diastolic wall thickness | SS-Nppbem2Mcwi-/- | male | 2.26 | mm | vehicle control condition | 99766 | vehicle control condition | | | | | | | | | | |

7 | heart left ventricle end-diastolic posterior wall thickness | SS-Nppbem2Mcwi-/- | male | 1.89 | mm | vehicle control condition | 99776 | vehicle control condition | | | | | | | | | | |

7 | heart left ventricle end-diastolic posterior wall thickness | SS-Nppbem2Mcwi-/- | male | 2.17 | mm | vehicle control condition | 99778 | vehicle control condition | | | | | | | | | | |

7 | heart intraventricular end-systolic wall thickness | SS-Nppbem2Mcwi-/- | male | 3.19 | mm | vehicle control condition | 99780 | vehicle control condition | | | | | | | | | | |

7 | heart intraventricular end-systolic wall thickness | SS-Nppbem2Mcwi-/- | male | 3.24 | mm | vehicle control condition | 99782 | vehicle control condition | | | | | | | | | | |

7 | heart intraventricular end-systolic wall thickness | SS-Nppbem2Mcwi-/- | male | 3.48 | mm | vehicle control condition | 99784 | vehicle control condition | | | | | | | | | | |

7 | heart left ventricle end-systolic diameter | SS-Nppbem2Mcwi-/- | male | 3.98 | mm | vehicle control condition | 99786 | vehicle control condition | | | | | | | | | | |

7 | heart left ventricle end-systolic diameter | SS-Nppbem2Mcwi-/- | male | 4.83 | mm | vehicle control condition | 99788 | vehicle control condition | | | | | | | | | | |

7 | heart left ventricle end-systolic diameter | SS-Nppbem2Mcwi-/- | male | 4.67 | mm | vehicle control condition | 99790 | vehicle control condition | | | | | | | | | | |

7 | body weight | MW | male | 220 | g | unilateral nephrectomy (for 14 days) then vehicle control condition | 101142 | unilateral nephrectomy (for 14 days) | | | vehicle control condition | | | | | | | |

7 | body weight | MW | male | 260 | g | unilateral nephrectomy (for 14 days) then vehicle control condition | 101146 | unilateral nephrectomy (for 14 days) | | | vehicle control condition | | | | | | | |

7 | body weight | MW | male | 286 | g | unilateral nephrectomy (for 70 days) then vehicle control condition | 101154 | unilateral nephrectomy (for 70 days) | | | vehicle control condition | | | | | | | |

7 | systolic blood pressure | MW | male | 118 | mmHg | unilateral nephrectomy (for 14 days) then vehicle control condition | 101159 | unilateral nephrectomy (for 14 days) | | | vehicle control condition | | | | | | | |

7 | systolic blood pressure | MW | male | 118 | mmHg | unilateral nephrectomy (for 14 days) then vehicle control condition | 101163 | unilateral nephrectomy (for 14 days) | | | vehicle control condition | | | | | | | |

7 | systolic blood pressure | MW | male | 122 | mmHg | unilateral nephrectomy (for 70 days) then vehicle control condition | 101168 | unilateral nephrectomy (for 70 days) | | | vehicle control condition | | | | | | | |

7 | mean arterial blood pressure | MW | male | 108 | mmHg | unilateral nephrectomy (for 70 days) then vehicle control condition | 101173 | unilateral nephrectomy (for 70 days) | | | vehicle control condition | | | | | | | |

7 | blood urea nitrogen level | MW | male | 25 | mg/dl | unilateral nephrectomy (for 14 days) then vehicle control condition | 101178 | unilateral nephrectomy (for 14 days) | | | vehicle control condition | | | | | | | |

7 | blood urea nitrogen level | MW | male | 25 | mg/dl | unilateral nephrectomy (for 14 days) then vehicle control condition | 101182 | unilateral nephrectomy (for 14 days) | | | vehicle control condition | | | | | | | |

7 | blood urea nitrogen level | MW | male | 26 | mg/dl | unilateral nephrectomy (for 70 days) then vehicle control condition | 101187 | unilateral nephrectomy (for 70 days) | | | vehicle control condition | | | | | | | |

7 | urine protein excretion rate | MW | male | 11 | mg/d | unilateral nephrectomy (for 14 days) then vehicle control condition | 101192 | unilateral nephrectomy (for 14 days) | | | vehicle control condition | | | | | | | |

7 | urine protein excretion rate | MW | male | 23 | mg/d | unilateral nephrectomy (for 14 days) then vehicle control condition | 101196 | unilateral nephrectomy (for 14 days) | | | vehicle control condition | | | | | | | |

7 | urine protein excretion rate | MW | male | 18 | mg/d | unilateral nephrectomy (for 70 days) then vehicle control condition | 101200 | unilateral nephrectomy (for 70 days) | | | vehicle control condition | | | | | | | |

18 | urine protein excretion rate | MW | male | 8 | mg/d | vehicle control condition | 101203 | vehicle control condition | | | | | | | | | | |

7 | blood glomerular filtration rate | MW | male | 1.46 | ml/min | unilateral nephrectomy (for 70 days) then vehicle control condition | 101205 | unilateral nephrectomy (for 70 days) | | | vehicle control condition | | | | | | | |

5 | blood sodium level | SHR/NCrlCrlj | male | 140 | mmol/l | unilateral nephrectomy (for 42 days) then vehicle control condition (for 28 days) | 101238 | unilateral nephrectomy (for 42 days) | | | vehicle control condition (for 28 days) | | | | | | | |

5 | blood potassium level | SHR/NCrlCrlj | male | 5.7 | mmol/l | unilateral nephrectomy (for 42 days) then vehicle control condition (for 28 days) | 101242 | unilateral nephrectomy (for 42 days) | | | vehicle control condition (for 28 days) | | | | | | | |

5 | serum creatinine level | SHR/NCrlCrlj | male | 0.95 | mg/dl | unilateral nephrectomy (for 42 days) then vehicle control condition (for 28 days) | 101246 | unilateral nephrectomy (for 42 days) | | | vehicle control condition (for 28 days) | | | | | | | |

5 | blood urea nitrogen level | SHR/NCrlCrlj | male | 72 | mg/dl | unilateral nephrectomy (for 42 days) then vehicle control condition (for 28 days) | 101250 | unilateral nephrectomy (for 42 days) | | | vehicle control condition (for 28 days) | | | | | | | |

15 | creatinine clearance to body weight ratio | SHR/NCrlCrlj | male | 0.3556 | ml/min/100g | unilateral nephrectomy (for 14 days) then vehicle control condition | 101254 | unilateral nephrectomy (for 14 days) | | | vehicle control condition | | | | | | | |

5 | creatinine clearance to body weight ratio | SHR/NCrlCrlj | male | 0.14 | ml/min/100g | unilateral nephrectomy (for 42 days) then vehicle control condition (for 28 days) | 101258 | unilateral nephrectomy (for 42 days) | | | vehicle control condition (for 28 days) | | | | | | | |

5 | plasma renin activity level | SHR/NCrlCrlj | male | 1.3 | ng/ml/h | unilateral nephrectomy (for 42 days) then vehicle control condition (for 28 days) | 101262 | unilateral nephrectomy (for 42 days) | | | vehicle control condition (for 28 days) | | | | | | | |

5 | plasma aldosterone level | SHR/NCrlCrlj | male | 389 | pg/ml | unilateral nephrectomy (for 42 days) then vehicle control condition (for 28 days) | 101266 | unilateral nephrectomy (for 42 days) | | | vehicle control condition (for 28 days) | | | | | | | |

5 | plasma angiotensin I level | SHR/NCrlCrlj | male | 169 | pg/ml | unilateral nephrectomy (for 42 days) then vehicle control condition (for 28 days) | 101270 | unilateral nephrectomy (for 42 days) | | | vehicle control condition (for 28 days) | | | | | | | |

5 | plasma angiotensin II level | SHR/NCrlCrlj | male | 11.6 | pg/ml | unilateral nephrectomy (for 42 days) then vehicle control condition (for 28 days) | 101274 | unilateral nephrectomy (for 42 days) | | | vehicle control condition (for 28 days) | | | | | | | |

6 | mean arterial blood pressure | Crlj:WI | male | 138 | mmHg | air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) | 103015 | air oxygen content (21 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | | | | | | |

7 | mean arterial blood pressure | Crlj:WI | male | 128 | mmHg | air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) | 103016 | air oxygen content (5 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | | | | | | |

5 | mean arterial blood pressure | GK | male | 137 | mmHg | air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) | 103017 | air oxygen content (21 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | | | | | | |

7 | mean arterial blood pressure | GK | male | 147 | mmHg | air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) | 103018 | air oxygen content (5 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | | | | | | |

6 | mean arterial blood pressure | Crlj:WI | male | 90 | mmHg | air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) | 103019 | air oxygen content (21 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | acetylcholine (5 ug/kg/min) (for 0.1 hours) | | | | | |

7 | mean arterial blood pressure | Crlj:WI | male | 96 | mmHg | air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) | 103020 | air oxygen content (5 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | acetylcholine (5 ug/kg/min) (for 0.1 hours) | | | | | |

5 | mean arterial blood pressure | GK | male | 108 | mmHg | air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) | 103021 | air oxygen content (21 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | acetylcholine (5 ug/kg/min) (for 0.1 hours) | | | | | |

7 | mean arterial blood pressure | GK | male | 111 | mmHg | air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) | 103022 | air oxygen content (5 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | acetylcholine (5 ug/kg/min) (for 0.1 hours) | | | | | |

6 | mean arterial blood pressure | Crlj:WI | male | 99 | mmHg | air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) | 103023 | air oxygen content (21 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | acetylcholine (5 ug/kg/min) (for 0.1 hours) | | sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) | | | |

7 | mean arterial blood pressure | Crlj:WI | male | 109 | mmHg | air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) | 103024 | air oxygen content (5 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | acetylcholine (5 ug/kg/min) (for 0.1 hours) | | sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) | | | |

7 | mean arterial blood pressure | GK | male | 123 | mmHg | air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) | 103026 | air oxygen content (5 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | acetylcholine (5 ug/kg/min) (for 0.1 hours) | | sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) | | | |

6 | mean arterial blood pressure | Crlj:WI | male | 155 | mmHg | air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) then meclofenamate (3 mg/kg) (for 0.5 hours) | 103027 | air oxygen content (21 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | acetylcholine (5 ug/kg/min) (for 0.1 hours) | | sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) | NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) | | meclofenamate (3 mg/kg) (for 0.5 hours) |

7 | mean arterial blood pressure | Crlj:WI | male | 136 | mmHg | air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) | 103028 | air oxygen content (5 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | acetylcholine (5 ug/kg/min) (for 0.1 hours) | | sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) | NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) | meclofenamate (3 mg/kg) (for 0.5 hours) | |

5 | mean arterial blood pressure | GK | male | 151 | mmHg | air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) | 103029 | air oxygen content (21 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | acetylcholine (5 ug/kg/min) (for 0.1 hours) | | sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) | NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) | meclofenamate (3 mg/kg) (for 0.5 hours) | |

7 | mean arterial blood pressure | GK | male | 140 | mmHg | air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) | 103030 | air oxygen content (5 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | acetylcholine (5 ug/kg/min) (for 0.1 hours) | | sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) | NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) | meclofenamate (3 mg/kg) (for 0.5 hours) | |

6 | mean arterial blood pressure | Crlj:WI | male | 120 | mmHg | air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) | 103031 | air oxygen content (21 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | acetylcholine (5 ug/kg/min) (for 0.1 hours) | | sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) | NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) | meclofenamate (3 mg/kg) (for 0.5 hours) | acetylcholine (5 ug/kg/min) (for 0.1 hours) |

7 | mean arterial blood pressure | Crlj:WI | male | 102 | mmHg | air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) | 103032 | air oxygen content (5 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | acetylcholine (5 ug/kg/min) (for 0.1 hours) | | sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) | NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) | meclofenamate (3 mg/kg) (for 0.5 hours) | acetylcholine (5 ug/kg/min) (for 0.1 hours) |

5 | mean arterial blood pressure | GK | male | 137 | mmHg | air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) | 103033 | air oxygen content (21 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | acetylcholine (5 ug/kg/min) (for 0.1 hours) | | sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) | NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) | meclofenamate (3 mg/kg) (for 0.5 hours) | acetylcholine (5 ug/kg/min) (for 0.1 hours) |

7 | mean arterial blood pressure | GK | male | 143 | mmHg | air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) | 103034 | air oxygen content (5 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | acetylcholine (5 ug/kg/min) (for 0.1 hours) | | sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) | NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) | meclofenamate (3 mg/kg) (for 0.5 hours) | acetylcholine (5 ug/kg/min) (for 0.1 hours) |

6 | heart rate | Crlj:WI | male | 372 | beats/min | air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) | 103035 | air oxygen content (21 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | | | | | | |

7 | heart rate | Crlj:WI | male | 415 | beats/min | air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) | 103036 | air oxygen content (5 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | | | | | | |

5 | heart rate | GK | male | 395 | beats/min | air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) | 103037 | air oxygen content (21 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | | | | | | |

7 | heart rate | GK | male | 147 | beats/min | air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) | 103038 | air oxygen content (5 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | | | | | | |

6 | heart rate | Crlj:WI | male | 90 | beats/min | air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) | 103039 | air oxygen content (21 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | acetylcholine (5 ug/kg/min) (for 0.1 hours) | | | | | |

7 | heart rate | Crlj:WI | male | 380 | beats/min | air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) | 103040 | air oxygen content (5 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | acetylcholine (5 ug/kg/min) (for 0.1 hours) | | | | | |

5 | heart rate | GK | male | 366 | beats/min | air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) | 103041 | air oxygen content (21 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | acetylcholine (5 ug/kg/min) (for 0.1 hours) | | | | | |

7 | heart rate | Crlj:WI | male | 379 | beats/min | air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) | 103042 | air oxygen content (5 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | acetylcholine (5 ug/kg/min) (for 0.1 hours) | | sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) | | | |

6 | heart rate | Crlj:WI | male | 351 | beats/min | air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) | 103043 | air oxygen content (21 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | acetylcholine (5 ug/kg/min) (for 0.1 hours) | | sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) | | | |

7 | heart rate | Crlj:WI | male | 384 | beats/min | air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) | 103044 | air oxygen content (5 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | acetylcholine (5 ug/kg/min) (for 0.1 hours) | | sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) | | | |

5 | heart rate | GK | male | 366 | beats/min | air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) | 103045 | air oxygen content (21 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | acetylcholine (5 ug/kg/min) (for 0.1 hours) | | sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) | | | |

7 | heart rate | GK | male | 390 | beats/min | air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) | 103046 | air oxygen content (5 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | acetylcholine (5 ug/kg/min) (for 0.1 hours) | | sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) | | | |

6 | heart rate | Crlj:WI | male | 288 | beats/min | air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) then meclofenamate (3 mg/kg) (for 0.5 hours) | 103047 | air oxygen content (21 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | acetylcholine (5 ug/kg/min) (for 0.1 hours) | | sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) | NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) | | meclofenamate (3 mg/kg) (for 0.5 hours) |

7 | heart rate | Crlj:WI | male | 287 | beats/min | air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) | 103048 | air oxygen content (5 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | acetylcholine (5 ug/kg/min) (for 0.1 hours) | | sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) | NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) | meclofenamate (3 mg/kg) (for 0.5 hours) | |

5 | heart rate | GK | male | 301 | beats/min | air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) | 103049 | air oxygen content (21 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | acetylcholine (5 ug/kg/min) (for 0.1 hours) | | sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) | NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) | meclofenamate (3 mg/kg) (for 0.5 hours) | |

7 | heart rate | GK | male | 344 | beats/min | air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) | 103050 | air oxygen content (5 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | acetylcholine (5 ug/kg/min) (for 0.1 hours) | | sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) | NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) | meclofenamate (3 mg/kg) (for 0.5 hours) | |

6 | heart rate | Crlj:WI | male | 275 | beats/min | air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) | 103051 | air oxygen content (21 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | acetylcholine (5 ug/kg/min) (for 0.1 hours) | | sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) | NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) | meclofenamate (3 mg/kg) (for 0.5 hours) | acetylcholine (5 ug/kg/min) (for 0.1 hours) |

7 | heart rate | Crlj:WI | male | 264 | beats/min | air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) | 103052 | air oxygen content (5 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | acetylcholine (5 ug/kg/min) (for 0.1 hours) | | sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) | NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) | meclofenamate (3 mg/kg) (for 0.5 hours) | acetylcholine (5 ug/kg/min) (for 0.1 hours) |

5 | heart rate | GK | male | 252 | beats/min | air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) | 103053 | air oxygen content (21 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | acetylcholine (5 ug/kg/min) (for 0.1 hours) | | sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) | NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) | meclofenamate (3 mg/kg) (for 0.5 hours) | acetylcholine (5 ug/kg/min) (for 0.1 hours) |

7 | heart rate | GK | male | 279 | beats/min | air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) | 103054 | air oxygen content (5 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | acetylcholine (5 ug/kg/min) (for 0.1 hours) | | sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) | NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) | meclofenamate (3 mg/kg) (for 0.5 hours) | acetylcholine (5 ug/kg/min) (for 0.1 hours) |

6 | heart rate | GK | male | 323 | beats/min | vehicle control condition (for 28 days) and dark phase of controlled light/dark cycle (for 12 hours) | 103568 | vehicle control condition (for 28 days) | dark phase of controlled light/dark cycle (for 12 hours) | | | | | | | | | |

6 | number of spontaneous locomotor movements per unit time | WKY/NCrl | male | 0.9 | /min | vehicle control condition (between 1 and 28 days) and light phase of controlled light/dark cycle (for 12 hours) | 103574 | vehicle control condition (between 1 and 28 days) | light phase of controlled light/dark cycle (for 12 hours) | | | | | | | | | |

6 | number of spontaneous locomotor movements per unit time | GK | male | 0.9 | /min | vehicle control condition (between 1 and 28 days) and light phase of controlled light/dark cycle (for 12 hours) | 103576 | vehicle control condition (between 1 and 28 days) | light phase of controlled light/dark cycle (for 12 hours) | | | | | | | | | |

6 | number of spontaneous locomotor movements per unit time | WKY/NCrl | male | 2.8 | /min | vehicle control condition (between 1 and 28 days) and dark phase of controlled light/dark cycle | 103582 | vehicle control condition (between 1 and 28 days) | dark phase of controlled light/dark cycle | | | | | | | | | |

6 | number of spontaneous locomotor movements per unit time | GK | male | 2.9 | /min | vehicle control condition (between 1 and 28 days) and dark phase of controlled light/dark cycle | 103584 | vehicle control condition (between 1 and 28 days) | dark phase of controlled light/dark cycle | | | | | | | | | |

7 | logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) | WKY/NCrl | male | -7.07 | | vehicle control condition (for 28 days) | 103586 | vehicle control condition (for 28 days) | | | | | | | | | | |

8 | logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) | GK | male | -7.29 | | vehicle control condition (for 28 days) | 103588 | vehicle control condition (for 28 days) | | | | | | | | | | |

7 | acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel | WKY/NCrl | male | 89.88 | % | vehicle control condition (for 28 days) | 103590 | vehicle control condition (for 28 days) | | | | | | | | | | |

8 | acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel | GK | male | 67.1 | % | vehicle control condition (for 28 days) | 103592 | vehicle control condition (for 28 days) | | | | | | | | | | |

7 | logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) | WKY/NCrl | male | -8.058 | | vehicle control condition (for 28 days) | 103594 | vehicle control condition (for 28 days) | | | | | | | | | | |

5 | systolic blood pressure | MW | male | 123 | mmHg | vehicle control condition (0 mg/kg/d) (for 5 days) then sham surgical control condition (for 4 days) | 101347 | vehicle control condition (0 mg/kg/d) (for 5 days) | | | sham surgical control condition (for 4 days) | | | | | | | |

7 | systolic blood pressure | MW | male | 116 | mmHg | vehicle control condition (0 mg/kg/d) (for 8 days) then artificial aortocaval fistula (for 7 days) | 101350 | vehicle control condition (0 mg/kg/d) (for 8 days) | | | artificial aortocaval fistula (for 7 days) | | | | | | | |

5 | systolic blood pressure | MW | male | 130 | mmHg | vehicle control condition (0 mg/kg/d) (for 8 days) then sham surgical control condition (for 7 days) | 101351 | vehicle control condition (0 mg/kg/d) (for 8 days) | | | sham surgical control condition (for 7 days) | | | | | | | |

7 | systolic blood pressure | MW | male | 130 | mmHg | vehicle control condition (0 mg/kg/d) (for 10 days) then artificial aortocaval fistula (for 9 days) | 101353 | vehicle control condition (0 mg/kg/d) (for 10 days) | | | artificial aortocaval fistula (for 9 days) | | | | | | | |

5 | systolic blood pressure | MW | male | 125 | mmHg | vehicle control condition (0 mg/kg/d) (for 3 days) then artificial aortocaval fistula (for 2 days) | 101356 | vehicle control condition (0 mg/kg/d) (for 3 days) | | | artificial aortocaval fistula (for 2 days) | | | | | | | |

6 | systolic blood pressure | MW | male | 150 | mmHg | vehicle control condition (0 mg/kg/d) (for 3 days) then sham surgical control condition (for 2 days) | 101357 | vehicle control condition (0 mg/kg/d) (for 3 days) | | | sham surgical control condition (for 2 days) | | | | | | | |

6 | systolic blood pressure | MW | male | 122 | mmHg | vehicle control condition (0 mg/kg/d) (for 5 days) then artificial aortocaval fistula (for 4 days) | 101360 | vehicle control condition (0 mg/kg/d) (for 5 days) | | | artificial aortocaval fistula (for 4 days) | | | | | | | |

5 | systolic blood pressure | MW | male | 160 | mmHg | vehicle control condition (0 mg/kg/d) (for 5 days) then sham surgical control condition (for 4 days) | 101361 | vehicle control condition (0 mg/kg/d) (for 5 days) | | | sham surgical control condition (for 4 days) | | | | | | | |

6 | systolic blood pressure | MW | male | 123 | mmHg | vehicle control condition (0 mg/kg/d) (for 8 days) then artificial aortocaval fistula (for 7 days) | 101364 | vehicle control condition (0 mg/kg/d) (for 8 days) | | | artificial aortocaval fistula (for 7 days) | | | | | | | |

5 | systolic blood pressure | MW | male | 165 | mmHg | vehicle control condition (0 mg/kg/d) (for 8 days) then sham surgical control condition (for 7 days) | 101365 | vehicle control condition (0 mg/kg/d) (for 8 days) | | | sham surgical control condition (for 7 days) | | | | | | | |

6 | heart rate | MW | male | 460 | beats/min | vehicle control condition (0 mg/kg/d) (for 5 days) then artificial aortocaval fistula (for 4 days) | 101368 | vehicle control condition (0 mg/kg/d) (for 5 days) | | | artificial aortocaval fistula (for 4 days) | | | | | | | |

5 | heart rate | MW | male | 406 | beats/min | vehicle control condition (0 mg/kg/d) (for 5 days) then sham surgical control condition (for 4 days) | 101369 | vehicle control condition (0 mg/kg/d) (for 5 days) | | | sham surgical control condition (for 4 days) | | | | | | | |

7 | heart rate | MW | male | 450 | beats/min | vehicle control condition (0 mg/kg/d) (for 8 days) then artificial aortocaval fistula (for 7 days) | 101372 | vehicle control condition (0 mg/kg/d) (for 8 days) | | | artificial aortocaval fistula (for 7 days) | | | | | | | |

5 | heart rate | MW | male | 358 | beats/min | vehicle control condition (0 mg/kg/d) (for 8 days) then sham surgical control condition (for 7 days) | 101373 | vehicle control condition (0 mg/kg/d) (for 8 days) | | | sham surgical control condition (for 7 days) | | | | | | | |

8 | heart left ventricle weight | MW | male | 0.243 | g | vehicle control condition (0 mg/kg/d) (for 3 days) then artificial aortocaval fistula (for 2 days) | 101400 | vehicle control condition (0 mg/kg/d) (for 3 days) | | | artificial aortocaval fistula (for 2 days) | | | | | | | |

6 | heart left ventricle weight | MW | male | 0.211 | g | vehicle control condition (0 mg/kg/d) (for 3 days) then sham surgical control condition (for 2 days) | 101401 | vehicle control condition (0 mg/kg/d) (for 3 days) | | | sham surgical control condition (for 2 days) | | | | | | | |

8 | heart left ventricle weight | MW | male | 0.256 | g | vehicle control condition (0 mg/kg/d) (for 5 days) then artificial aortocaval fistula (for 4 days) | 101404 | vehicle control condition (0 mg/kg/d) (for 5 days) | | | artificial aortocaval fistula (for 4 days) | | | | | | | |

5 | heart left ventricle weight | MW | male | 0.214 | g | vehicle control condition (0 mg/kg/d) (for 5 days) then sham surgical control condition (for 4 days) | 101405 | vehicle control condition (0 mg/kg/d) (for 5 days) | | | sham surgical control condition (for 4 days) | | | | | | | |

8 | heart left ventricle weight | MW | male | 0.285 | g | vehicle control condition (0 mg/kg/d) (for 8 days) then artificial aortocaval fistula (for 7 days) | 101408 | vehicle control condition (0 mg/kg/d) (for 8 days) | | | artificial aortocaval fistula (for 7 days) | | | | | | | |

6 | heart left ventricle weight | MW | male | 0.196 | g | vehicle control condition (0 mg/kg/d) (for 8 days) then sham surgical control condition (for 7 days) | 101409 | vehicle control condition (0 mg/kg/d) (for 8 days) | | | sham surgical control condition (for 7 days) | | | | | | | |

8 | logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) | GK | male | -7.96 | | vehicle control condition (for 28 days) | 103596 | vehicle control condition (for 28 days) | | | | | | | | | | |

7 | sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel | WKY/NCrl | male | 97.56 | % | vehicle control condition (for 28 days) | 103598 | vehicle control condition (for 28 days) | | | | | | | | | | |

8 | sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel | GK | male | 94.07 | % | vehicle control condition (for 28 days) | 103600 | vehicle control condition (for 28 days) | | | | | | | | | | |

7 | logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) | WKY/NCrl | male | -7.6 | | vehicle control condition (for 28 days) | 103602 | vehicle control condition (for 28 days) | | | | | | | | | | |

8 | logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) | GK | male | -7.39 | | vehicle control condition (for 28 days) | 103604 | vehicle control condition (for 28 days) | | | | | | | | | | |

7 | acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel | WKY/NCrl | male | 99.75 | % | vehicle control condition (for 28 days) | 103606 | vehicle control condition (for 28 days) | | | | | | | | | | |

8 | acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel | GK | male | 96.96 | % | vehicle control condition (for 28 days) | 103608 | vehicle control condition (for 28 days) | | | | | | | | | | |

7 | logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) | WKY/NCrl | male | -8.15 | | vehicle control condition (for 28 days) | 103610 | vehicle control condition (for 28 days) | | | | | | | | | | |

8 | logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) | GK | male | -8.74 | | vehicle control condition (for 28 days) | 103612 | vehicle control condition (for 28 days) | | | | | | | | | | |

7 | sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel | WKY/NCrl | male | 96.54 | % | vehicle control condition (for 28 days) | 103614 | vehicle control condition (for 28 days) | | | | | | | | | | |

8 | sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel | GK | male | 86.87 | % | vehicle control condition (for 28 days) | 103616 | vehicle control condition (for 28 days) | | | | | | | | | | |

7 | aorta wall phosphorylated eNOS level to total eNOS level ratio | WKY/NCrl | male | 1.45 | | vehicle control condition (for 35 days) | 103618 | vehicle control condition (for 35 days) | | | | | | | | | | |

8 | aorta wall phosphorylated eNOS level to total eNOS level ratio | GK | male | 1.61 | | vehicle control condition (for 35 days) | 103620 | vehicle control condition (for 35 days) | | | | | | | | | | |

7 | mesenteric artery phosphorylated eNOS level to total eNOS level ratio | WKY/NCrl | male | 0.94 | | vehicle control condition (for 35 days) | 103622 | vehicle control condition (for 35 days) | | | | | | | | | | |

8 | mesenteric artery phosphorylated eNOS level to total eNOS level ratio | GK | male | 0.9 | | vehicle control condition (for 35 days) | 103624 | vehicle control condition (for 35 days) | | | | | | | | | | |

6 | heart rate | MW | male | 448 | beats/min | vehicle control condition (0 mg/kg/d) (for 8 days) then artificial aortocaval fistula (for 7 days) | 101387 | vehicle control condition (0 mg/kg/d) (for 8 days) | | | artificial aortocaval fistula (for 7 days) | | | | | | | |

5 | heart rate | MW | male | 382 | beats/min | vehicle control condition (0 mg/kg/d) (for 8 days) then sham surgical control condition (for 7 days) | 101388 | vehicle control condition (0 mg/kg/d) (for 8 days) | | | sham surgical control condition (for 7 days) | | | | | | | |

7 | heart insulin-like growth factor 1 receptor mRNA level | MW | male | 0.26 | pmol/l | vehicle control condition (0 mg/kg/d) (for 5 days) then artificial aortocaval fistula (for 4 days) | 101434 | vehicle control condition (0 mg/kg/d) (for 5 days) | | | artificial aortocaval fistula (for 4 days) | | | | | | | |

5 | heart insulin-like growth factor 1 receptor mRNA level | MW | male | 0.26 | pmol/l | vehicle control condition (0 mg/kg/d) (for 5 days) then sham surgical control condition (for 4 days) | 101435 | vehicle control condition (0 mg/kg/d) (for 5 days) | | | sham surgical control condition (for 4 days) | | | | | | | |

7 | heart insulin-like growth factor 1 mRNA level | MW | male | 0.53 | pmol/l | vehicle control condition (0 mg/kg/d) (for 5 days) then artificial aortocaval fistula (for 4 days) | 101456 | vehicle control condition (0 mg/kg/d) (for 5 days) | | | artificial aortocaval fistula (for 4 days) | | | | | | | |

13 | blood glucose level | LL/Mav | male | 65 | mg/dl | vehicle control condition then fasting (for 16 hours) | 102656 | vehicle control condition | | | fasting (for 16 hours) | | | | | | | |

8 | blood glucose level | LH/Mav | male | 67 | mg/dl | vehicle control condition then fasting (for 16 hours) | 102657 | vehicle control condition | | | fasting (for 16 hours) | | | | | | | |

13 | blood glucose level | LL/Mav | male | 132 | mg/dl | vehicle control condition then fasting (for 16 hours) then glucose (2 g/kg) (for 1 hours) | 102659 | vehicle control condition | | | fasting (for 16 hours) | | glucose (2 g/kg) (for 1 hours) | | | | | |

8 | blood glucose level | LH/Mav | male | 121 | mg/dl | vehicle control condition then fasting (for 16 hours) then glucose (2 g/kg) (for 1 hours) | 102660 | vehicle control condition | | | fasting (for 16 hours) | | glucose (2 g/kg) (for 1 hours) | | | | | |

13 | plasma total cholesterol level | LL/Mav | male | 50.5791 | mg/dl | vehicle control condition | 102662 | vehicle control condition | | | | | | | | | | |

8 | plasma total cholesterol level | LH/Mav | male | 66.4092 | mg/dl | vehicle control condition | 102663 | vehicle control condition | | | | | | | | | | |

13 | plasma triglyceride level | LL/Mav | male | 1.58 | mmol/l | vehicle control condition | 102668 | vehicle control condition | | | | | | | | | | |

8 | plasma triglyceride level | LH/Mav | male | 1.57 | mmol/l | vehicle control condition | 102669 | vehicle control condition | | | | | | | | | | |

13 | plasma creatinine level | LL/Mav | male | 0.518 | mg/dl | vehicle control condition | 102674 | vehicle control condition | | | | | | | | | | |

8 | plasma creatinine level | LH/MavRrrc | male | 0.53 | mg/dl | vehicle control condition | 102675 | vehicle control condition | | | | | | | | | | |

13 | heart left ventricle weight to body weight ratio | LL/Mav | male | 20.4 | mg/g | vehicle control condition | 102680 | vehicle control condition | | | | | | | | | | |

8 | heart left ventricle weight to body weight ratio | LH/MavRrrc | male | 23 | mg/g | vehicle control condition | 102681 | vehicle control condition | | | | | | | | | | |

13 | aorta weight to body weight ratio | LL/Mav | male | 11.6 | mg/100g | vehicle control condition | 102686 | vehicle control condition | | | | | | | | | | |

8 | aorta weight to body weight ratio | LH/MavRrrc | male | 12.2 | mg/100g | vehicle control condition | 102687 | vehicle control condition | | | | | | | | | | |

13 | both kidneys wet weight to body weight ratio | LL/Mav | male | 6.53 | g/kg | vehicle control condition | 102692 | vehicle control condition | | | | | | | | | | |

8 | both kidneys wet weight to body weight ratio | LH/MavRrrc | male | 6.36 | g/kg | vehicle control condition | 102693 | vehicle control condition | | | | | | | | | | |

4 | mean arterial blood pressure | SD-Nfe2l2em1Mcwi+/+ | male | 95 | mmHg | controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days) | 100739 | controlled sodium content diet (0.4 %) (between 70 and 84 days) | | | controlled sodium content diet (4 %) (for 6 days) | | vehicle control condition (for 3 days) | | | | | |

3 | mean arterial blood pressure | SD-Nfe2l2em1Mcwi-/- | male | 102 | mmHg | controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days) | 100740 | controlled sodium content diet (0.4 %) (between 70 and 84 days) | | | controlled sodium content diet (4 %) (for 6 days) | | vehicle control condition (for 3 days) | | | | | |

5 | middle cerebral artery inner diameter | SD-Nfe2l2em1Mcwi+/+ | male | 246 | um | controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days) then controlled calcium ion content physiological salt solution perfusate (0 %) | 100745 | controlled sodium content diet (0.4 %) (between 70 and 84 days) | | | controlled sodium content diet (4 %) (for 6 days) | | vehicle control condition (for 3 days) | | controlled calcium ion content physiological salt solution perfusate (0 %) | | | |

4 | middle cerebral artery inner diameter | SD-Nfe2l2em1Mcwi-/- | male | 248 | um | controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days) then controlled calcium ion content physiological salt solution perfusate (0 %) | 100746 | controlled sodium content diet (0.4 %) (between 70 and 84 days) | | | controlled sodium content diet (4 %) (for 6 days) | | vehicle control condition (for 3 days) | | controlled calcium ion content physiological salt solution perfusate (0 %) | | | |

5 | middle cerebral artery inner diameter | SD-Nfe2l2em1Mcwi+/+ | male | 145 | um | controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days) then physiological salt solution perfusate | 100751 | controlled sodium content diet (0.4 %) (between 70 and 84 days) | | | controlled sodium content diet (4 %) (for 6 days) | | vehicle control condition (for 3 days) | | physiological salt solution perfusate | | | |

4 | middle cerebral artery inner diameter | SD-Nfe2l2em1Mcwi-/- | male | 154 | um | controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days) then physiological salt solution perfusate | 100752 | controlled sodium content diet (0.4 %) (between 70 and 84 days) | | | controlled sodium content diet (4 %) (for 6 days) | | vehicle control condition (for 3 days) | | physiological salt solution perfusate | | | |

5 | percent change in middle cerebral artery inner diameter | SD-Nfe2l2em1Mcwi+/+ | male | 41.4 | % | controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days) then physiological salt solution perfusate | 100757 | controlled sodium content diet (0.4 %) (between 70 and 84 days) | | | controlled sodium content diet (4 %) (for 6 days) | | vehicle control condition (for 3 days) | | physiological salt solution perfusate | | | |

4 | percent change in middle cerebral artery inner diameter | SD-Nfe2l2em1Mcwi-/- | male | 37.4 | % | controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days) then physiological salt solution perfusate | 100758 | controlled sodium content diet (0.4 %) (between 70 and 84 days) | | | controlled sodium content diet (4 %) (for 6 days) | | vehicle control condition (for 3 days) | | physiological salt solution perfusate | | | |

6 | serum total cholesterol level | SS.ZUC-Leprfa-/-/Slc | male | 333 | mg/dl | vehicle control condition (0.5 %) (for 28 days) | 101941 | vehicle control condition (0.5 %) (for 28 days) | | | | | | | | | | |

6 | serum low density lipoprotein cholesterol level | SS.ZUC-Leprfa-/-/Slc | male | 102.5 | mg/dl | vehicle control condition (0.5 %) (for 28 days) | 101944 | vehicle control condition (0.5 %) (for 28 days) | | | | | | | | | | |

6 | serum high density lipoprotein cholesterol level | SS.ZUC-Leprfa-/-/Slc | male | 97.25 | mg/dl | vehicle control condition (0.5 %) (for 28 days) | 101947 | vehicle control condition (0.5 %) (for 28 days) | | | | | | | | | | |

6 | serum triglyceride level | SS.ZUC-Leprfa-/-/Slc | male | 2196.13 | mg/dl | vehicle control condition (0.5 %) (for 28 days) | 101950 | vehicle control condition (0.5 %) (for 28 days) | | | | | | | | | | |

6 | serum free fatty acids level | SS.ZUC-Leprfa-/-/Slc | male | 1.42 | mmol/l | vehicle control condition (0.5 %) (for 28 days) | 101953 | vehicle control condition (0.5 %) (for 28 days) | | | | | | | | | | |

6 | serum glucose level | SS.ZUC-Leprfa-/-/Slc | male | 149.4 | mg/dl | vehicle control condition (0.5 %) (for 28 days) | 101956 | vehicle control condition (0.5 %) (for 28 days) | | | | | | | | | | |

6 | serum insulin level | SS.ZUC-Leprfa-/-/Slc | male | 0.000807 | mg/dl | vehicle control condition (0.5 %) (for 28 days) | 101959 | vehicle control condition (0.5 %) (for 28 days) | | | | | | | | | | |

13 | body weight | LL/Mav | male | 219 | g | vehicle control condition | 102641 | vehicle control condition | | | | | | | | | | |

8 | body weight | LH/Mav | male | 232 | g | vehicle control condition | 102642 | vehicle control condition | | | | | | | | | | |

13 | systolic blood pressure | LL/Mav | male | 115 | mmHg | vehicle control condition | 102644 | vehicle control condition | | | | | | | | | | |

8 | systolic blood pressure | LH/Mav | male | 136 | mmHg | vehicle control condition | 102645 | vehicle control condition | | | | | | | | | | |

13 | timed urine volume | LL/Mav | male | 8.4 | ml/d | vehicle control condition | 102647 | vehicle control condition | | | | | | | | | | |

8 | timed urine volume | LH/Mav | male | 8.7 | ml/d | vehicle control condition | 102648 | vehicle control condition | | | | | | | | | | |

13 | urine creatinine excretion rate | LL/Mav | male | 7.1 | mg/d | vehicle control condition | 102650 | vehicle control condition | | | | | | | | | | |

8 | urine creatinine excretion rate | LH/Mav | male | 8 | mg/d | vehicle control condition | 102651 | vehicle control condition | | | | | | | | | | |

13 | urine protein level to urine creatinine level ratio | LL/Mav | male | 2.7 | | vehicle control condition | 102653 | vehicle control condition | | | | | | | | | | |

8 | urine protein level to urine creatinine level ratio | LH/Mav | male | 5.9 | | vehicle control condition | 102654 | vehicle control condition | | | | | | | | | | |

8 | body weight | MWF/ZtmRrrc | male | 378 | g | vehicle control condition | 100901 | vehicle control condition | | | | | | | | | | |

7 | body weight | MWF/ZtmRrrc | male | 385 | g | vehicle control condition | 100903 | vehicle control condition | | | | | | | | | | |

8 | body weight | MWF/ZtmRrrc | male | 433 | g | vehicle control condition | 100905 | vehicle control condition | | | | | | | | | | |

6 | heart rate | MW | male | 448 | beats/min | vehicle control condition (0 mg/kg/d) (for 5 days) then artificial aortocaval fistula (for 4 days) | 101382 | vehicle control condition (0 mg/kg/d) (for 5 days) | | | artificial aortocaval fistula (for 4 days) | | | | | | | |

5 | heart rate | MW | male | 366 | beats/min | vehicle control condition (0 mg/kg/d) (for 5 days) then sham surgical control condition (for 4 days) | 101383 | vehicle control condition (0 mg/kg/d) (for 5 days) | | | sham surgical control condition (for 4 days) | | | | | | | |

13 | tibia straight segment length | SS.ZUC-Leprfa-/-/Slc | male | 34.62 | mm | vehicle control condition (0.5 %) (for 28 days) | 101971 | vehicle control condition (0.5 %) (for 28 days) | | | | | | | | | | |

13 | heart weight to tibia length ratio | SS.ZUC-Leprfa-/-/Slc | male | 0.4295 | g/cm | vehicle control condition (0.5 %) (for 28 days) | 101974 | vehicle control condition (0.5 %) (for 28 days) | | | | | | | | | | |

13 | heart left ventricle weight to tibia length ratio | SS.ZUC-Leprfa-/-/Slc | male | 0.3101 | g/cm | vehicle control condition (0.5 %) (for 28 days) | 101977 | vehicle control condition (0.5 %) (for 28 days) | | | | | | | | | | |

13 | retroperitoneal fat pad weight to tibia length ratio | SS.ZUC-Leprfa-/-/Slc | male | 429.56 | mg/mm | vehicle control condition (0.5 %) (for 28 days) | 101980 | vehicle control condition (0.5 %) (for 28 days) | | | | | | | | | | |

13 | epididymal fat pad weight to tibia length ratio | SS.ZUC-Leprfa-/-/Slc | male | 3.5481 | g/cm | vehicle control condition (0.5 %) (for 28 days) | 101983 | vehicle control condition (0.5 %) (for 28 days) | | | | | | | | | | |

13 | mesenteric fat pad weight to tibia length ratio | SS.ZUC-Leprfa-/-/Slc | male | 364.22 | mg/mm | vehicle control condition (0.5 %) (for 28 days) | 101986 | vehicle control condition (0.5 %) (for 28 days) | | | | | | | | | | |

13 | inguinal fat pad weight to tibia length ratio | SS.ZUC-Leprfa-/-/Slc | male | 1501.32 | mg/mm | vehicle control condition (0.5 %) (for 28 days) | 101989 | vehicle control condition (0.5 %) (for 28 days) | | | | | | | | | | |

13 | heart ventricle septal wall thickness | SS.ZUC-Leprfa-/-/Slc | male | 0.206 | cm | vehicle control condition (0.5 %) (for 28 days) | 101992 | vehicle control condition (0.5 %) (for 28 days) | | | | | | | | | | |

13 | heart left ventricular end-diastolic diameter | SS.ZUC-Leprfa-/-/Slc | male | 8.27 | mm | vehicle control condition (0.5 %) (for 28 days) | 101995 | vehicle control condition (0.5 %) (for 28 days) | | | | | | | | | | |

8 | body weight | SS/NEisSlc | male | 361 | g | controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days) | 102311 | controlled sodium content diet (0.3 %) (for 42 days) | | | controlled sodium content diet (8 %) (for 77 days) | | vehicle control condition (for 49 days) | | | | | |

8 | systolic blood pressure | SS/NEisSlc | male | 226 | mmHg | controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days) | 102314 | controlled sodium content diet (0.3 %) (for 42 days) | | | controlled sodium content diet (8 %) (for 77 days) | | vehicle control condition (for 49 days) | | | | | |

8 | heart left ventricle fractional shortening | SS/NEisSlc | male | 24.8 | % | controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days) | 102317 | controlled sodium content diet (0.3 %) (for 42 days) | | | controlled sodium content diet (8 %) (for 77 days) | | vehicle control condition (for 49 days) | | | | | |

6 | systolic blood pressure | WKY/NCrl | male | 121 | mmHg | vehicle control condition (for 28 days) and light phase of controlled light/dark cycle (for 12 hours) | 103526 | vehicle control condition (for 28 days) | light phase of controlled light/dark cycle (for 12 hours) | | | | | | | | | |

6 | systolic blood pressure | GK | male | 145 | mmHg | vehicle control condition (for 28 days) and light phase of controlled light/dark cycle (for 12 hours) | 103528 | vehicle control condition (for 28 days) | light phase of controlled light/dark cycle (for 12 hours) | | | | | | | | | |

6 | systolic blood pressure | WKY/NCrl | male | 126 | mmHg | vehicle control condition (for 28 days) and dark phase of controlled light/dark cycle (for 12 hours) | 103534 | vehicle control condition (for 28 days) | dark phase of controlled light/dark cycle (for 12 hours) | | | | | | | | | |

6 | systolic blood pressure | GK | male | 145 | mmHg | vehicle control condition (for 28 days) and dark phase of controlled light/dark cycle (for 12 hours) | 103536 | vehicle control condition (for 28 days) | dark phase of controlled light/dark cycle (for 12 hours) | | | | | | | | | |

6 | diastolic blood pressure | WKY/NCrl | male | 85 | mmHg | vehicle control condition (for 28 days) and light phase of controlled light/dark cycle (for 12 hours) | 103542 | vehicle control condition (for 28 days) | light phase of controlled light/dark cycle (for 12 hours) | | | | | | | | | |

6 | diastolic blood pressure | GK | male | 98 | mmHg | vehicle control condition (for 28 days) and light phase of controlled light/dark cycle (for 12 hours) | 103544 | vehicle control condition (for 28 days) | light phase of controlled light/dark cycle (for 12 hours) | | | | | | | | | |

4 | neuron mitochondrion area to neuron cytoplasm area ratio | WI | male | 10.4 | % | vehicle control condition (for 180 days) | 103644 | vehicle control condition (for 180 days) | | | | | | | | | | |

4 | neuron mitochondrion area to neuron cytoplasm area ratio | OXYS/Nov | male | 3.6 | % | vehicle control condition (for 180 days) | 103645 | vehicle control condition (for 180 days) | | | | | | | | | | |

4 | neuron lysosome area to neuron cytoplasm area ratio | WI | male | 8.3 | % | vehicle control condition (for 180 days) | 103647 | vehicle control condition (for 180 days) | | | | | | | | | | |

4 | neuron lysosome area to neuron cytoplasm area ratio | OXYS/Nov | male | 11.9 | % | vehicle control condition (for 180 days) | 103648 | vehicle control condition (for 180 days) | | | | | | | | | | |

4 | neuron golgi apparatus area to neuron cytoplasm area ratio | WI | male | 1.05 | % | vehicle control condition (for 180 days) | 103650 | vehicle control condition (for 180 days) | | | | | | | | | | |

4 | neuron golgi apparatus area to neuron cytoplasm area ratio | OXYS/Nov | male | 1.2 | % | vehicle control condition (for 180 days) | 103651 | vehicle control condition (for 180 days) | | | | | | | | | | |

4 | neuron rough endoplasmic reticulum area to neuron cytoplasm area ratio | WI | male | 27.4 | % | vehicle control condition (for 180 days) | 103653 | vehicle control condition (for 180 days) | | | | | | | | | | |

4 | neuron rough endoplasmic reticulum area to neuron cytoplasm area ratio | OXYS/Nov | male | 11.2 | % | vehicle control condition (for 180 days) | 103654 | vehicle control condition (for 180 days) | | | | | | | | | | |

4 | neuron vacuole area to neuron cytoplasm area ratio | WI | male | 3.97 | % | vehicle control condition (for 180 days) | 103656 | vehicle control condition (for 180 days) | | | | | | | | | | |

4 | neuron vacuole area to neuron cytoplasm area ratio | OXYS/Nov | male | 8.23 | % | vehicle control condition (for 180 days) | 103657 | vehicle control condition (for 180 days) | | | | | | | | | | |

N/A | heart weight to body weight ratio | SHRSP/Gcrc | male | 4.66 | g/kg | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102100 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

N/A | heart weight to body weight ratio | WKY/Gcrc | male | 3.48 | g/kg | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102101 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

N/A | heart weight to body weight ratio | SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrc | male | 4.03 | g/kg | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102102 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

6 | heart weight to body weight ratio | SHRSP.WKY-(D3Wox20-D3Rat114)/Gcrc | male | 4.47 | g/kg | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102103 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

N/A | heart weight to body weight ratio | SHRSP.WKY-(D3Mgh16-D3Rat80)/Gcrc | male | 3.88 | g/kg | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102104 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

7 | heart weight to body weight ratio | SHRSP.WKY-(D3Mgh16-D3Wox3)/Gcrc | male | 4.07 | g/kg | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102105 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

N/A | heart weight to body weight ratio | SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrc | male | 4.26 | g/kg | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102106 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

N/A | heart weight to body weight ratio | SHRSP.WKY-(D3Mgh16-rs197649383)/Gcrc | male | 4.72 | g/kg | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102107 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

17 | urine urea level to urine creatinine level ratio | SHRSP/Gcrc | male | 112.69 | | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 103791 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

18 | urine urea level to urine creatinine level ratio | WKY/Gcrc | male | 68.85 | | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 103792 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

9 | urine urea level to urine creatinine level ratio | SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrc | male | 87.33 | | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 103793 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

7 | urine urea level to urine creatinine level ratio | SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrc | male | 101.15 | | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 103794 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

6 | urine urea level to urine creatinine level ratio | SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrc | male | 76.34 | | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 103795 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

N/A | heart weight to body weight ratio | SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrc | male | 4.67 | g/kg | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102108 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

N/A | heart left ventricle weight to body weight ratio | SHRSP/Gcrc | male | 3.64 | mg/g | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102109 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

N/A | heart left ventricle weight to body weight ratio | WKY/Gcrc | male | 2.52 | mg/g | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102110 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

N/A | heart left ventricle weight to body weight ratio | SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrc | male | 3.04 | mg/g | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102111 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

6 | heart left ventricle weight to body weight ratio | SHRSP.WKY-(D3Wox20-D3Rat114)/Gcrc | male | 3.33 | mg/g | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102112 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

N/A | heart left ventricle weight to body weight ratio | SHRSP.WKY-(D3Mgh16-D3Rat80)/Gcrc | male | 2.79 | mg/g | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102113 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

7 | heart left ventricle weight to body weight ratio | SHRSP.WKY-(D3Mgh16-D3Wox3)/Gcrc | male | 3 | mg/g | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102114 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

N/A | heart left ventricle weight to body weight ratio | SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrc | male | 3.12 | mg/g | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102115 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

N/A | heart left ventricle weight to body weight ratio | SHRSP.WKY-(D3Mgh16-rs197649383)/Gcrc | male | 3.57 | mg/g | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102116 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

N/A | heart left ventricle weight to body weight ratio | SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrc | male | 3.28 | mg/g | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102117 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

N/A | both kidneys wet weight to body weight ratio | SHRSP/Gcrc | male | 4.11 | g/kg | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102118 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

N/A | both kidneys wet weight to body weight ratio | WKY/Gcrc | male | 2.87 | g/kg | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102119 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

N/A | both kidneys wet weight to body weight ratio | SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrc | male | 3.65 | g/kg | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102120 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

6 | both kidneys wet weight to body weight ratio | SHRSP.WKY-(D3Wox20-D3Rat114)/Gcrc | male | 3.78 | g/kg | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102121 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

N/A | both kidneys wet weight to body weight ratio | SHRSP.WKY-(D3Mgh16-D3Rat80)/Gcrc | male | 3.77 | g/kg | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102122 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

N/A | both kidneys wet weight to body weight ratio | SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrc | male | 4.16 | g/kg | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102123 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

N/A | blood glycated albumin level | Slc:W | male | 1.5 | % | vehicle control condition | 102874 | vehicle control condition | | | | | | | | | | |

N/A | blood glycated albumin level | GK/Slc | male | 2.3 | % | vehicle control condition | 102876 | vehicle control condition | | | | | | | | | | |

N/A | blood hemoglobin A1c level | Slc:W | male | 5.32 | % | vehicle control condition | 102878 | vehicle control condition | | | | | | | | | | |

N/A | blood hemoglobin A1c level | GK/Slc | male | 5.21 | % | vehicle control condition | 102880 | vehicle control condition | | | | | | | | | | |

N/A | blood triglyceride level | Slc:W | male | 119.5 | mg/dl | vehicle control condition | 102886 | vehicle control condition | | | | | | | | | | |

N/A | blood triglyceride level | GK/Slc | male | 52.3 | mg/dl | vehicle control condition | 102888 | vehicle control condition | | | | | | | | | | |

N/A | blood total cholesterol level | Slc:W | male | 67 | mg/dl | vehicle control condition | 102890 | vehicle control condition | | | | | | | | | | |

N/A | blood total cholesterol level | GK/Slc | male | 77.8 | mg/dl | vehicle control condition | 102892 | vehicle control condition | | | | | | | | | | |

N/A | blood high density lipoprotein cholesterol level | Slc:W | male | 4.2 | mg/dl | vehicle control condition | 102894 | vehicle control condition | | | | | | | | | | |

N/A | blood high density lipoprotein cholesterol level | GK/Slc | male | 9 | mg/dl | vehicle control condition | 102896 | vehicle control condition | | | | | | | | | | |

N/A | blood low density lipoprotein cholesterol level | Slc:W | male | 26.8 | mg/dl | vehicle control condition | 102898 | vehicle control condition | | | | | | | | | | |

N/A | blood low density lipoprotein cholesterol level | GK/Slc | male | 24.3 | mg/dl | vehicle control condition | 102900 | vehicle control condition | | | | | | | | | | |

N/A | blood urea nitrogen level | Slc:W | male | 19.8 | mg/dl | vehicle control condition | 102902 | vehicle control condition | | | | | | | | | | |

N/A | blood urea nitrogen level | GK/Slc | male | 15.7 | mg/dl | vehicle control condition | 102904 | vehicle control condition | | | | | | | | | | |

N/A | blood creatinine level | Slc:W | male | 0.33 | mg/dl | vehicle control condition | 102906 | vehicle control condition | | | | | | | | | | |

N/A | blood creatinine level | GK/Slc | male | 0.26 | mg/dl | vehicle control condition | 102908 | vehicle control condition | | | | | | | | | | |

N/A | urine acetoacetone level | Slc:W | male | 50.3 | umol/l | vehicle control condition | 102914 | vehicle control condition | | | | | | | | | | |

N/A | urine acetoacetone level | GK/Slc | male | 91.5 | umol/l | vehicle control condition | 102916 | vehicle control condition | | | | | | | | | | |

N/A | urine 3-hydroxybutyrate level | Slc:W | male | 265.3 | umol/l | vehicle control condition | 102918 | vehicle control condition | | | | | | | | | | |

N/A | urine 3-hydroxybutyrate level | GK/Slc | male | 323.3 | umol/l | vehicle control condition | 102920 | vehicle control condition | | | | | | | | | | |

N/A | timed urine volume | Slc:W | male | 11.2 | ml/d | vehicle control condition | 102922 | vehicle control condition | | | | | | | | | | |

N/A | timed urine volume | GK/Slc | male | 9.6 | ml/d | vehicle control condition | 102924 | vehicle control condition | | | | | | | | | | |

N/A | urine glucose level | Slc:W | male | 31.8 | mg/dl | vehicle control condition | 102926 | vehicle control condition | | | | | | | | | | |

N/A | urine glucose level | GK/Slc | male | 588.3 | mg/dl | vehicle control condition | 102928 | vehicle control condition | | | | | | | | | | |

6 | diastolic blood pressure | WKY/NCrl | male | 89 | mmHg | vehicle control condition (for 28 days) and dark phase of controlled light/dark cycle (for 12 hours) | 103550 | vehicle control condition (for 28 days) | dark phase of controlled light/dark cycle (for 12 hours) | | | | | | | | | |

6 | diastolic blood pressure | GK | male | 104 | mmHg | vehicle control condition (for 28 days) and dark phase of controlled light/dark cycle (for 12 hours) | 103552 | vehicle control condition (for 28 days) | dark phase of controlled light/dark cycle (for 12 hours) | | | | | | | | | |

6 | heart rate | WKY/NCrl | male | 294 | beats/min | vehicle control condition (for 28 days) and light phase of controlled light/dark cycle (for 12 hours) | 103558 | vehicle control condition (for 28 days) | light phase of controlled light/dark cycle (for 12 hours) | | | | | | | | | |

6 | heart rate | GK | male | 279 | beats/min | vehicle control condition (for 28 days) and light phase of controlled light/dark cycle (for 12 hours) | 103560 | vehicle control condition (for 28 days) | light phase of controlled light/dark cycle (for 12 hours) | | | | | | | | | |

6 | heart rate | WKY/NCrl | male | 344 | beats/min | vehicle control condition (for 28 days) and dark phase of controlled light/dark cycle (for 12 hours) | 103566 | vehicle control condition (for 28 days) | dark phase of controlled light/dark cycle (for 12 hours) | | | | | | | | | |

7 | heart left ventricle weight | MW | male | 0.28 | g | vehicle control condition (0 mg/kg/d) (for 5 days) then artificial aortocaval fistula (for 4 days) | 101390 | vehicle control condition (0 mg/kg/d) (for 5 days) | | | artificial aortocaval fistula (for 4 days) | | | | | | | |

5 | heart left ventricle weight | MW | male | 0.22 | g | vehicle control condition (0 mg/kg/d) (for 5 days) then sham surgical control condition (for 4 days) | 101391 | vehicle control condition (0 mg/kg/d) (for 5 days) | | | sham surgical control condition (for 4 days) | | | | | | | |

7 | heart left ventricle weight | MW | male | 0.297 | g | vehicle control condition (0 mg/kg/d) (for 8 days) then artificial aortocaval fistula (for 7 days) | 101394 | vehicle control condition (0 mg/kg/d) (for 8 days) | | | artificial aortocaval fistula (for 7 days) | | | | | | | |

5 | heart left ventricle weight | MW | male | 0.214 | g | vehicle control condition (0 mg/kg/d) (for 8 days) then sham surgical control condition (for 7 days) | 101395 | vehicle control condition (0 mg/kg/d) (for 8 days) | | | sham surgical control condition (for 7 days) | | | | | | | |

7 | heart left ventricle weight | MW | male | 0.288 | g | vehicle control condition (0 mg/kg/d) (for 10 days) then artificial aortocaval fistula (for 9 days) | 101397 | vehicle control condition (0 mg/kg/d) (for 10 days) | | | artificial aortocaval fistula (for 9 days) | | | | | | | |

9 | heart left ventricle weight to tibia length ratio | SS.ZUC-Leprfa+/+/Slc | female | 0.2 | g/cm | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101695 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

8 | heart left ventricle weight to tibia length ratio | SS.ZUC-Leprfa-/-/Slc | female | 0.28 | g/cm | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101697 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

9 | retroperitoneal fat pad weight to tibia length ratio | SS.ZUC-Leprfa+/+/Slc | female | 105 | mg/mm | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101699 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

8 | retroperitoneal fat pad weight to tibia length ratio | SS.ZUC-Leprfa-/-/Slc | female | 482 | mg/mm | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101701 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

9 | inguinal fat pad weight to tibia length ratio | SS.ZUC-Leprfa+/+/Slc | female | 32 | mg/mm | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101703 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

8 | inguinal fat pad weight to tibia length ratio | SS.ZUC-Leprfa-/-/Slc | female | 209 | mg/mm | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101705 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

9 | heart ventricle septal wall thickness | SS.ZUC-Leprfa+/+/Slc | female | 0.158 | cm | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101707 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

8 | heart ventricle septal wall thickness | SS.ZUC-Leprfa-/-/Slc | female | 0.205 | cm | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101709 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

15 | right kidney wet weight | WKY | male | 1.3533 | g | left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) | 100373 | left anterior descending coronary artery occlusion (for 196 days) | | | vehicle control condition (for 182 days) | | | | | | | |

7 | timed urine volume | WKY | male | 10.6 | ml/d | left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) | 100376 | left anterior descending coronary artery occlusion (for 196 days) | | | vehicle control condition (for 182 days) | | | | | | | |

6 | plasma creatinine level | WKY | male | 0.52 | mg/dl | left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) | 100379 | left anterior descending coronary artery occlusion (for 196 days) | | | vehicle control condition (for 182 days) | | | | | | | |

15 | kidney fibrotic lesion area to total kidney area ratio | WKY | male | 0.75 | % | left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) | 100385 | left anterior descending coronary artery occlusion (for 196 days) | | | vehicle control condition (for 182 days) | | | | | | | |

15 | artery tunica media width to artery inner diameter ratio | WKY | male | 1.82 | | left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) | 100388 | left anterior descending coronary artery occlusion (for 196 days) | | | vehicle control condition (for 182 days) | | | | | | | |

7 | heart right ventricle weight | MW | male | 0.098 | g | vehicle control condition (0 mg/kg/d) (for 5 days) then artificial aortocaval fistula (for 4 days) | 101412 | vehicle control condition (0 mg/kg/d) (for 5 days) | | | artificial aortocaval fistula (for 4 days) | | | | | | | |

5 | heart left ventricle weight | MW | male | 0.061 | g | vehicle control condition (0 mg/kg/d) (for 5 days) then sham surgical control condition (for 4 days) | 101413 | vehicle control condition (0 mg/kg/d) (for 5 days) | | | sham surgical control condition (for 4 days) | | | | | | | |

7 | heart right ventricle weight | MW | male | 0.095 | g | vehicle control condition (0 mg/kg/d) (for 8 days) then artificial aortocaval fistula (for 7 days) | 101416 | vehicle control condition (0 mg/kg/d) (for 8 days) | | | artificial aortocaval fistula (for 7 days) | | | | | | | |

5 | heart right ventricle weight | MW | male | 0.061 | g | vehicle control condition (0 mg/kg/d) (for 8 days) then sham surgical control condition (for 7 days) | 101417 | vehicle control condition (0 mg/kg/d) (for 8 days) | | | sham surgical control condition (for 7 days) | | | | | | | |

8 | heart right ventricle weight | MW | male | 0.067 | g | vehicle control condition (0 mg/kg/d) (for 3 days) then artificial aortocaval fistula (for 2 days) | 101422 | vehicle control condition (0 mg/kg/d) (for 3 days) | | | artificial aortocaval fistula (for 2 days) | | | | | | | |

6 | heart right ventricle weight | MW | male | 0.054 | g | vehicle control condition (0 mg/kg/d) (for 3 days) then sham surgical control condition (for 2 days) | 101423 | vehicle control condition (0 mg/kg/d) (for 3 days) | | | sham surgical control condition (for 2 days) | | | | | | | |

8 | heart right ventricle weight | MW | male | 0.068 | g | vehicle control condition (0 mg/kg/d) (for 5 days) then artificial aortocaval fistula (for 4 days) | 101426 | vehicle control condition (0 mg/kg/d) (for 5 days) | | | artificial aortocaval fistula (for 4 days) | | | | | | | |

5 | heart right ventricle weight | MW | male | 0.048 | g | vehicle control condition (0 mg/kg/d) (for 5 days) then sham surgical control condition (for 4 days) | 101427 | vehicle control condition (0 mg/kg/d) (for 5 days) | | | sham surgical control condition (for 4 days) | | | | | | | |

8 | heart right ventricle weight | MW | male | 0.074 | g | vehicle control condition (0 mg/kg/d) (for 8 days) then artificial aortocaval fistula (for 7 days) | 101430 | vehicle control condition (0 mg/kg/d) (for 8 days) | | | artificial aortocaval fistula (for 7 days) | | | | | | | |

6 | heart right ventricle weight | MW | male | 0.048 | g | vehicle control condition (0 mg/kg/d) (for 8 days) then sham surgical control condition (for 7 days) | 101431 | vehicle control condition (0 mg/kg/d) (for 8 days) | | | sham surgical control condition (for 7 days) | | | | | | | |

7 | heart insulin-like growth factor 1 receptor mRNA level | MW | male | 0.3 | pmol/l | vehicle control condition (0 mg/kg/d) (for 8 days) then artificial aortocaval fistula (for 7 days) | 101438 | vehicle control condition (0 mg/kg/d) (for 8 days) | | | artificial aortocaval fistula (for 7 days) | | | | | | | |

5 | heart insulin-like growth factor 1 receptor mRNA level | MW | male | 0.39 | pmol/l | vehicle control condition (0 mg/kg/d) (for 8 days) then sham surgical control condition (for 7 days) | 101439 | vehicle control condition (0 mg/kg/d) (for 8 days) | | | sham surgical control condition (for 7 days) | | | | | | | |

7 | heart insulin-like growth factor 1 receptor mRNA level | MW | male | 0.31 | pmol/l | vehicle control condition (0 mg/kg/d) (for 10 days) then artificial aortocaval fistula (for 9 days) | 101441 | vehicle control condition (0 mg/kg/d) (for 10 days) | | | artificial aortocaval fistula (for 9 days) | | | | | | | |

6 | heart insulin-like growth factor 1 receptor mRNA level | MW | male | 0.21 | pmol/l | vehicle control condition (0 mg/kg/d) (for 3 days) then artificial aortocaval fistula (for 2 days) | 101444 | vehicle control condition (0 mg/kg/d) (for 3 days) | | | artificial aortocaval fistula (for 2 days) | | | | | | | |

6 | heart insulin-like growth factor 1 receptor mRNA level | MW | male | 0.23 | pmol/l | vehicle control condition (0 mg/kg/d) (for 3 days) then sham surgical control condition (for 2 days) | 101445 | vehicle control condition (0 mg/kg/d) (for 3 days) | | | sham surgical control condition (for 2 days) | | | | | | | |

8 | heart insulin-like growth factor 1 receptor mRNA level | MW | male | 0.41 | pmol/l | vehicle control condition (0 mg/kg/d) (for 5 days) then artificial aortocaval fistula (for 4 days) | 101448 | vehicle control condition (0 mg/kg/d) (for 5 days) | | | artificial aortocaval fistula (for 4 days) | | | | | | | |

5 | heart insulin-like growth factor 1 receptor mRNA level | MW | male | 0.37 | pmol/l | vehicle control condition (0 mg/kg/d) (for 5 days) then sham surgical control condition (for 4 days) | 101449 | vehicle control condition (0 mg/kg/d) (for 5 days) | | | sham surgical control condition (for 4 days) | | | | | | | |

8 | heart insulin-like growth factor 1 receptor mRNA level | MW | male | 0.24 | pmol/l | vehicle control condition (0 mg/kg/d) (for 8 days) then artificial aortocaval fistula (for 7 days) | 101452 | vehicle control condition (0 mg/kg/d) (for 8 days) | | | artificial aortocaval fistula (for 7 days) | | | | | | | |

6 | heart insulin-like growth factor 1 receptor mRNA level | MW | male | 0.32 | pmol/l | vehicle control condition (0 mg/kg/d) (for 8 days) then sham surgical control condition (for 7 days) | 101453 | vehicle control condition (0 mg/kg/d) (for 8 days) | | | sham surgical control condition (for 7 days) | | | | | | | |

5 | heart insulin-like growth factor 1 mRNA level | MW | male | 0.43 | pmol/l | vehicle control condition (0 mg/kg/d) (for 5 days) then sham surgical control condition (for 4 days) | 101457 | vehicle control condition (0 mg/kg/d) (for 5 days) | | | sham surgical control condition (for 4 days) | | | | | | | |

7 | heart insulin-like growth factor 1 mRNA level | MW | male | 1.03 | pmol/l | vehicle control condition (0 mg/kg/d) (for 8 days) then artificial aortocaval fistula (for 7 days) | 101460 | vehicle control condition (0 mg/kg/d) (for 8 days) | | | artificial aortocaval fistula (for 7 days) | | | | | | | |

5 | heart insulin-like growth factor 1 mRNA level | MW | male | 0.59 | pmol/l | vehicle control condition (0 mg/kg/d) (for 8 days) then sham surgical control condition (for 7 days) | 101461 | vehicle control condition (0 mg/kg/d) (for 8 days) | | | sham surgical control condition (for 7 days) | | | | | | | |

7 | heart insulin-like growth factor 1 mRNA level | MW | male | 0.61 | pmol/l | vehicle control condition (0 mg/kg/d) (for 10 days) then artificial aortocaval fistula (for 9 days) | 101463 | vehicle control condition (0 mg/kg/d) (for 10 days) | | | artificial aortocaval fistula (for 9 days) | | | | | | | |

6 | heart insulin-like growth factor 1 mRNA level | MW | male | 0.48 | pmol/l | vehicle control condition (0 mg/kg/d) (for 3 days) then artificial aortocaval fistula (for 2 days) | 101466 | vehicle control condition (0 mg/kg/d) (for 3 days) | | | artificial aortocaval fistula (for 2 days) | | | | | | | |

6 | heart insulin-like growth factor 1 mRNA level | MW | male | 0.4 | pmol/l | vehicle control condition (0 mg/kg/d) (for 3 days) then sham surgical control condition (for 2 days) | 101467 | vehicle control condition (0 mg/kg/d) (for 3 days) | | | sham surgical control condition (for 2 days) | | | | | | | |

8 | heart insulin-like growth factor 1 mRNA level | MW | male | 0.7 | pmol/l | vehicle control condition (0 mg/kg/d) (for 5 days) then artificial aortocaval fistula (for 4 days) | 101470 | vehicle control condition (0 mg/kg/d) (for 5 days) | | | artificial aortocaval fistula (for 4 days) | | | | | | | |

5 | heart insulin-like growth factor 1 mRNA level | MW | male | 0.58 | pmol/l | vehicle control condition (0 mg/kg/d) (for 5 days) then sham surgical control condition (for 4 days) | 101471 | vehicle control condition (0 mg/kg/d) (for 5 days) | | | sham surgical control condition (for 4 days) | | | | | | | |

8 | heart insulin-like growth factor 1 mRNA level | MW | male | 0.8 | pmol/l | vehicle control condition (0 mg/kg/d) (for 8 days) then artificial aortocaval fistula (for 7 days) | 101474 | vehicle control condition (0 mg/kg/d) (for 8 days) | | | artificial aortocaval fistula (for 7 days) | | | | | | | |

6 | heart insulin-like growth factor 1 mRNA level | MW | male | 0.34 | pmol/l | vehicle control condition (0 mg/kg/d) (for 8 days) then sham surgical control condition (for 7 days) | 101475 | vehicle control condition (0 mg/kg/d) (for 8 days) | | | sham surgical control condition (for 7 days) | | | | | | | |

7 | heart insulin-like growth factor 1 receptor mRNA level | MW | male | 0.64 | pmol/l | vehicle control condition (0 mg/kg/d) (for 5 days) then artificial aortocaval fistula (for 4 days) | 101478 | vehicle control condition (0 mg/kg/d) (for 5 days) | | | artificial aortocaval fistula (for 4 days) | | | | | | | |

5 | heart insulin-like growth factor 1 receptor mRNA level | MW | male | 0.85 | pmol/l | vehicle control condition (0 mg/kg/d) (for 5 days) then sham surgical control condition (for 4 days) | 101479 | vehicle control condition (0 mg/kg/d) (for 5 days) | | | sham surgical control condition (for 4 days) | | | | | | | |

7 | heart insulin-like growth factor 1 receptor mRNA level | MW | male | 1.07 | pmol/l | vehicle control condition (0 mg/kg/d) (for 8 days) then artificial aortocaval fistula (for 7 days) | 101482 | vehicle control condition (0 mg/kg/d) (for 8 days) | | | artificial aortocaval fistula (for 7 days) | | | | | | | |

5 | heart insulin-like growth factor 1 receptor mRNA level | MW | male | 1.24 | pmol/l | vehicle control condition (0 mg/kg/d) (for 8 days) then sham surgical control condition (for 7 days) | 101483 | vehicle control condition (0 mg/kg/d) (for 8 days) | | | sham surgical control condition (for 7 days) | | | | | | | |

7 | heart insulin-like growth factor 1 receptor mRNA level | MW | male | 0.83 | pmol/l | vehicle control condition (0 mg/kg/d) (for 10 days) then artificial aortocaval fistula (for 9 days) | 101485 | vehicle control condition (0 mg/kg/d) (for 10 days) | | | artificial aortocaval fistula (for 9 days) | | | | | | | |

6 | heart insulin-like growth factor 1 receptor mRNA level | MW | male | 1.08 | pmol/l | vehicle control condition (0 mg/kg/d) (for 3 days) then artificial aortocaval fistula (for 2 days) | 101488 | vehicle control condition (0 mg/kg/d) (for 3 days) | | | artificial aortocaval fistula (for 2 days) | | | | | | | |

6 | heart insulin-like growth factor 1 receptor mRNA level | MW | male | 1 | pmol/l | vehicle control condition (0 mg/kg/d) (for 3 days) then sham surgical control condition (for 2 days) | 101489 | vehicle control condition (0 mg/kg/d) (for 3 days) | | | sham surgical control condition (for 2 days) | | | | | | | |

8 | heart insulin-like growth factor 1 receptor mRNA level | MW | male | 0.99 | pmol/l | vehicle control condition (0 mg/kg/d) (for 5 days) then artificial aortocaval fistula (for 4 days) | 101493 | vehicle control condition (0 mg/kg/d) (for 5 days) | | | artificial aortocaval fistula (for 4 days) | | | | | | | |

5 | heart insulin-like growth factor 1 receptor mRNA level | MW | male | 0.79 | pmol/l | vehicle control condition (0 mg/kg/d) (for 5 days) then sham surgical control condition (for 4 days) | 101494 | vehicle control condition (0 mg/kg/d) (for 5 days) | | | sham surgical control condition (for 4 days) | | | | | | | |

8 | heart insulin-like growth factor 1 receptor mRNA level | MW | male | 0.99 | pmol/l | vehicle control condition (0 mg/kg/d) (for 8 days) then artificial aortocaval fistula (for 7 days) | 101497 | vehicle control condition (0 mg/kg/d) (for 8 days) | | | artificial aortocaval fistula (for 7 days) | | | | | | | |

6 | heart insulin-like growth factor 1 receptor mRNA level | MW | male | 0.65 | pmol/l | vehicle control condition (0 mg/kg/d) (for 8 days) then sham surgical control condition (for 7 days) | 101498 | vehicle control condition (0 mg/kg/d) (for 8 days) | | | sham surgical control condition (for 7 days) | | | | | | | |

9 | body weight | SS.ZUC-Leprfa+/+/Slc | female | 294 | g | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101661 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

8 | body weight | SS.ZUC-Leprfa-/-/Slc | female | 393 | g | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101663 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

9 | tibia straight segment length | SS.ZUC-Leprfa+/+/Slc | female | 35.8 | mm | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101665 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

8 | tibia straight segment length | SS.ZUC-Leprfa-/-/Slc | female | 32.5 | mm | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101667 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

9 | systolic blood pressure | SS.ZUC-Leprfa+/+/Slc | female | 138 | mmHg | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101669 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

8 | systolic blood pressure | SS.ZUC-Leprfa-/-/Slc | female | 221 | mmHg | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101671 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

9 | heart rate | SS.ZUC-Leprfa+/+/Slc | female | 380 | beats/min | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101673 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

8 | heart rate | SS.ZUC-Leprfa-/-/Slc | female | 339 | beats/min | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101675 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

9 | rate-pressure product | SS.ZUC-Leprfa+/+/Slc | female | 52376 | beats/min/mmHg | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101677 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

8 | rate-pressure product | SS.ZUC-Leprfa-/-/Slc | female | 73513 | beats/min/mmHg | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101679 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

9 | heart weight to tibia length ratio | SS.ZUC-Leprfa+/+/Slc | female | 0.263 | g/cm | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101681 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

9 | heart left ventricle posterior wall thickness | SS.ZUC-Leprfa+/+/Slc | female | 1.5 | mm | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101711 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

8 | heart left ventricle posterior wall thickness | SS.ZUC-Leprfa-/-/Slc | female | 2.06 | mm | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101713 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

9 | heart left ventricular end-diastolic diameter | SS.ZUC-Leprfa+/+/Slc | female | 7.21 | mm | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101715 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

8 | heart left ventricular end-diastolic diameter | SS.ZUC-Leprfa-/-/Slc | female | 7.2 | mm | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101717 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

9 | heart left ventricle fractional shortening | SS.ZUC-Leprfa+/+/Slc | female | 39.8 | % | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101719 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

8 | heart left ventricle fractional shortening | SS.ZUC-Leprfa-/-/Slc | female | 47.7 | % | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101721 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

9 | calculated heart left ventricle weight | SS.ZUC-Leprfa+/+/Slc | female | 764 | mg | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101723 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

8 | calculated heart left ventricle weight | SS.ZUC-Leprfa-/-/Slc | female | 1114 | mg | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101725 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

9 | heart relative wall thickness | SS.ZUC-Leprfa+/+/Slc | female | 0.44 | | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101727 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

8 | heart relative wall thickness | SS.ZUC-Leprfa-/-/Slc | female | 0.57 | | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101729 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

9 | E wave deceleration time | SS.ZUC-Leprfa+/+/Slc | female | 35.4 | ms | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101731 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

8 | E wave deceleration time | SS.ZUC-Leprfa-/-/Slc | female | 56.9 | ms | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101733 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

9 | heart isovolumetric relaxation time | SS.ZUC-Leprfa+/+/Slc | female | 24.8 | ms | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101735 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

8 | heart isovolumetric relaxation time | SS.ZUC-Leprfa-/-/Slc | female | 43.1 | ms | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101737 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

9 | myocardial performance index | SS.ZUC-Leprfa+/+/Slc | female | 0.44 | | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101739 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

8 | myocardial performance index | SS.ZUC-Leprfa-/-/Slc | female | 0.61 | | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101741 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

9 | left ventricular end-diastolic blood pressure | SS.ZUC-Leprfa+/+/Slc | female | 2.27 | mmHg | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101743 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

8 | left ventricular end-diastolic blood pressure | SS.ZUC-Leprfa-/-/Slc | female | 4.43 | mmHg | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101745 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

9 | time constant of left ventricular pressure decay | SS.ZUC-Leprfa+/+/Slc | female | 36.2 | ms | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101747 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

8 | time constant of left ventricular pressure decay | SS.ZUC-Leprfa-/-/Slc | female | 47.3 | ms | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101749 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

9 | heart left ventricular end-diastolic blood pressure to heart left ventricular end-diastolic diameter ratio | SS.ZUC-Leprfa+/+/Slc | female | 0.32 | mmHg/mm | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101751 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

8 | heart left ventricular end-diastolic blood pressure to heart left ventricular end-diastolic diameter ratio | SS.ZUC-Leprfa-/-/Slc | female | 0.63 | mmHg/mm | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101753 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

13 | heart posterior wall thickness | SS.ZUC-Leprfa-/-/Slc | male | 0.206 | cm | vehicle control condition (0.5 %) (for 28 days) | 101998 | vehicle control condition (0.5 %) (for 28 days) | | | | | | | | | | |

13 | heart relative wall thickness | SS.ZUC-Leprfa-/-/Slc | male | 0.49 | | vehicle control condition (0.5 %) (for 28 days) | 102004 | vehicle control condition (0.5 %) (for 28 days) | | | | | | | | | | |

13 | heart left ventricle fractional shortening | SS.ZUC-Leprfa-/-/Slc | male | 47.66 | % | vehicle control condition (0.5 %) (for 28 days) | 102007 | vehicle control condition (0.5 %) (for 28 days) | | | | | | | | | | |

13 | ejection fraction | SS.ZUC-Leprfa-/-/Slc | male | 82.5 | % | vehicle control condition (0.5 %) (for 28 days) | 102010 | vehicle control condition (0.5 %) (for 28 days) | | | | | | | | | | |

13 | E wave deceleration time | SS.ZUC-Leprfa-/-/Slc | male | 53.05 | ms | vehicle control condition (0.5 %) (for 28 days) | 102013 | vehicle control condition (0.5 %) (for 28 days) | | | | | | | | | | |

13 | heart isovolumetric relaxation time | SS.ZUC-Leprfa-/-/Slc | male | 40.75 | ms | vehicle control condition (0.5 %) (for 28 days) | 102016 | vehicle control condition (0.5 %) (for 28 days) | | | | | | | | | | |

13 | time constant of left ventricular pressure decay | SS.ZUC-Leprfa-/-/Slc | male | 33.52 | ms | vehicle control condition (0.5 %) (for 28 days) | 102019 | vehicle control condition (0.5 %) (for 28 days) | | | | | | | | | | |

13 | left ventricular end-diastolic blood pressure | SS.ZUC-Leprfa-/-/Slc | male | 17.65 | mmHg | vehicle control condition (0.5 %) (for 28 days) | 102022 | vehicle control condition (0.5 %) (for 28 days) | | | | | | | | | | |

13 | heart left ventricular end-diastolic blood pressure to heart left ventricular end-diastolic diameter ratio | SS.ZUC-Leprfa-/-/Slc | male | 2.1 | mmHg/mm | vehicle control condition (0.5 %) (for 28 days) | 102025 | vehicle control condition (0.5 %) (for 28 days) | | | | | | | | | | |

8 | heart left ventricular end-diastolic diameter | SS/NEisSlc | male | 8.7 | mm | controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days) | 102320 | controlled sodium content diet (0.3 %) (for 42 days) | | | controlled sodium content diet (8 %) (for 77 days) | | vehicle control condition (for 49 days) | | | | | |

8 | both kidneys wet weight to body weight ratio | SS/NEisSlc | male | 5.19 | g/kg | controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days) | 102323 | controlled sodium content diet (0.3 %) (for 42 days) | | | controlled sodium content diet (8 %) (for 77 days) | | vehicle control condition (for 49 days) | | | | | |

8 | serum creatinine level | SS/NEisSlc | male | 0.47 | mg/dl | controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days) | 102326 | controlled sodium content diet (0.3 %) (for 42 days) | | | controlled sodium content diet (8 %) (for 77 days) | | vehicle control condition (for 49 days) | | | | | |

8 | serum urea nitrogen level | SS/NEisSlc | male | 33.6 | mg/dl | controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days) | 102329 | controlled sodium content diet (0.3 %) (for 42 days) | | | controlled sodium content diet (8 %) (for 77 days) | | vehicle control condition (for 49 days) | | | | | |

8 | creatinine clearance | SS/NEisSlc | male | 1.9 | ml/min | controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days) | 102332 | controlled sodium content diet (0.3 %) (for 42 days) | | | controlled sodium content diet (8 %) (for 77 days) | | vehicle control condition (for 49 days) | | | | | |

8 | timed urine volume | SS/NEisSlc | male | 53.6 | ml/d | controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days) | 102335 | controlled sodium content diet (0.3 %) (for 42 days) | | | controlled sodium content diet (8 %) (for 77 days) | | vehicle control condition (for 49 days) | | | | | |

8 | urine protein excretion rate | SS/NEisSlc | male | 307 | mg/d | controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days) | 102338 | controlled sodium content diet (0.3 %) (for 42 days) | | | controlled sodium content diet (8 %) (for 77 days) | | vehicle control condition (for 49 days) | | | | | |

8 | body weight | SD-Nfe2l2em1Mcwi+/+ | male | 281 | g | controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days) | 100733 | controlled sodium content diet (0.4 %) (between 70 and 84 days) | | | controlled sodium content diet (4 %) (for 6 days) | | vehicle control condition (for 3 days) | | | | | |

4 | body weight | SD-Nfe2l2em1Mcwi-/- | male | 299 | g | controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days) | 100734 | controlled sodium content diet (0.4 %) (between 70 and 84 days) | | | controlled sodium content diet (4 %) (for 6 days) | | vehicle control condition (for 3 days) | | | | | |

7 | both kidneys wet weight to body weight ratio | SHRSP.WKY-(D3Mgh16-D3Wox3)/Gcrc | male | 3.77 | g/kg | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102161 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

7 | body weight | MW | male | 186 | g | vehicle control condition (0 mg/kg/d) (for 5 days) then artificial aortocaval fistula (for 4 days) | 101302 | vehicle control condition (0 mg/kg/d) (for 5 days) | | | artificial aortocaval fistula (for 4 days) | | | | | | | |

5 | body weight | MW | male | 188 | g | vehicle control condition (0 mg/kg/d) (for 5 days) then sham surgical control condition (for 4 days) | 101303 | vehicle control condition (0 mg/kg/d) (for 5 days) | | | sham surgical control condition (for 4 days) | | | | | | | |

7 | body weight | MW | male | 184 | g | vehicle control condition (0 mg/kg/d) (for 8 days) then artificial aortocaval fistula (for 7 days) | 101306 | vehicle control condition (0 mg/kg/d) (for 8 days) | | | artificial aortocaval fistula (for 7 days) | | | | | | | |

5 | body weight | MW | male | 180 | g | vehicle control condition (0 mg/kg/d) (for 8 days) then sham surgical control condition (for 7 days) | 101307 | vehicle control condition (0 mg/kg/d) (for 8 days) | | | sham surgical control condition (for 7 days) | | | | | | | |

7 | body weight | MW | male | 180 | g | vehicle control condition (0 mg/kg/d) (for 10 days) then artificial aortocaval fistula (for 9 days) | 101309 | vehicle control condition (0 mg/kg/d) (for 10 days) | | | artificial aortocaval fistula (for 9 days) | | | | | | | |

8 | body weight | MW | male | 202 | g | vehicle control condition (0 mg/kg/d) (for 3 days) then artificial aortocaval fistula (for 2 days) | 101312 | vehicle control condition (0 mg/kg/d) (for 3 days) | | | artificial aortocaval fistula (for 2 days) | | | | | | | |

6 | body weight | MW | male | 200 | g | vehicle control condition (0 mg/kg/d) (for 3 days) then sham surgical control condition (for 2 days) | 101313 | vehicle control condition (0 mg/kg/d) (for 3 days) | | | sham surgical control condition (for 2 days) | | | | | | | |

8 | body weight | MW | male | 194 | g | vehicle control condition (0 mg/kg/d) (for 5 days) then artificial aortocaval fistula (for 4 days) | 101316 | vehicle control condition (0 mg/kg/d) (for 5 days) | | | artificial aortocaval fistula (for 4 days) | | | | | | | |

5 | body weight | MW | male | 192 | g | vehicle control condition (0 mg/kg/d) (for 5 days) then sham surgical control condition (for 4 days) | 101317 | vehicle control condition (0 mg/kg/d) (for 5 days) | | | sham surgical control condition (for 4 days) | | | | | | | |

8 | body weight | MW | male | 193 | g | vehicle control condition (0 mg/kg/d) (for 8 days) then artificial aortocaval fistula (for 7 days) | 101320 | vehicle control condition (0 mg/kg/d) (for 8 days) | | | artificial aortocaval fistula (for 7 days) | | | | | | | |

6 | body weight | MW | male | 201 | g | vehicle control condition (0 mg/kg/d) (for 8 days) then sham surgical control condition (for 7 days) | 101321 | vehicle control condition (0 mg/kg/d) (for 8 days) | | | sham surgical control condition (for 7 days) | | | | | | | |

8 | systolic blood pressure | LH/Mav | male | 160 | mmHg | vehicle control condition | 102848 | vehicle control condition | | | | | | | | | | |

8 | systolic blood pressure | LH/Mav | male | 160 | mmHg | vehicle control condition | 102849 | vehicle control condition | | | | | | | | | | |

8 | renal blood flow rate to kidney weight ratio | LH/Mav | male | 5 | ml/min/g | vehicle control condition then ketamine (20 mg/kg) and thiobutabarbital (75 mg/kg) | 102853 | vehicle control condition | | | ketamine (20 mg/kg) | thiobutabarbital (75 mg/kg) | | | | | | |

8 | renal vascular resistance to kidney weight ratio | LH/Mav | male | 33 | ml/min/g/mmHg | vehicle control condition then ketamine (20 mg/kg) and thiobutabarbital (75 mg/kg) | 102857 | vehicle control condition | | | ketamine (20 mg/kg) | thiobutabarbital (75 mg/kg) | | | | | | |

7 | body weight gain | MW | male | -10 | g | vehicle control condition (0 mg/kg/d) (for 5 days) then artificial aortocaval fistula (for 4 days) | 101324 | vehicle control condition (0 mg/kg/d) (for 5 days) | | | artificial aortocaval fistula (for 4 days) | | | | | | | |

5 | body weight gain | MW | male | 18 | g | vehicle control condition (0 mg/kg/d) (for 5 days) then sham surgical control condition (for 4 days) | 101325 | vehicle control condition (0 mg/kg/d) (for 5 days) | | | sham surgical control condition (for 4 days) | | | | | | | |

5 | body weight gain | MW | male | 12 | g | vehicle control condition (0 mg/kg/d) (for 8 days) then artificial aortocaval fistula (for 7 days) | 101328 | vehicle control condition (0 mg/kg/d) (for 8 days) | | | artificial aortocaval fistula (for 7 days) | | | | | | | |

5 | body weight gain | MW | male | 34 | g | vehicle control condition (0 mg/kg/d) (for 8 days) then sham surgical control condition (for 7 days) | 101329 | vehicle control condition (0 mg/kg/d) (for 8 days) | | | sham surgical control condition (for 7 days) | | | | | | | |

7 | body weight gain | MW | male | 29 | g | vehicle control condition (0 mg/kg/d) (for 10 days) then artificial aortocaval fistula (for 9 days) | 101331 | vehicle control condition (0 mg/kg/d) (for 10 days) | | | artificial aortocaval fistula (for 9 days) | | | | | | | |

7 | body weight gain | MW | male | -14 | g | vehicle control condition (0 mg/kg/d) (for 3 days) then artificial aortocaval fistula (for 2 days) | 101334 | vehicle control condition (0 mg/kg/d) (for 3 days) | | | artificial aortocaval fistula (for 2 days) | | | | | | | |

6 | body weight gain | MW | male | -6 | g | vehicle control condition (0 mg/kg/d) (for 3 days) then sham surgical control condition (for 2 days) | 101335 | vehicle control condition (0 mg/kg/d) (for 3 days) | | | sham surgical control condition (for 2 days) | | | | | | | |

7 | body weight gain | MW | male | -5 | g | vehicle control condition (0 mg/kg/d) (for 5 days) then artificial aortocaval fistula (for 4 days) | 101338 | vehicle control condition (0 mg/kg/d) (for 5 days) | | | artificial aortocaval fistula (for 4 days) | | | | | | | |

5 | body weight gain | MW | male | 6 | g | vehicle control condition (0 mg/kg/d) (for 5 days) then sham surgical control condition (for 4 days) | 101339 | vehicle control condition (0 mg/kg/d) (for 5 days) | | | sham surgical control condition (for 4 days) | | | | | | | |

8 | heart weight to tibia length ratio | SS.ZUC-Leprfa-/-/Slc | female | 0.35 | g/cm | bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) | 101693 | bilateral ovariectomy (for 42 days) | | | vehicle control condition (for 35 days) | | | | | | | |

N/A | both kidneys wet weight to body weight ratio | SHRSP.WKY-(D3Mgh16-rs197649383)/Gcrc | male | 4.25 | g/kg | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102124 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

N/A | both kidneys wet weight to body weight ratio | SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrc | male | 4.2 | g/kg | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102125 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

17 | water drink intake rate | SHRSP/Gcrc | male | 78.62 | ml/d | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102126 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

18 | water drink intake rate | WKY/Gcrc | male | 53.12 | ml/d | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102127 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

9 | water drink intake rate | SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrc | male | 58.47 | ml/d | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102128 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

7 | water drink intake rate | SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrc | male | 57.55 | ml/d | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102129 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

6 | water drink intake rate | SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrc | male | 79.16 | ml/d | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102130 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

17 | timed urine volume | SHRSP/Gcrc | male | 55.29 | ml/d | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102131 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

18 | timed urine volume | WKY/Gcrc | male | 31.8 | ml/d | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102132 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

9 | timed urine volume | SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrc | male | 34.03 | ml/d | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102133 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

7 | timed urine volume | SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrc | male | 30.68 | ml/d | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102134 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

6 | timed urine volume | SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrc | male | 55.86 | ml/d | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102135 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

17 | urine sodium level | SHRSP/Gcrc | male | 211.14 | mmol/l | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102136 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

18 | urine sodium level | WKY/Gcrc | male | 220.23 | mmol/l | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102137 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

30 | heart ventricle septal wall thickness | WKY | male | 0.1 | cm | left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) | 100338 | left anterior descending coronary artery occlusion (for 196 days) | | | vehicle control condition (for 182 days) | | | | | | | |

30 | heart left ventricular end-diastolic diameter | WKY | male | 10.6 | mm | left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) | 100341 | left anterior descending coronary artery occlusion (for 196 days) | | | vehicle control condition (for 182 days) | | | | | | | |

30 | heart left ventricle end-systolic diameter | WKY | male | 8.9 | mm | left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) | 100344 | left anterior descending coronary artery occlusion (for 196 days) | | | vehicle control condition (for 182 days) | | | | | | | |

30 | heart posterior wall thickness | WKY | male | 0.18 | cm | left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) | 100347 | left anterior descending coronary artery occlusion (for 196 days) | | | vehicle control condition (for 182 days) | | | | | | | |

30 | heart left ventricle fractional shortening | WKY | male | 15.8 | % | left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) | 100350 | left anterior descending coronary artery occlusion (for 196 days) | | | vehicle control condition (for 182 days) | | | | | | | |

30 | ejection fraction | WKY | male | 37 | % | left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) | 100353 | left anterior descending coronary artery occlusion (for 196 days) | | | vehicle control condition (for 182 days) | | | | | | | |

30 | E/A wave ratio | WKY | male | 1.85 | | left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) | 100356 | left anterior descending coronary artery occlusion (for 196 days) | | | vehicle control condition (for 182 days) | | | | | | | |

15 | right kidney wet weight | WKY | male | 1.3533 | g | left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) | 100359 | left anterior descending coronary artery occlusion (for 196 days) | | | vehicle control condition (for 182 days) | | | | | | | |

7 | timed urine volume | WKY | male | 10.6 | ml/d | left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) | 100362 | left anterior descending coronary artery occlusion (for 196 days) | | | vehicle control condition (for 182 days) | | | | | | | |

6 | plasma creatinine level | WKY | male | 0.52 | mg/dl | left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) | 100365 | left anterior descending coronary artery occlusion (for 196 days) | | | vehicle control condition (for 182 days) | | | | | | | |

15 | index of glomerular damage | WKY | male | 1.6 | | left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) | 100368 | left anterior descending coronary artery occlusion (for 196 days) | | | vehicle control condition (for 182 days) | | | | | | | |

9 | urine sodium level | SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrc | male | 268.97 | mmol/l | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102138 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

7 | urine sodium level | SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrc | male | 260.49 | mmol/l | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102139 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

6 | urine sodium level | SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrc | male | 169.89 | mmol/l | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102140 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

17 | urine potassium level | SHRSP/Gcrc | male | 44.48 | mmol/l | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102141 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

18 | urine potassium level | WKY/Gcrc | male | 71.25 | mmol/l | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102142 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

9 | urine potassium level | SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrc | male | 72.41 | mmol/l | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102143 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

7 | urine potassium level | SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrc | male | 80.72 | mmol/l | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102144 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

6 | urine potassium level | SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrc | male | 28.25 | mmol/l | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102145 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

17 | urine urea level | SHRSP/Gcrc | male | 131.16 | mmol/l | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102146 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

18 | urine urea level | WKY/Gcrc | male | 235.52 | mmol/l | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102147 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

9 | urine urea level | SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrc | male | 228.93 | mmol/l | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102148 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

7 | urine urea level | SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrc | male | 316.61 | mmol/l | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102149 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

6 | urine urea level | SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrc | male | 103 | mmol/l | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102150 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

17 | urine creatinine level | SHRSP/Gcrc | male | 6.85368 | mg/dl | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102151 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

18 | urine creatinine level | WKY/Gcrc | male | 13.90776 | mg/dl | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102152 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

9 | urine creatinine level | SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrc | male | 10.4208 | mg/dl | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102153 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

7 | urine creatinine level | SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrc | male | 12.38472 | mg/dl | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102154 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

6 | urine creatinine level | SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrc | male | 5.37072 | mg/dl | vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days) | 102155 | vehicle control condition (for 126 days) | | | sodium chloride solution (1 %) (for 21 days) | | | | | | | |

6 | body weight | WKY/NCrl | male | 463 | g | vehicle control condition (for 28 days) | 103490 | vehicle control condition (for 28 days) | | | | | | | | | | |

6 | body weight | GK | male | 380 | g | vehicle control condition (for 28 days) | 103492 | vehicle control condition (for 28 days) | | | | | | | | | | |

6 | water intake drink rate to body weight ratio | WKY/NCrl | male | 50 | ml/d/kg | vehicle control condition (between 1 and 35 days) | 103498 | vehicle control condition (between 1 and 35 days) | | | | | | | | | | |

6 | water intake drink rate to body weight ratio | GK | male | 99 | ml/d/kg | vehicle control condition (between 1 and 35 days) | 103500 | vehicle control condition (between 1 and 35 days) | | | | | | | | | | |

6 | serum fructosamine level | WKY/NCrl | male | 153 | umol/l | vehicle control condition (for 35 days) | 103502 | vehicle control condition (for 35 days) | | | | | | | | | | |

6 | serum fructosamine level | GK | male | 187 | umol/l | vehicle control condition (for 35 days) | 103504 | vehicle control condition (for 35 days) | | | | | | | | | | |

6 | blood glucose level | WKY/NCrl | male | 113 | mg/dl | vehicle control condition (for 28 days) then fasting (for 16 hours) | 103510 | vehicle control condition (for 28 days) | | | fasting (for 16 hours) | | | | | | | |

6 | blood glucose level | GK | male | 122 | mg/dl | vehicle control condition (for 28 days) then fasting (for 16 hours) | 103512 | vehicle control condition (for 28 days) | | | fasting (for 16 hours) | | | | | | | |

6 | blood glucose level | WKY/NCrl | male | 125 | mg/dl | vehicle control condition (for 28 days) then fasting (for 16 hours) then glucose (2 g/kg) (for 2 hours) | 103518 | vehicle control condition (for 28 days) | | | fasting (for 16 hours) | | glucose (2 g/kg) (for 2 hours) | | | | | |

6 | blood glucose level | GK | male | 278 | mg/dl | vehicle control condition (for 28 days) then fasting (for 16 hours) then glucose (2 g/kg) (for 2 hours) | 103520 | vehicle control condition (for 28 days) | | | fasting (for 16 hours) | | glucose (2 g/kg) (for 2 hours) | | | | | |

30 | heart left ventricle infarction size to total heart left ventricle size ratio | WKY | male | 35.8 | % | left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) | 100264 | left anterior descending coronary artery occlusion (for 196 days) | | | vehicle control condition (for 182 days) | | | | | | | |

30 | body weight | WKY | male | 225 | g | left anterior descending coronary artery occlusion then vehicle control condition | 100269 | left anterior descending coronary artery occlusion | | | vehicle control condition | | | | | | | |

30 | body weight | WKY | male | 617 | g | left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) | 100272 | left anterior descending coronary artery occlusion (for 196 days) | | | vehicle control condition (for 182 days) | | | | | | | |

30 | heart weight | WKY | male | 1.573 | g | left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) | 100278 | left anterior descending coronary artery occlusion (for 196 days) | | | vehicle control condition (for 182 days) | | | | | | | |

30 | heart left ventricle weight | WKY | male | 0.969 | g | left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) | 100290 | left anterior descending coronary artery occlusion (for 196 days) | | | vehicle control condition (for 182 days) | | | | | | | |

30 | lung wet weight | WKY | male | 2.134 | g | left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) | 100299 | left anterior descending coronary artery occlusion (for 196 days) | | | vehicle control condition (for 182 days) | | | | | | | |

13 | body weight | SD | female | 283.6 | g | controlled calcium content diet (0.6 %) (for 97 days) and controlled content diet (0.9 %) (for 97 days) and unilateral nephrectomy (for 97 days) then vehicle control condition (100 ul) (for 90 days) | 100632 | controlled calcium content diet (0.6 %) (for 97 days) | controlled content diet (0.9 %) (for 97 days) | unilateral nephrectomy (for 97 days) | vehicle control condition (100 ul) (for 90 days) | | | | | | | |

13 | serum creatinine level | SD | female | 1.65 | mg/dl | controlled calcium content diet (0.6 %) (for 97 days) and controlled content diet (0.9 %) (for 97 days) and unilateral nephrectomy (for 97 days) then vehicle control condition (100 ul) (for 90 days) | 100637 | controlled calcium content diet (0.6 %) (for 97 days) | controlled content diet (0.9 %) (for 97 days) | unilateral nephrectomy (for 97 days) | vehicle control condition (100 ul) (for 90 days) | | | | | | | |

13 | creatinine clearance | SD | female | 0.3 | ml/min | controlled calcium content diet (0.6 %) (for 97 days) and controlled content diet (0.9 %) (for 97 days) and unilateral nephrectomy (for 97 days) then vehicle control condition (100 ul) (for 90 days) | 100642 | controlled calcium content diet (0.6 %) (for 97 days) | controlled content diet (0.9 %) (for 97 days) | unilateral nephrectomy (for 97 days) | vehicle control condition (100 ul) (for 90 days) | | | | | | | |

13 | serum parathyroid hormone level | SD | female | 3496 | pg/ml | controlled calcium content diet (0.6 %) (for 97 days) and controlled content diet (0.9 %) (for 97 days) and unilateral nephrectomy (for 97 days) then vehicle control condition (100 ul) (for 90 days) | 100647 | controlled calcium content diet (0.6 %) (for 97 days) | controlled content diet (0.9 %) (for 97 days) | unilateral nephrectomy (for 97 days) | vehicle control condition (100 ul) (for 90 days) | | | | | | | |

5 | blood urea nitrogen level | PCK-Pkhd1pck/CrljCrl | male | 20.6 | mg/dl | naive control condition (for 28 days) then vehicle control condition (for 84 days) | 100763 | naive control condition (for 28 days) | | | vehicle control condition (for 84 days) | | | | | | | |

5 | blood urea nitrogen level | Crl:CD(SD) | male | 19.3 | mg/dl | naive control condition (for 28 days) then vehicle control condition (for 84 days) | 100764 | naive control condition (for 28 days) | | | vehicle control condition (for 84 days) | | | | | | | |

5 | serum creatinine level | PCK-Pkhd1pck/CrljCrl | male | 0.51 | mg/dl | naive control condition (for 28 days) then vehicle control condition (for 84 days) | 100765 | naive control condition (for 28 days) | | | vehicle control condition (for 84 days) | | | | | | | |

5 | serum creatinine level | Crl:CD(SD) | male | 0.43 | mg/dl | naive control condition (for 28 days) then vehicle control condition (for 84 days) | 100766 | naive control condition (for 28 days) | | | vehicle control condition (for 84 days) | | | | | | | |

5 | urine total protein excretion rate | Crl:CD(SD) | male | 36.7 | mg/d | naive control condition (for 28 days) then vehicle control condition (for 84 days) | 100768 | naive control condition (for 28 days) | | | vehicle control condition (for 84 days) | | | | | | | |

6 | urine protein level to urine creatinine level ratio | PCK-Pkhd1pck/CrljCrl | male | 12 | | naive control condition (for 28 days) then vehicle control condition (for 84 days) | 100769 | naive control condition (for 28 days) | | | vehicle control condition (for 84 days) | | | | | | | |

5 | urine protein level to urine creatinine level ratio | Crl:CD(SD) | male | 1.98 | | naive control condition (for 28 days) then vehicle control condition (for 84 days) | 100770 | naive control condition (for 28 days) | | | vehicle control condition (for 84 days) | | | | | | | |

5 | plasma angiotensin II level to plasma angiotensin I level ratio | SHR/NCrlCrlj | male | 80 | | unilateral nephrectomy (for 42 days) then vehicle control condition (for 28 days) | 101278 | unilateral nephrectomy (for 42 days) | | | vehicle control condition (for 28 days) | | | | | | | |

6 | body weight gain | MW | male | 8 | g | vehicle control condition (0 mg/kg/d) (for 8 days) then artificial aortocaval fistula (for 7 days) | 101342 | vehicle control condition (0 mg/kg/d) (for 8 days) | | | artificial aortocaval fistula (for 7 days) | | | | | | | |

5 | body weight gain | MW | male | 23 | g | vehicle control condition (0 mg/kg/d) (for 8 days) then sham surgical control condition (for 7 days) | 101343 | vehicle control condition (0 mg/kg/d) (for 8 days) | | | sham surgical control condition (for 7 days) | | | | | | | |

6 | systolic blood pressure | MW | male | 103 | mmHg | vehicle control condition (0 mg/kg/d) (for 5 days) then artificial aortocaval fistula (for 4 days) | 101346 | vehicle control condition (0 mg/kg/d) (for 5 days) | | | artificial aortocaval fistula (for 4 days) | | | | | | | |

7 | heart rate | MW | male | 460 | beats/min | vehicle control condition (0 mg/kg/d) (for 10 days) then artificial aortocaval fistula (for 9 days) | 101375 | vehicle control condition (0 mg/kg/d) (for 10 days) | | | artificial aortocaval fistula (for 9 days) | | | | | | | |

5 | heart rate | MW | male | 470 | beats/min | vehicle control condition (0 mg/kg/d) (for 3 days) then artificial aortocaval fistula (for 2 days) | 101378 | vehicle control condition (0 mg/kg/d) (for 3 days) | | | artificial aortocaval fistula (for 2 days) | | | | | | | |

6 | heart rate | MW | male | 377 | beats/min | vehicle control condition (0 mg/kg/d) (for 3 days) then sham surgical control condition (for 2 days) | 101379 | vehicle control condition (0 mg/kg/d) (for 3 days) | | | sham surgical control condition (for 2 days) | | | | | | | |

7 | heart right ventricle weight | MW | male | 0.093 | g | vehicle control condition (0 mg/kg/d) (for 10 days) then artificial aortocaval fistula (for 9 days) | 101419 | vehicle control condition (0 mg/kg/d) (for 10 days) | | | artificial aortocaval fistula (for 9 days) | | | | | | | |

5 | mean arterial blood pressure | GK | male | 118 | mmHg | air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) | 103025 | air oxygen content (21 %) (for 28 days) | | | vehicle control condition (0.15 ml) (for 0.1 hours) | | acetylcholine (5 ug/kg/min) (for 0.1 hours) | | sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) | | | |

6 | heart rate | SS/JrHsdMcwi | male | 358 | beats/min | vehicle control condition | 106798 | vehicle control condition | | | | | | | | | | |

8 | heart rate | SS-Sod3m1Mcwi | male | 354 | beats/min | vehicle control condition | 106799 | vehicle control condition | | | | | | | | | | |

6 | systolic blood pressure | SS/JrHsdMcwi | male | 115 | mmHg | vehicle control condition | 106802 | vehicle control condition | | | | | | | | | | |

8 | systolic blood pressure | SS-Sod3m1Mcwi | male | 115 | mmHg | vehicle control condition | 106803 | vehicle control condition | | | | | | | | | | |

6 | diastolic blood pressure | SS/JrHsdMcwi | male | 84 | mmHg | vehicle control condition | 106806 | vehicle control condition | | | | | | | | | | |

8 | diastolic blood pressure | SS-Sod3m1Mcwi | male | 84.2 | mmHg | vehicle control condition | 106807 | vehicle control condition | | | | | | | | | | |

6 | mean aortic pressure | SS/JrHsdMcwi | male | 94.4 | mmHg | vehicle control condition | 106810 | vehicle control condition | | | | | | | | | | |

8 | mean aortic pressure | SS-Sod3m1Mcwi | male | 94.5 | mmHg | vehicle control condition | 106811 | vehicle control condition | | | | | | | | | | |

10 | plasma creatinine level | SS/NEisSlc | not specified | 0.59049684 | mg/dl | vehicle control condition (for 547.5 days) | 107421 | vehicle control condition (for 547.5 days) | | | | | | | | | | |

10 | urine total protein excretion rate | SS/NEisSlc | not specified | 215.9 | mg/d | vehicle control condition (for 547.5 days) | 107437 | vehicle control condition (for 547.5 days) | | | | | | | | | | |

N/A | urine protein excretion rate | SHRSP/A3N | male | 127 | mg/d | controlled sodium chloride content drinking water (1 %) (between 35 and 49 days) and controlled fat content diet (24.5 %) (between 35 and 49 days) and vehicle control condition (between 35 and 49 days) | 107520 | controlled sodium chloride content drinking water (1 %) (between 35 and 49 days) | controlled fat content diet (24.5 %) (between 35 and 49 days) | vehicle control condition (between 35 and 49 days) | | | | | | | | |

N/A | body weight | SHRSP/A3N | male | 254 | g | controlled sodium chloride content drinking water (1 %) (for 42 days) and controlled fat content diet (24.5 %) (for 42 days) and vehicle control condition (for 42 days) | 107527 | controlled sodium chloride content drinking water (1 %) (for 42 days) | controlled fat content diet (24.5 %) (for 42 days) | vehicle control condition (for 42 days) | | | | | | | | |

N/A | kidney weight | SHRSP/A3N | male | 2.65 | g | controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days) | 107531 | controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) | controlled fat content diet (24.5 %) (between 42 and 77 days) | vehicle control condition (between 42 and 77 days) | | | | | | | | |

17 | kidney glomerular tuft surface area | WKY | male | 13.2 | x 10E3 um2 | unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition | 107511 | unilateral nephrectomy (for 150 days) | | | streptozotocin (35 mg/kg) | | vehicle control condition | | | | | |

N/A | kidney tubule regeneration foci count | SHRSP/A3N | male | 27.3 | /section | controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days) | 107547 | controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) | controlled fat content diet (24.5 %) (between 42 and 77 days) | vehicle control condition (between 42 and 77 days) | | | | | | | | |

N/A | interstitial nephritis foci count | SHRSP/A3N | male | 8.5 | /section | controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days) | 107551 | controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) | controlled fat content diet (24.5 %) (between 42 and 77 days) | vehicle control condition (between 42 and 77 days) | | | | | | | | |

10 | plasma total cholesterol level | WAG/Nov | male | 74.4 | mg/dl | vehicle control condition (2 ml/kg) (for 1 days) | 107781 | vehicle control condition (2 ml/kg) (for 1 days) | | | | | | | | | | |

10 | plasma total cholesterol level | ISIAH | male | 59.5 | mg/dl | vehicle control condition (2 ml/kg) (for 1 days) | 107784 | vehicle control condition (2 ml/kg) (for 1 days) | | | | | | | | | | |

10 | plasma high density lipoprotein phospholipid level | WAG/Nov | male | 47.1 | mg/dl | vehicle control condition (2 ml/kg) (for 1 days) | 107787 | vehicle control condition (2 ml/kg) (for 1 days) | | | | | | | | | | |

10 | plasma high density lipoprotein phospholipid level | ISIAH | male | 36.2 | mg/dl | vehicle control condition (2 ml/kg) (for 1 days) | 107790 | vehicle control condition (2 ml/kg) (for 1 days) | | | | | | | | | | |

10 | platelet distribution width | BDIX/CrCrl | male | 8.7 | fl | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107882 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

10 | platelet distribution width | BDIX/CrCrl | male | 8.6 | fl | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107884 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

10 | serum urea nitrogen level | BDIX/CrCrl | male | 35 | mg/dl | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107887 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

10 | serum urea nitrogen level | BDIX/CrCrl | male | 34.5 | mg/dl | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107889 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

17 | left kidney wet weight to body weight ratio | WKY | male | 9.9 | mg/g | unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition | 107456 | unilateral nephrectomy (for 150 days) | | | streptozotocin (35 mg/kg) | | vehicle control condition | | | | | |

10 | mean platelet volume | BDIX/CrCrl | male | 5.9 | fl | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107821 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

10 | mean platelet volume | BDIX/CrCrl | male | 5.9 | fl | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107823 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

10 | total white blood cell count | BDIX/CrCrl | male | 12.9 | x 1000 cells/ul | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107826 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

10 | total white blood cell count | BDIX/CrCrl | male | 10 | x 1000 cells/ul | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107828 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

10 | blood hemoglobin level | BDIX/CrCrl | male | 19.9 | g/dl | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107831 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

10 | blood hemoglobin level | BDIX/CrCrl | male | 18.9 | g/dl | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107833 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

N/A | kidney total tubule cast count | SHRSP/A3N | male | 349 | /section | controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days) | 107555 | controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) | controlled fat content diet (24.5 %) (between 42 and 77 days) | vehicle control condition (between 42 and 77 days) | | | | | | | | |

N/A | renal fibrosis foci count | SHRSP/A3N | male | 16.4 | /section | controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days) | 107559 | controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) | controlled fat content diet (24.5 %) (between 42 and 77 days) | vehicle control condition (between 42 and 77 days) | | | | | | | | |

10 | systolic blood pressure | SS/NEisSlc | not specified | 137 | mmHg | vehicle control condition (for 547.5 days) | 106791 | vehicle control condition (for 547.5 days) | | | | | | | | | | |

10 | heart weight to body weight ratio | SS/NEisSlc | not specified | 3.2 | g/kg | vehicle control condition (for 547.5 days) | 106792 | vehicle control condition (for 547.5 days) | | | | | | | | | | |

17 | body weight | WKY | male | 256 | g | unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition | 107446 | unilateral nephrectomy (for 150 days) | | | streptozotocin (35 mg/kg) | | vehicle control condition | | | | | |

17 | heart weight to body weight ratio | WKY | male | 3.5 | g/kg | unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition | 107451 | unilateral nephrectomy (for 150 days) | | | streptozotocin (35 mg/kg) | | vehicle control condition | | | | | |

17 | kidney glomerular surface area | WKY | male | 19.3 | x 10E3 um2 | unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition | 107461 | unilateral nephrectomy (for 150 days) | | | streptozotocin (35 mg/kg) | | vehicle control condition | | | | | |

10 | thymus weight to body weight ratio | WAG/Nov | male | 0.77 | mg/g | vehicle control condition (2 ml/kg) (for 1 days) | 107688 | vehicle control condition (2 ml/kg) (for 1 days) | | | | | | | | | | |

10 | thymus weight to body weight ratio | ISIAH | male | 1.95 | mg/g | vehicle control condition (2 ml/kg) (for 1 days) | 107689 | vehicle control condition (2 ml/kg) (for 1 days) | | | | | | | | | | |

10 | thymocyte count | WAG/Nov | male | 1028.62 | x10E6/organ | vehicle control condition (2 ml/kg) (for 1 days) | 107693 | vehicle control condition (2 ml/kg) (for 1 days) | | | | | | | | | | |

10 | red blood cell count | BDIX/CrCrl | male | 11 | x 10E6 cells/ul | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107801 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

10 | mean corpuscular volume | BDIX/CrCrl | male | 47.5 | fl | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107806 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

10 | mean corpuscular volume | BDIX/CrCrl | male | 47.5 | fl | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107808 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

10 | hematocrit | BDIX/CrCrl | male | 52.3 | % | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107811 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

10 | hematocrit | BDIX/CrCrl | male | 51 | % | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107813 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

11 | kidney glomerular tuft surface area | WKY | male | 8.7 | x 10E3 um2 | unilateral nephrectomy (for 150 days) then vehicle control condition | 107510 | unilateral nephrectomy (for 150 days) | | | vehicle control condition | | | | | | | |

10 | spleen cell count | WAG/Nov | male | 707.11 | x10E6/organ | vehicle control condition (2 ml/kg) (for 1 days) | 107700 | vehicle control condition (2 ml/kg) (for 1 days) | | | | | | | | | | |

10 | spleen cell count | ISIAH | male | 583.56 | x10E6/organ | vehicle control condition (2 ml/kg) (for 1 days) | 107703 | vehicle control condition (2 ml/kg) (for 1 days) | | | | | | | | | | |

10 | apoptotic hypodiploid thymocyte count to total thymocyte count ratio | WAG/Nov | male | 0.45 | % | vehicle control condition (2 ml/kg) (for 1 days) | 107706 | vehicle control condition (2 ml/kg) (for 1 days) | | | | | | | | | | |

10 | G0 stage diploid thymocyte count to total thymocyte count ratio | WAG/Nov | male | 93.31 | % | vehicle control condition (2 ml/kg) (for 1 days) | 107709 | vehicle control condition (2 ml/kg) (for 1 days) | | | | | | | | | | |

10 | G2/M stage tetraploid thymocyte count to total thymocyte count ratio | WAG/Nov | male | 2.62 | % | vehicle control condition (2 ml/kg) (for 1 days) | 107712 | vehicle control condition (2 ml/kg) (for 1 days) | | | | | | | | | | |

16 | body weight | WAG | male | 272.4 | g | CC531 cells (5 X 10E6) (for 21 days) then vehicle control condition (1 ml) (for 21 days) | 107872 | CC531 cells (5 X 10E6) (for 21 days) | | | vehicle control condition (1 ml) (for 21 days) | | | | | | | |

16 | metastatic intraperitoneal tumor weight | WAG/OlaHsd | male | 7.42 | g | CC531 cells (5 X 10E6) (for 21 days) then vehicle control condition (1 ml) (for 21 days) | 107874 | CC531 cells (5 X 10E6) (for 21 days) | | | vehicle control condition (1 ml) (for 21 days) | | | | | | | |

10 | serum total cholesterol level | BDIX/CrCrl | male | 40.5 | mg/dl | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107894 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

10 | serum alanine aminotransferase activity level | BDIX/CrCrl | male | 59.2 | U/l | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107907 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

10 | serum alanine aminotransferase activity level | BDIX/CrCrl | male | 44.8 | U/l | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107909 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

10 | serum alkaline phosphatase activity level | BDIX/CrCrl | male | 476 | U/l | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107912 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

10 | serum amylase activity level | BDIX/CrCrl | male | 3096 | U/l | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107944 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

11 | body weight | WKY | male | 408 | g | unilateral nephrectomy (for 150 days) then vehicle control condition | 107445 | unilateral nephrectomy (for 150 days) | | | vehicle control condition | | | | | | | |

11 | heart weight to body weight ratio | WKY | male | 2.4 | g/kg | unilateral nephrectomy (for 150 days) then vehicle control condition | 107450 | unilateral nephrectomy (for 150 days) | | | vehicle control condition | | | | | | | |

10 | red blood cell count | BDIX/CrCrl | male | 10.7 | x 10E6 cells/ul | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107803 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

10 | thymus weight to body weight ratio | SD | female | 1.5 | mg/g | vehicle control condition (5 ml/kg) (for 28 days) | 105884 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | | | |

10 | thymus weight to body weight ratio | SD-Ahrem2Sage | female | 1.61 | mg/g | vehicle control condition (5 ml/kg) (for 28 days) | 105885 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | | | |

10 | spleen weight to body weight ratio | SD | female | 0.299 | % | vehicle control condition (5 ml/kg) (for 28 days) | 105896 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | | | |

10 | spleen weight to body weight ratio | SD-Ahrem2Sage | female | 0.286 | % | vehicle control condition (5 ml/kg) (for 28 days) | 105897 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | | | |

10 | brain weight to body weight ratio | SD | female | 0.742 | % | vehicle control condition (5 ml/kg) (for 28 days) | 105908 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | | | |

10 | brain weight to body weight ratio | SD-Ahrem2Sage | female | 0.742 | % | vehicle control condition (5 ml/kg) (for 28 days) | 105909 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | | | |

10 | both ovaries weight to body weight ratio | SD | female | 0.049 | % | vehicle control condition (5 ml/kg) (for 28 days) | 105920 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | | | |

10 | both ovaries weight to body weight ratio | SD-Ahrem2Sage | female | 0.047 | % | vehicle control condition (5 ml/kg) (for 28 days) | 105921 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | | | |

10 | red blood cell count | SD | female | 7.47 | x 10E6 cells/ul | vehicle control condition (5 ml/kg) (for 28 days) | 105932 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | | | |

10 | red blood cell count | SD-Ahrem2Sage | female | 7.41 | x 10E6 cells/ul | vehicle control condition (5 ml/kg) (for 28 days) | 105933 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | | | |

10 | hemoglobin concentration | SD | female | 2.17775 | mmol/l | vehicle control condition (5 ml/kg) (for 28 days) | 105944 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | | | |

10 | hemoglobin concentration | SD-Ahrem2Sage | female | 2.17155 | mmol/l | vehicle control condition (5 ml/kg) (for 28 days) | 105945 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | | | |

10 | hematocrit | SD | female | 43.31 | % | vehicle control condition (5 ml/kg) (for 28 days) | 105956 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | | | |

10 | hematocrit | SD-Ahrem2Sage | female | 43.31 | % | vehicle control condition (5 ml/kg) (for 28 days) | 105957 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | | | |

10 | mean corpuscular volume | SD | female | 57.96 | fl | vehicle control condition (5 ml/kg) (for 28 days) | 105968 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | | | |

10 | mean corpuscular volume | SD-Ahrem2Sage | female | 58.44 | fl | vehicle control condition (5 ml/kg) (for 28 days) | 105969 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | | | |

10 | mean corpuscular hemoglobin level | SD | female | 18.82 | pg | vehicle control condition (5 ml/kg) (for 28 days) | 105980 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | | | |

10 | mean corpuscular hemoglobin level | SD-Ahrem2Sage | female | 18.92 | pg | vehicle control condition (5 ml/kg) (for 28 days) | 105981 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | | | |

10 | mean corpuscular hemoglobin concentration | SD | female | 32.48 | g/dl | vehicle control condition (5 ml/kg) (for 28 days) | 105992 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | | | |

10 | mean corpuscular hemoglobin concentration | SD-Ahrem2Sage | female | 32.37 | g/dl | vehicle control condition (5 ml/kg) (for 28 days) | 105993 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | | | |

10 | platelet distribution width (percentage) | BDIX/CrCrl | male | 5.2 | % | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 108146 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

10 | platelet distribution width (percentage) | BDIX/CrCrl | male | 8.5 | % | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 108148 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

10 | platelet count | SD | female | 1308.4 | x 1000 cells/ul | vehicle control condition (5 ml/kg) (for 28 days) | 106004 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | | | |

10 | platelet count | SD-Ahrem2Sage | female | 1388 | x 1000 cells/ul | vehicle control condition (5 ml/kg) (for 28 days) | 106005 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | | | |

10 | white blood cell count | SD | female | 9.42 | x 1000 cells/ul | vehicle control condition (5 ml/kg) (for 28 days) | 106016 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | | | |

10 | white blood cell count | SD-Ahrem2Sage | female | 10.8 | x 1000 cells/ul | vehicle control condition (5 ml/kg) (for 28 days) | 106017 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | | | |

10 | blood neutrophil count | SD | female | 1.48 | x 1000 cells/ul | vehicle control condition (5 ml/kg) (for 28 days) | 106028 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | | | |

10 | blood neutrophil count | SD-Ahrem2Sage | female | 1.89 | x 1000 cells/ul | vehicle control condition (5 ml/kg) (for 28 days) | 106029 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | | | |

10 | blood lymphocyte count | SD | female | 7.36 | x 1000 cells/ul | vehicle control condition (5 ml/kg) (for 28 days) | 106040 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | | | |

10 | blood lymphocyte count | SD-Ahrem2Sage | female | 8.25 | x 1000 cells/ul | vehicle control condition (5 ml/kg) (for 28 days) | 106041 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | | | |

10 | blood monocyte count | SD | female | 0.29 | x 1000 cells/ul | vehicle control condition (5 ml/kg) (for 28 days) | 106052 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | | | |

10 | blood monocyte count | SD-Ahrem2Sage | female | 0.31 | x 1000 cells/ul | vehicle control condition (5 ml/kg) (for 28 days) | 106053 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | | | |

10 | blood eosinophil count | SD | female | 0.13 | x 1000 cells/ul | vehicle control condition (5 ml/kg) (for 28 days) | 106064 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | | | |

10 | blood eosinophil count | SD-Ahrem2Sage | female | 0.18 | x 1000 cells/ul | vehicle control condition (5 ml/kg) (for 28 days) | 106065 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | | | |

10 | blood basophil count | SD | female | 0.07 | x 1000 cells/ul | vehicle control condition (5 ml/kg) (for 28 days) | 106076 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | | | |

10 | blood basophil count | SD-Ahrem2Sage | female | 0.08 | x 1000 cells/ul | vehicle control condition (5 ml/kg) (for 28 days) | 106077 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | | | |

10 | serum total cholesterol level | BDIX/CrCrl | male | 60 | mg/dl | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107892 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

10 | serum alkaline phosphatase activity level | BDIX/CrCrl | male | 620 | U/l | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107914 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

10 | CD3+ thymocyte count | WAG/Nov | male | 1021.26 | x10E6/organ | vehicle control condition (2 ml/kg) (for 1 days) | 107715 | vehicle control condition (2 ml/kg) (for 1 days) | | | | | | | | | | |

10 | CD4+CD8- thymocyte count | WAG/Nov | male | 239.75 | x 10E6/organ | vehicle control condition (2 ml/kg) (for 1 days) | 107718 | vehicle control condition (2 ml/kg) (for 1 days) | | | | | | | | | | |

10 | CD4+CD8+ thymocyte count | WAG/Nov | male | 596.53 | x10E6/organ | vehicle control condition (2 ml/kg) (for 1 days) | 107721 | vehicle control condition (2 ml/kg) (for 1 days) | | | | | | | | | | |

10 | CD4-CD8+ thymocyte count | WAG/Nov | male | 74.18 | x10E6/organ | vehicle control condition (2 ml/kg) (for 1 days) | 107724 | vehicle control condition (2 ml/kg) (for 1 days) | | | | | | | | | | |

10 | CD4+CD25+ thymocyte count | WAG/Nov | male | 40.63 | x10E6/organ | vehicle control condition (2 ml/kg) (for 1 days) | 107727 | vehicle control condition (2 ml/kg) (for 1 days) | | | | | | | | | | |

10 | CD3+ splenocyte count to total splenocyte count ratio | WAG/Nov | male | 30.13 | % | vehicle control condition (2 ml/kg) (for 1 days) | 107733 | vehicle control condition (2 ml/kg) (for 1 days) | | | | | | | | | | |

10 | CD11b/c+ splenocyte count to total splenocyte count ratio | WAG/Nov | male | 12.4 | % | vehicle control condition (2 ml/kg) (for 1 days) | 107736 | vehicle control condition (2 ml/kg) (for 1 days) | | | | | | | | | | |

10 | CD11b/c+ splenocyte count | WAG/Nov | male | 92.63 | x10E6/organ | vehicle control condition (2 ml/kg) (for 1 days) | 107739 | vehicle control condition (2 ml/kg) (for 1 days) | | | | | | | | | | |

10 | CD4+CD25+ splenocyte count to total splenocyte count ratio | ISIAH | male | 1.7 | % | vehicle control condition (2 ml/kg) (for 1 days) | 107742 | vehicle control condition (2 ml/kg) (for 1 days) | | | | | | | | | | |

10 | CD45RA+ splenocyte count to total splenocyte count ratio | ISIAH | male | 34.86 | % | vehicle control condition (2 ml/kg) (for 1 days) | 107745 | vehicle control condition (2 ml/kg) (for 1 days) | | | | | | | | | | |

10 | CD11b/c+ splenocyte count to total splenocyte count ratio | ISIAH | male | 8.4 | % | vehicle control condition (2 ml/kg) (for 1 days) | 107748 | vehicle control condition (2 ml/kg) (for 1 days) | | | | | | | | | | |

10 | CD4+CD25+ splenocyte count | ISIAH | male | 9.83 | x10E6/organ | vehicle control condition (2 ml/kg) (for 1 days) | 107751 | vehicle control condition (2 ml/kg) (for 1 days) | | | | | | | | | | |

10 | CD4-CD25+ splenocyte count | ISIAH | male | 3.21 | x 10E6/organ | vehicle control condition (2 ml/kg) (for 1 days) | 107754 | vehicle control condition (2 ml/kg) (for 1 days) | | | | | | | | | | |

10 | CD3+ splenocyte count | ISIAH | male | 214.09 | x10E6/organ | vehicle control condition (2 ml/kg) (for 1 days) | 107757 | vehicle control condition (2 ml/kg) (for 1 days) | | | | | | | | | | |

10 | CD11b/c+ splenocyte count | ISIAH | male | 50.17 | x10E6/organ | vehicle control condition (2 ml/kg) (for 1 days) | 107760 | vehicle control condition (2 ml/kg) (for 1 days) | | | | | | | | | | |

10 | CD3+ thymocyte count | ISIAH | male | 716.82 | x10E6/organ | vehicle control condition (2 ml/kg) (for 1 days) | 107763 | vehicle control condition (2 ml/kg) (for 1 days) | | | | | | | | | | |

10 | CD4+CD8+ thymocyte count | ISIAH | male | 419 | x10E6/organ | vehicle control condition (2 ml/kg) (for 1 days) | 107766 | vehicle control condition (2 ml/kg) (for 1 days) | | | | | | | | | | |

8 | lumen diameter at maximum constriction expressed as percent of baseline | SS/JrHsdMcwi | not specified | 75.9 | % | controlled sodium content diet (1 %) (between 70 and 91 days) then pentobarbital (50 mg/kg) then vehicle control condition (for 0.1 hours) then Adenosine triphosphate (100 umol/l) (for 0.1 hours) | 106499 | controlled sodium content diet (1 %) (between 70 and 91 days) | | | pentobarbital (50 mg/kg) | | vehicle control condition (for 0.1 hours) | | Adenosine triphosphate (100 umol/l) (for 0.1 hours) | | | |

10 | timed urine volume to body weight ratio | SS/NEisSlc | not specified | 0.0218736 | ul/min/g | vehicle control condition (for 547.5 days) | 107429 | vehicle control condition (for 547.5 days) | | | | | | | | | | |

10 | urine sodium excretion rate to body weight ratio | SS/NEisSlc | not specified | 0.0038192 | uEq/min/g | vehicle control condition (for 547.5 days) | 107433 | vehicle control condition (for 547.5 days) | | | | | | | | | | |

10 | serum triglyceride level | BDIX/CrCrl | male | 249 | mg/dl | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107899 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

3 | quinidine uptake index in retina | SD | male | 212 | % | tritiated quinidine (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours) | 106114 | tritiated quinidine (10 uCi) (for 0 hours) | vehicle control condition (for 0 hours) | | | | | | | | | |

3 | digoxin uptake index in retina | SD | male | 24 | % | tritiated digoxin (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours) | 106117 | tritiated digoxin (10 uCi) (for 0 hours) | vehicle control condition (for 0 hours) | | | | | | | | | |

3 | verapamil uptake index in retina | SD | male | 336 | % | tritiated verapamil (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours) | 106120 | tritiated verapamil (10 uCi) (for 0 hours) | vehicle control condition (for 0 hours) | | | | | | | | | |

3 | quinidine uptake index in retina | SD-Abcb1aem1Sage-/- | male | 227 | % | tritiated quinidine (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours) | 106123 | tritiated quinidine (10 uCi) (for 0 hours) | vehicle control condition (for 0 hours) | | | | | | | | | |

3 | digoxin uptake index in retina | SD-Abcb1aem1Sage-/- | male | 88 | % | tritiated digoxin (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours) | 106126 | tritiated digoxin (10 uCi) (for 0 hours) | vehicle control condition (for 0 hours) | | | | | | | | | |

3 | verapamil uptake index in retina | SD-Abcb1aem1Sage-/- | male | 536 | % | tritiated verapamil (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours) | 106129 | tritiated verapamil (10 uCi) (for 0 hours) | vehicle control condition (for 0 hours) | | | | | | | | | |

3 | quinidine uptake index in aqueous humor | SD | male | 5.95 | % | tritiated quinidine (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours) | 106132 | tritiated quinidine (10 uCi) (for 0 hours) | vehicle control condition (for 0 hours) | | | | | | | | | |

3 | digoxin uptake index in aqueous humor | SD-Abcb1aem1Sage-/- | male | 55.9 | % | tritiated digoxin (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours) | 106144 | tritiated digoxin (10 uCi) (for 0 hours) | vehicle control condition (for 0 hours) | | | | | | | | | |

3 | verapamil uptake index in aqueous humor | SD-Abcb1aem1Sage-/- | male | 24.8 | % | tritiated verapamil (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours) | 106147 | tritiated verapamil (10 uCi) (for 0 hours) | vehicle control condition (for 0 hours) | | | | | | | | | |

3 | quinidine uptake index in brain | SD | male | 2.12 | % | tritiated quinidine (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours) | 106150 | tritiated quinidine (10 uCi) (for 0 hours) | vehicle control condition (for 0 hours) | | | | | | | | | |

3 | digoxin uptake index in brain | SD | male | 0.987 | % | tritiated digoxin (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours) | 106153 | tritiated digoxin (10 uCi) (for 0 hours) | vehicle control condition (for 0 hours) | | | | | | | | | |

3 | verapamil uptake index in brain | SD | male | 9.07 | % | tritiated verapamil (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours) | 106156 | tritiated verapamil (10 uCi) (for 0 hours) | vehicle control condition (for 0 hours) | | | | | | | | | |

3 | quinidine uptake index in brain | SD-Abcb1aem1Sage-/- | male | 26.1 | % | tritiated quinidine (10 uCi) (for 0 hours) and vehicle control condition | 106159 | tritiated quinidine (10 uCi) (for 0 hours) | vehicle control condition | | | | | | | | | |

10 | creatinine clearance to body weight ratio | SS/NEisSlc | not specified | 0.38241 | ml/min/100g | vehicle control condition (for 547.5 days) | 107441 | vehicle control condition (for 547.5 days) | | | | | | | | | | |

10 | time to first movement outside a discrete space in an experimental apparatus | SS/NEisSlc | not specified | 235 | s | vehicle control condition (for 547.5 days) then tactile electric shock exposure (500 mA) (for 0 hours) | 107468 | vehicle control condition (for 547.5 days) | | | tactile electric shock exposure (500 mA) (for 0 hours) | | | | | | | |

10 | total serum bilirubin level | BDIX/CrCrl | male | 0.4 | mg/dl | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107924 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

10 | total serum bilirubin level | BDIX/CrCrl | male | 0.35 | mg/dl | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107926 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

10 | serum lactate dehydrogenase activity level | BDIX/CrCrl | male | 964 | U/l | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107929 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

10 | serum lactate dehydrogenase activity level | BDIX/CrCrl | male | 2717 | U/l | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107931 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

4 | serum interleukin-4 level | SD | not specified | 0.14 | ug/l | vehicle control condition then acetic acid (for 0 hours) then physical restraint in tube type rodent restrainer (for 2 hours) then fasting (for 1 days) | 105411 | vehicle control condition | | | acetic acid (for 0 hours) | | physical restraint in tube type rodent restrainer (for 2 hours) | | fasting (for 1 days) | | | |

4 | serum interleukin-9 level | SD | not specified | 0.1 | ug/l | vehicle control condition then acetic acid (for 0 hours) then physical restraint in tube type rodent restrainer (for 2 hours) then fasting (for 1 days) | 105415 | vehicle control condition | | | acetic acid (for 0 hours) | | physical restraint in tube type rodent restrainer (for 2 hours) | | fasting (for 1 days) | | | |

4 | intestine trypsin level | SD | not specified | 0.17 | ug/l | vehicle control condition then acetic acid (for 0 hours) then physical restraint in tube type rodent restrainer (for 2 hours) then fasting (for 1 days) | 105419 | vehicle control condition | | | acetic acid (for 0 hours) | | physical restraint in tube type rodent restrainer (for 2 hours) | | fasting (for 1 days) | | | |

5 | retinal outer nuclear layer thickness | Crl:CD(SD) | male | 41 | um | vehicle control condition (0 mg/kg) (for 5 days) | 105434 | vehicle control condition (0 mg/kg) (for 5 days) | | | | | | | | | | |

5 | retinal outer layer thickness | Crl:CD(SD) | male | 142.2 | um | vehicle control condition (0 mg/kg) (for 5 days) | 105466 | vehicle control condition (0 mg/kg) (for 5 days) | | | | | | | | | | |

5 | retinal outer layer thickness | Crl:CD(SD) | male | 138.5 | um | vehicle control condition (0 mg/kg) (for 13 days) | 105474 | vehicle control condition (0 mg/kg) (for 13 days) | | | | | | | | | | |

10 | retinal outer layer thickness | Crl:CD(SD) | male | 136 | um | vehicle control condition (0 mg/kg) (for 26 days) | 105482 | vehicle control condition (0 mg/kg) (for 26 days) | | | | | | | | | | |

10 | liver weight as percentage of body weight | SD | female | 3.647 | % | vehicle control condition (5 ml/kg) (for 28 days) | 105720 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | | | |

10 | liver weight as percentage of body weight | SD-Ahrem2Sage | female | 3.428 | % | vehicle control condition (5 ml/kg) (for 28 days) | 105726 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | | | |

6 | lumen diameter at maximum constriction expressed as percent of baseline | SS-Chr 2BN/Mcwi | not specified | 80.2 | % | controlled sodium content diet (1 %) (between 70 and 91 days) then pentobarbital (50 mg/kg) then vehicle control condition (for 0.1 hours) then Adenosine triphosphate (100 umol/l) (for 0.1 hours) | 106500 | controlled sodium content diet (1 %) (between 70 and 91 days) | | | pentobarbital (50 mg/kg) | | vehicle control condition (for 0.1 hours) | | Adenosine triphosphate (100 umol/l) (for 0.1 hours) | | | |

10 | lumen diameter at maximum constriction expressed as percent of baseline | SS-Shc1em1Mcwi | not specified | 78.6 | % | controlled sodium content diet (1 %) (between 70 and 91 days) then pentobarbital (50 mg/kg) then vehicle control condition (for 0.1 hours) then Adenosine triphosphate (100 umol/l) (for 0.1 hours) | 106501 | controlled sodium content diet (1 %) (between 70 and 91 days) | | | pentobarbital (50 mg/kg) | | vehicle control condition (for 0.1 hours) | | Adenosine triphosphate (100 umol/l) (for 0.1 hours) | | | |

4 | lumen diameter at maximum constriction expressed as percent of baseline | SS-Shc1em4Mcwi | not specified | 75.9 | % | controlled sodium content diet (1 %) (between 70 and 91 days) then pentobarbital (50 mg/kg) then vehicle control condition (for 0.1 hours) then Adenosine triphosphate (100 umol/l) (for 0.1 hours) | 106502 | controlled sodium content diet (1 %) (between 70 and 91 days) | | | pentobarbital (50 mg/kg) | | vehicle control condition (for 0.1 hours) | | Adenosine triphosphate (100 umol/l) (for 0.1 hours) | | | |

5 | lumen diameter at maximum constriction expressed as percent of baseline | SS-Shc1em5Mcwi | not specified | 75.5 | % | controlled sodium content diet (1 %) (between 70 and 91 days) then pentobarbital (50 mg/kg) then vehicle control condition (for 0.1 hours) then Adenosine triphosphate (100 umol/l) (for 0.1 hours) | 106503 | controlled sodium content diet (1 %) (between 70 and 91 days) | | | pentobarbital (50 mg/kg) | | vehicle control condition (for 0.1 hours) | | Adenosine triphosphate (100 umol/l) (for 0.1 hours) | | | |

10 | lumen diameter at maximum constriction expressed as percent of baseline | SS/JrHsdMcwi | not specified | 75.4 | % | controlled sodium content diet (1 %) (between 70 and 91 days) then pentobarbital (50 mg/kg) then vehicle control condition (for 0.1 hours) then Endothelin-1 (10 umol/l) (for 0.1 hours) | 106504 | controlled sodium content diet (1 %) (between 70 and 91 days) | | | pentobarbital (50 mg/kg) | | vehicle control condition (for 0.1 hours) | | Endothelin-1 (10 umol/l) (for 0.1 hours) | | | |

6 | lumen diameter at maximum constriction expressed as percent of baseline | SS-Chr 2BN/Mcwi | not specified | 79.3 | % | controlled sodium content diet (1 %) (between 70 and 91 days) then pentobarbital (50 mg/kg) then vehicle control condition (for 0.1 hours) then Endothelin-1 (10 umol/l) (for 0.1 hours) | 106505 | controlled sodium content diet (1 %) (between 70 and 91 days) | | | pentobarbital (50 mg/kg) | | vehicle control condition (for 0.1 hours) | | Endothelin-1 (10 umol/l) (for 0.1 hours) | | | |

7 | lumen diameter at maximum constriction expressed as percent of baseline | SS-Shc1em4Mcwi | not specified | 76.1 | % | controlled sodium content diet (1 %) (between 70 and 91 days) then pentobarbital (50 mg/kg) then vehicle control condition (for 0.1 hours) then Endothelin-1 (10 umol/l) (for 0.1 hours) | 106506 | controlled sodium content diet (1 %) (between 70 and 91 days) | | | pentobarbital (50 mg/kg) | | vehicle control condition (for 0.1 hours) | | Endothelin-1 (10 umol/l) (for 0.1 hours) | | | |

8 | lumen diameter at maximum constriction expressed as percent of baseline | SS-Shc1em5Mcwi | not specified | 75.5 | % | controlled sodium content diet (1 %) (between 70 and 91 days) then pentobarbital (50 mg/kg) then vehicle control condition (for 0.1 hours) then Endothelin-1 (10 umol/l) (for 0.1 hours) | 106507 | controlled sodium content diet (1 %) (between 70 and 91 days) | | | pentobarbital (50 mg/kg) | | vehicle control condition (for 0.1 hours) | | Endothelin-1 (10 umol/l) (for 0.1 hours) | | | |

3 | digoxin uptake index in brain | SD-Abcb1aem1Sage-/- | male | 14 | % | tritiated digoxin (10 uCi) (for 0 hours) and vehicle control condition | 106162 | tritiated digoxin (10 uCi) (for 0 hours) | vehicle control condition | | | | | | | | | |

3 | verapamil uptake index in brain | SD-Abcb1aem1Sage-/- | male | 75 | % | tritiated verapamil (10 uCi) (for 0 hours) and vehicle control condition | 106165 | tritiated verapamil (10 uCi) (for 0 hours) | vehicle control condition | | | | | | | | | |

10 | serum NAG activity level | SS/NEisSlc | not specified | 20.1 | uU/ml | vehicle control condition (for 547.5 days) | 107425 | vehicle control condition (for 547.5 days) | | | | | | | | | | |

10 | CD4-CD8+ thymocyte count | ISIAH | male | 63.99 | x10E6/organ | vehicle control condition (2 ml/kg) (for 1 days) | 107769 | vehicle control condition (2 ml/kg) (for 1 days) | | | | | | | | | | |

10 | CD4+CD25+ thymocyte count | ISIAH | male | 32.19 | x10E6/organ | vehicle control condition (2 ml/kg) (for 1 days) | 107772 | vehicle control condition (2 ml/kg) (for 1 days) | | | | | | | | | | |

10 | plasma triglyceride level | WAG/Nov | male | 1.1865 | mmol/l | vehicle control condition (2 ml/kg) (for 1 days) | 107775 | vehicle control condition (2 ml/kg) (for 1 days) | | | | | | | | | | |

10 | plasma triglyceride level | ISIAH | male | 1.2995 | mmol/l | vehicle control condition (2 ml/kg) (for 1 days) | 107778 | vehicle control condition (2 ml/kg) (for 1 days) | | | | | | | | | | |

5 | retinal outer nuclear layer thickness | Crl:CD(SD) | male | 53.4 | um | vehicle control condition (0 mg/kg) (for 25 days) | 105442 | vehicle control condition (0 mg/kg) (for 25 days) | | | | | | | | | | |

5 | retinal outer nuclear layer photoreceptor nucleus count | Crl:CD(SD) | male | 10.5 | | vehicle control condition (for 25 days) | 105462 | vehicle control condition (for 25 days) | | | | | | | | | | |

10 | retinal inner layer thickness | Crl:CD(SD) | male | 126 | um | vehicle control condition (0 mg/kg) (for 26 days) | 105486 | vehicle control condition (0 mg/kg) (for 26 days) | | | | | | | | | | |

5 | retinal outer layer thickness | Crl:CD(SD) | male | 132.2 | um | vehicle control condition (0 mg/kg) (for 25 days) | 105490 | vehicle control condition (0 mg/kg) (for 25 days) | | | | | | | | | | |

5 | retinal outer layer thickness | Crl:CD(SD) | male | 129.8 | um | vehicle control condition (0 mg/kg) (for 25 days) | 105498 | vehicle control condition (0 mg/kg) (for 25 days) | | | | | | | | | | |

5 | retinal inner layer thickness | Crl:CD(SD) | male | 123.8 | um | vehicle control condition (0 mg/kg) (for 25 days) | 105502 | vehicle control condition (0 mg/kg) (for 25 days) | | | | | | | | | | |

5 | full retina thickness | Crl:CD(SD) | male | 129.7 | um | vehicle control condition (0 mg/kg) (for 5 days) | 105438 | vehicle control condition (0 mg/kg) (for 5 days) | | | | | | | | | | |

5 | retinal outer nuclear layer photoreceptor nucleus count | Crl:CD(SD) | male | 11.3 | | vehicle control condition (0 mg/kg) (for 25 days) | 105450 | vehicle control condition (0 mg/kg) (for 25 days) | | | | | | | | | | |

5 | retinal outer nuclear layer thickness | Crl:CD(SD) | male | 50.6 | um | vehicle control condition (for 25 days) | 105454 | vehicle control condition (for 25 days) | | | | | | | | | | |

5 | full retina thickness | Crl:CD(SD) | male | 191.6 | um | vehicle control condition (0 mg/kg) (for 25 days) | 105458 | vehicle control condition (0 mg/kg) (for 25 days) | | | | | | | | | | |

5 | retinal inner layer thickness | Crl:CD(SD) | male | 131.6 | um | vehicle control condition (0 mg/kg) (for 5 days) | 105470 | vehicle control condition (0 mg/kg) (for 5 days) | | | | | | | | | | |

5 | retinal inner layer thickness | Crl:CD(SD) | male | 128.7 | um | vehicle control condition (0 mg/kg) (for 13 days) | 105478 | vehicle control condition (0 mg/kg) (for 13 days) | | | | | | | | | | |

5 | retinal inner layer thickness | Crl:CD(SD) | male | 121.9 | um | vehicle control condition (0 mg/kg) (for 25 days) | 105494 | vehicle control condition (0 mg/kg) (for 25 days) | | | | | | | | | | |

6 | cerebrum infarct volume to total cerebrum volume ratio | F344-Pde4dTn(sb-T2/Bart3)2.285Mcwi | male | 20 | % | isoflurane (1.5 %) (for 4 hours) then vehicle control condition then middle cerebral artery occlusion (for 1 hours) | 106360 | isoflurane (1.5 %) (for 4 hours) | | | vehicle control condition | | middle cerebral artery occlusion (for 1 hours) | | | | | |

4 | serum total immunoglobulin E level | SD | not specified | 0.2 | ug/l | vehicle control condition then acetic acid (for 0 hours) then physical restraint in tube type rodent restrainer (for 2 hours) then fasting (for 1 days) | 105407 | vehicle control condition | | | acetic acid (for 0 hours) | | physical restraint in tube type rodent restrainer (for 2 hours) | | fasting (for 1 days) | | | |

5 | full retina thickness | Crl:CD(SD) | male | 177.2 | um | vehicle control condition (0 mg/kg) (for 25 days) | 105446 | vehicle control condition (0 mg/kg) (for 25 days) | | | | | | | | | | |

4 | measurement of the 50% threshold of mechanical stimulus needed to elicit evasive reaction | F344 | male | 2.88 | g | vehicle control condition | 105566 | vehicle control condition | | | | | | | | | | |

12 | percentage of survivors in a study population during a period of time | SHRSP/A3NCrl | male | 50 | % | controlled sodium chloride content drinking water (1 %) (for 91 days) and controlled fat content diet (24.5 %) (for 91 days) then vehicle control condition (for 35 days) | 109030 | controlled sodium chloride content drinking water (1 %) (for 91 days) | controlled fat content diet (24.5 %) (for 91 days) | | vehicle control condition (for 35 days) | | | | | | | |

3 | verapamil uptake index in aqueous humor | SD | male | 8.46 | % | tritiated verapamil (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours) | 106138 | tritiated verapamil (10 uCi) (for 0 hours) | vehicle control condition (for 0 hours) | | | | | | | | | |

3 | quinidine uptake index in aqueous humor | SD-Abcb1aem1Sage-/- | male | 12 | % | tritiated quinidine (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours) | 106141 | tritiated quinidine (10 uCi) (for 0 hours) | vehicle control condition (for 0 hours) | | | | | | | | | |

16 | cerebrum infarct volume to total cerebrum volume ratio | WI | male | 23 | % | isoflurane (1.5 %) (for 4 hours) then vehicle control condition then Embolism injection at middle cerebral artery (for 1 days) | 106358 | isoflurane (1.5 %) (for 4 hours) | | | vehicle control condition | | Embolism injection at middle cerebral artery (for 1 days) | | | | | |

18 | cerebrum infarct volume to total cerebrum volume ratio | F344 | male | 11 | % | isoflurane (1.5 %) (for 4 hours) then vehicle control condition then middle cerebral artery occlusion (for 1 hours) | 106172 | isoflurane (1.5 %) (for 4 hours) | | | vehicle control condition | | middle cerebral artery occlusion (for 1 hours) | | | | | |

6 | cerebrum infarct volume to total cerebrum volume ratio | F344 | male | 18 | % | isoflurane (1.5 %) (for 4 hours) then vehicle control condition then middle cerebral artery occlusion (for 1 hours) | 106361 | isoflurane (1.5 %) (for 4 hours) | | | vehicle control condition | | middle cerebral artery occlusion (for 1 hours) | | | | | |

7 | heart right ventricle weight to left ventricle plus septum weight ratio | SS/JrHsdMcwi | male | 0.25 | g/g | vehicle control condition | 106536 | vehicle control condition | | | | | | | | | | |

10 | heart right ventricle weight to left ventricle plus septum weight ratio | SS-Sod3m1Mcwi | male | 0.25 | g/g | vehicle control condition | 106537 | vehicle control condition | | | | | | | | | | |

7 | heart left ventricle weight | SS/JrHsdMcwi | male | 0.641 | g | vehicle control condition | 106538 | vehicle control condition | | | | | | | | | | |

10 | heart left ventricle weight | SS-Sod3m1Mcwi | male | 0.64 | g | vehicle control condition | 106539 | vehicle control condition | | | | | | | | | | |

7 | heart right ventricle weight | SS/JrHsdMcwi | male | 0.162 | g | vehicle control condition | 106540 | vehicle control condition | | | | | | | | | | |

10 | heart right ventricle weight | SS-Sod3m1Mcwi | male | 0.157 | g | vehicle control condition | 106541 | vehicle control condition | | | | | | | | | | |

7 | body weight | SS/JrHsdMcwi | male | 261 | g | vehicle control condition | 106550 | vehicle control condition | | | | | | | | | | |

10 | body weight | SS-Sod3m1Mcwi | male | 259 | g | vehicle control condition | 106551 | vehicle control condition | | | | | | | | | | |

7 | tibia length | SS/JrHsdMcwi | male | 3.64 | cm | vehicle control condition | 106554 | vehicle control condition | | | | | | | | | | |

10 | tibia length | SS-Sod3m1Mcwi | male | 3.64 | cm | vehicle control condition | 106555 | vehicle control condition | | | | | | | | | | |

7 | lung weight | SS/JrHsdMcwi | male | 1.23 | g | vehicle control condition | 106558 | vehicle control condition | | | | | | | | | | |

10 | lung weight | SS-Sod3m1Mcwi | male | 1.2 | g | vehicle control condition | 106559 | vehicle control condition | | | | | | | | | | |

7 | right atrium weight | SS/JrHsdMcwi | male | 0.0161 | g | vehicle control condition | 106562 | vehicle control condition | | | | | | | | | | |

10 | right atrium weight | SS-Sod3m1Mcwi | male | 0.0149 | g | vehicle control condition | 106563 | vehicle control condition | | | | | | | | | | |

7 | left atrium weight | SS/JrHsdMcwi | male | 0.0148 | g | vehicle control condition | 106566 | vehicle control condition | | | | | | | | | | |

10 | left atrium weight | SS-Sod3m1Mcwi | male | 0.0164 | g | vehicle control condition | 106567 | vehicle control condition | | | | | | | | | | |

7 | heart right atrium weight to left atrium weight ratio | SS/JrHsdMcwi | male | 1.09 | | vehicle control condition | 106570 | vehicle control condition | | | | | | | | | | |

10 | heart right atrium weight to left atrium weight ratio | SS-Sod3m1Mcwi | male | 0.94 | | vehicle control condition | 106571 | vehicle control condition | | | | | | | | | | |

7 | liver weight | SS/JrHsdMcwi | male | 10.6 | g | vehicle control condition | 106574 | vehicle control condition | | | | | | | | | | |

10 | liver weight | SS-Sod3m1Mcwi | male | 10.6 | g | vehicle control condition | 106575 | vehicle control condition | | | | | | | | | | |

7 | kidney weight | SS/JrHsdMcwi | male | 2.13 | g | vehicle control condition | 106578 | vehicle control condition | | | | | | | | | | |

10 | kidney weight | SS-Sod3m1Mcwi | male | 2.03 | g | vehicle control condition | 106579 | vehicle control condition | | | | | | | | | | |

7 | heart right ventricle weight to body weight ratio | SS/JrHsdMcwi | male | 0.62 | mg/g | vehicle control condition | 106582 | vehicle control condition | | | | | | | | | | |

10 | heart right ventricle weight to body weight ratio | SS-Sod3m1Mcwi | male | 0.61 | mg/g | vehicle control condition | 106583 | vehicle control condition | | | | | | | | | | |

7 | heart left ventricle weight to body weight ratio | SS/JrHsdMcwi | male | 2.43 | mg/g | vehicle control condition | 106586 | vehicle control condition | | | | | | | | | | |

10 | heart left ventricle weight to body weight ratio | SS-Sod3m1Mcwi | male | 2.49 | mg/g | vehicle control condition | 106587 | vehicle control condition | | | | | | | | | | |

7 | lung weight to body weight ratio | SS/JrHsdMcwi | male | 0.403 | % | vehicle control condition | 106590 | vehicle control condition | | | | | | | | | | |

10 | lung weight to body weight ratio | SS-Sod3m1Mcwi | male | 0.465 | % | vehicle control condition | 106591 | vehicle control condition | | | | | | | | | | |

7 | heart right atrium weight to body weight ratio | SS/JrHsdMcwi | male | 0.06 | mg/g | vehicle control condition | 106594 | vehicle control condition | | | | | | | | | | |

10 | heart right atrium weight to body weight ratio | SS-Sod3m1Mcwi | male | 0.06 | mg/g | vehicle control condition | 106595 | vehicle control condition | | | | | | | | | | |

7 | heart left atrium weight to body weight ratio | SS/JrHsdMcwi | male | 0.06 | mg/g | vehicle control condition | 106598 | vehicle control condition | | | | | | | | | | |

10 | heart left atrium weight to body weight ratio | SS-Sod3m1Mcwi | male | 0.06 | mg/g | vehicle control condition | 106599 | vehicle control condition | | | | | | | | | | |

7 | liver weight to body weight ratio | SS/JrHsdMcwi | male | 40.5 | g/kg | vehicle control condition | 106602 | vehicle control condition | | | | | | | | | | |

10 | liver weight to body weight ratio | SS-Sod3m1Mcwi | male | 40.9 | g/kg | vehicle control condition | 106603 | vehicle control condition | | | | | | | | | | |

7 | single kidney wet weight to body weight ratio | SS/JrHsdMcwi | male | 8.14 | g/kg | vehicle control condition | 106606 | vehicle control condition | | | | | | | | | | |

10 | single kidney wet weight to body weight ratio | SS-Sod3m1Mcwi | male | 7.83 | g/kg | vehicle control condition | 106607 | vehicle control condition | | | | | | | | | | |

6 | systolic blood pressure | SHRSP/A3N | male | 284 | mmHg | controlled sodium chloride content drinking water (1 %) (for 84 days) and controlled fat content diet (24.5 %) (for 84 days) and vehicle control condition (for 84 days) | 107499 | controlled sodium chloride content drinking water (1 %) (for 84 days) | controlled fat content diet (24.5 %) (for 84 days) | vehicle control condition (for 84 days) | | | | | | | | |

10 | blood non-specified leukocyte count | ISIAH | male | 2.96 | 10E3/ul | vehicle control condition (2 ml/kg) (for 1 days) | 107696 | vehicle control condition (2 ml/kg) (for 1 days) | | | | | | | | | | |

N/A | both kidneys wet weight to body weight ratio | SHRSP/A3N | male | 13 | g/kg | controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days) | 107535 | controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) | controlled fat content diet (24.5 %) (between 42 and 77 days) | vehicle control condition (between 42 and 77 days) | | | | | | | | |

N/A | kidney glomerular lesion count | SHRSP/A3N | male | 76.5 | /section | controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days) | 107539 | controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) | controlled fat content diet (24.5 %) (between 42 and 77 days) | vehicle control condition (between 42 and 77 days) | | | | | | | | |

10 | mean corpuscular hemoglobin level | BDIX/CrCrl | male | 18 | pg | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107836 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

10 | mean corpuscular hemoglobin level | BDIX/CrCrl | male | 17.5 | pg | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107838 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

10 | mean corpuscular hemoglobin concentration | BDIX/CrCrl | male | 38 | g/dl | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107841 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

10 | mean corpuscular hemoglobin concentration | BDIX/CrCrl | male | 37 | g/dl | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107843 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

10 | red blood cell distribution width-coefficient of variation | BDIX/CrCrl | male | 16.9 | % | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107846 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

10 | red blood cell distribution width-coefficient of variation | BDIX/CrCrl | male | 17.7 | % | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107848 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

10 | blood lymphocyte count to total leukocyte count ratio | BDIX/CrCrl | male | 8.1 | % | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107851 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

10 | blood lymphocyte count to total leukocyte count ratio | BDIX/CrCrl | male | 8 | % | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107853 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

10 | serum triglyceride level | BDIX/CrCrl | male | 265 | mg/dl | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107897 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

10 | serum aspartate aminotransferase activity level | BDIX/CrCrl | male | 139 | U/l | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107902 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

10 | serum aspartate aminotransferase activity level | BDIX/CrCrl | male | 193 | U/l | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107904 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

10 | serum amylase activity level | BDIX/CrCrl | male | 3190 | U/l | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107946 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

7 | heart right ventricle weight to tibia length ratio | SS/JrHsdMcwi | male | 4.51 | mg/mm | vehicle control condition | 106610 | vehicle control condition | | | | | | | | | | |

10 | heart right ventricle weight to tibia length ratio | SS-Sod3m1Mcwi | male | 4.33 | mg/mm | vehicle control condition | 106611 | vehicle control condition | | | | | | | | | | |

7 | heart left ventricle weight to tibia length ratio | SS/JrHsdMcwi | male | 0.178 | g/cm | vehicle control condition | 106614 | vehicle control condition | | | | | | | | | | |

10 | heart left ventricle weight to tibia length ratio | SS-Sod3m1Mcwi | male | 0.177 | g/cm | vehicle control condition | 106615 | vehicle control condition | | | | | | | | | | |

7 | lung weight to tibia length ratio | SS/JrHsdMcwi | male | 0.291 | g/cm | vehicle control condition | 106618 | vehicle control condition | | | | | | | | | | |

10 | lung weight to tibia length ratio | SS-Sod3m1Mcwi | male | 0.33 | g/cm | vehicle control condition | 106619 | vehicle control condition | | | | | | | | | | |

7 | heart right atrium weight to tibia length ratio | SS/JrHsdMcwi | male | 0.44 | mg/mm | vehicle control condition | 106622 | vehicle control condition | | | | | | | | | | |

10 | heart right atrium weight to tibia length ratio | SS-Sod3m1Mcwi | male | 0.41 | mg/mm | vehicle control condition | 106623 | vehicle control condition | | | | | | | | | | |

7 | heart left atrium weight to tibia length ratio | SS/JrHsdMcwi | male | 0.41 | mg/mm | vehicle control condition | 106626 | vehicle control condition | | | | | | | | | | |

10 | heart left atrium weight to tibia length ratio | SS-Sod3m1Mcwi | male | 0.45 | mg/mm | vehicle control condition | 106627 | vehicle control condition | | | | | | | | | | |

7 | liver weight to tibia length ratio | SS/JrHsdMcwi | male | 29.2 | mg/mm | vehicle control condition | 106630 | vehicle control condition | | | | | | | | | | |

10 | liver weight to tibia length ratio | SS-Sod3m1Mcwi | male | 29.1 | mg/mm | vehicle control condition | 106631 | vehicle control condition | | | | | | | | | | |

7 | single kidney weight to tibia length ratio | SS/JrHsdMcwi | male | 0.0586 | g/cm | vehicle control condition | 106634 | vehicle control condition | | | | | | | | | | |

10 | single kidney weight to tibia length ratio | SS-Sod3m1Mcwi | male | 0.0556 | g/cm | vehicle control condition | 106635 | vehicle control condition | | | | | | | | | | |

10 | neuron count | SS/NEisSlc | not specified | 1258 | cells/mm2 | vehicle control condition (for 547.5 days) | 107465 | vehicle control condition (for 547.5 days) | | | | | | | | | | |

11 | left kidney wet weight to body weight ratio | WKY | male | 3.9 | mg/g | unilateral nephrectomy (for 150 days) then vehicle control condition | 107455 | unilateral nephrectomy (for 150 days) | | | vehicle control condition | | | | | | | |

11 | kidney glomerular surface area | WKY | male | 12.6 | x 10E3 um2 | unilateral nephrectomy (for 150 days) then vehicle control condition | 107460 | unilateral nephrectomy (for 150 days) | | | vehicle control condition | | | | | | | |

10 | blood granulocyte count to total leukocyte count ratio | BDIX/CrCrl | male | 1.2 | % | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107856 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

10 | blood granulocyte count to total leukocyte count ratio | BDIX/CrCrl | male | 0.8 | % | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107858 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

10 | blood lymphocyte count | BDIX/CrCrl | male | 62.8 | x 1000 cells/ul | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107861 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

10 | blood lymphocyte count | BDIX/CrCrl | male | 77.7 | x 1000 cells/ul | DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) | 107863 | DHD/K12/TRb cells (1.5 X 10E6) | | | vehicle control condition (1 ml) | | | | | | | |

6 | time to peak measurement of Gd-DTPA uptake by kidney cortex | SHRSP/A3NCrl | male | 14.3 | s | controlled sodium chloride content drinking water (1 %) (for 91 days) and controlled fat content diet (24.5 %) (for 91 days) then vehicle control condition (for 35 days) | 107374 | controlled sodium chloride content drinking water (1 %) (for 91 days) | controlled fat content diet (24.5 %) (for 91 days) | | vehicle control condition (for 35 days) | | | | | | | |

6 | multiregional glomerular filtration rate index | SHRSP/A3NCrl | male | 2.25 | mmol/min | controlled sodium chloride content drinking water (1 %) (for 91 days) and controlled fat content diet (24.5 %) (for 91 days) then vehicle control condition (between 35 and 63 days) | 107379 | controlled sodium chloride content drinking water (1 %) (for 91 days) | controlled fat content diet (24.5 %) (for 91 days) | | vehicle control condition (between 35 and 63 days) | | | | | | | |

6 | body weight | SHRSP/A3NCrl | male | 307 | g | controlled sodium chloride content drinking water (1 %) (for 91 days) and controlled fat content diet (24.5 %) (for 91 days) then vehicle control condition (for 35 days) | 107382 | controlled sodium chloride content drinking water (1 %) (for 91 days) | controlled fat content diet (24.5 %) (for 91 days) | | vehicle control condition (for 35 days) | | | | | | | |

6 | systolic blood pressure | SHRSP/A3NCrl | male | 162 | mmHg | controlled sodium chloride content drinking water (1 %) (for 91 days) and controlled fat content diet (24.5 %) (for 91 days) then vehicle control condition (for 35 days) | 107385 | controlled sodium chloride content drinking water (1 %) (for 91 days) | controlled fat content diet (24.5 %) (for 91 days) | | vehicle control condition (for 35 days) | | | | | | | |

6 | creatinine clearance | SHRSP/A3NCrl | male | 2 | ml/min | controlled sodium chloride content drinking water (1 %) (for 91 days) and controlled fat content diet (24.5 %) (for 91 days) then vehicle control condition (for 35 days) | 107388 | controlled sodium chloride content drinking water (1 %) (for 91 days) | controlled fat content diet (24.5 %) (for 91 days) | | vehicle control condition (for 35 days) | | | | | | | |

6 | blood urea nitrogen level | SHRSP/A3NCrl | male | 20.5 | mg/dl | controlled sodium chloride content drinking water (1 %) (for 91 days) and controlled fat content diet (24.5 %) (for 91 days) then vehicle control condition (for 35 days) | 107391 | controlled sodium chloride content drinking water (1 %) (for 91 days) | controlled fat content diet (24.5 %) (for 91 days) | | vehicle control condition (for 35 days) | | | | | | | |